Clustering O
of O
missense O
mutations O
in O
the O
ataxia B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
telangiectasia I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene O
in O
a O
sporadic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
T I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
- I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
cell I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
leukaemia I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

Ataxia B_DISEASE/B_GENE
- I_DISEASE/I_GENE
telangiectasia I_DISEASE/I_GENE
( O
A B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
a O
recessive B_DISEASE/B_GENE
multi I_DISEASE/I_GENE
- I_DISEASE/I_GENE
system I_DISEASE/I_GENE
disorder I_DISEASE/I_GENE
caused O
by O
mutations O
in O
the O
ATM O
gene O
at O
11q22 O
- O
q23 O
( O
ref O
. O
3 O
) O
. O

The O
risk O
of O
cancer B_DISEASE
, O
especially O
lymphoid B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
neoplasias I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
is O
substantially O
elevated O
in O
A B_DISEASE/B_MEASURE
- I_DISEASE/I_MEASURE
T I_DISEASE/I_MEASURE
patients O
and O
has O
long O
been O
associated O
with O
chromosomal O
instability O
. O

By O
analysing O
tumour B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
DNA O
from O
patients O
with O
sporadic B_DISEASE/B_GENE
T I_DISEASE/I_GENE
- I_DISEASE/I_GENE
cell I_DISEASE/I_GENE
prolymphocytic I_DISEASE/I_GENE
leukaemia I_DISEASE/I_GENE
( O
T B_DISEASE/B_LOCATION
- I_DISEASE/I_LOCATION
PLL I_DISEASE/I_LOCATION
) O
, O
a O
rare O
clonal B_DISEASE
malignancy I_DISEASE
with O
similarities O
to O
a O
mature B_DISEASE/B_MEASURE
T I_DISEASE/I_MEASURE
- I_DISEASE/I_MEASURE
cell I_DISEASE/I_MEASURE
leukaemia I_DISEASE/I_MEASURE
seen O
in O
A B_PERSON/B_BIO
- I_PERSON/I_BIO
T I_PERSON/I_BIO
, O
we O
demonstrate O
a O
high O
frequency O
of O
ATM O
mutations O
in O
T B_DISEASE/B_PERSON
- I_DISEASE/I_PERSON
PLL I_DISEASE/I_PERSON
. O

In O
marked O
contrast O
to O
the O
ATM O
mutation O
pattern O
in O
A B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
most O
frequent O
nucleotide O
changes O
in O
this O
leukaemia B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
missense O
mutations O
. O

These O
clustered O
in O
the O
region B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
corresponding I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
to O
the O
kinase B_GENE/B_LOCATION
domain I_GENE/I_LOCATION
, O
which O
is O
highly O
conserved O
in O
ATM B_GENE/B_DISEASE
- O
related O
proteins B_LOCATION/B_DISEASE
in O
mouse B_SPECIES[BIO]/B_DISEASE
, O
yeast B_SPECIES[BIO]
and O
Drosophila B_SPECIES[BIO]/B_PERSON
. O

The O
resulting B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amino I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
acid B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
substitutions I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
predicted O
to O
interfere O
with O
ATP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
binding B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENZYME[GENE]
or O
substrate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recognition I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Two O
of O
seventeen O
mutated O
T B_DISEASE/B_GENE
- B_DISEASE/I_GENE
PLL B_DISEASE/I_GENE
samples O
had O
a O
previously O
reported O
A B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allele O
. O

In O
contrast O
, O
no O
mutations O
were O
detected O
in O
the O
p53 O
gene O
, O
suggesting O
that O
this O
tumour B_DISEASE/B_GENE
suppressor O
is O
not O
frequently O
altered O
in O
this O
leukaemia B_DISEASE/B_PERSON
. O

occasional O
missense O
mutations O
in O
ATM O
were O
also O
found O
in O
tumour B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
DNA O
from O
patients O
with O
B B_DISEASE/B_GENE
- I_DISEASE/I_GENE
cell I_DISEASE/I_GENE
non I_DISEASE/I_GENE
- I_DISEASE/I_GENE
Hodgkins I_DISEASE/I_GENE
lymphomas I_DISEASE/I_GENE
( O
B B_DISEASE
- I_DISEASE
NHL I_DISEASE
) O
and O
a O
B B_DISEASE
- I_DISEASE
NHL I_DISEASE
cell O
line O
. O

The O
evidence O
of O
a O
significant O
proportion O
of O
loss O
- O
of O
- O
function O
mutations O
and O
a O
complete O
absence O
of O
the O
normal O
copy O
of O
ATM O
in O
the O
majority O
of O
mutated O
tumours B_DISEASE/B_BIO
establishes O
somatic O
inactivation O
of O
this O
gene O
in O
the O
pathogenesis O
of O
sporadic B_DISEASE
T I_DISEASE
- I_DISEASE
PLL I_DISEASE
and O
suggests O
that O
ATM O
acts O
as O
a O
tumour B_DISEASE
suppressor O
. O

As O
constitutional O
DNA O
was O
not O
available O
, O
a O
putative O
hereditary O
predisposition O
to O
T B_DISEASE/B_LOCATION
- I_DISEASE/I_LOCATION
PLL I_DISEASE/I_LOCATION
will O
require O
further O
investigation O
. O
. O

Myotonic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
dystrophy B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
protein O
kinase O
is O
involved O
in O
the O
modulation O
of O
the O
Ca2 O
+ O
homeostasis O
in O
skeletal O
muscle O
cells O
. O

Myotonic B_DISEASE/B_LOCATION
dystrophy I_DISEASE/I_LOCATION
( O
DM B_LOCATION/B_ORGANIZATION
) O
, O
the O
most O
prevalent O
muscular B_DISEASE
disorder I_DISEASE
in O
adults O
, O
is O
caused O
by O
( O
CTG O
) O
n O
- O
repeat O
expansion O
in O
a O
gene O
encoding O
a O
protein O
kinase O
( O
DM B_DISEASE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
protein O
kinase O
; O
DMPK O
) O
and O
involves O
changes O
in O
cytoarchitecture O
and O
ion O
homeostasis O
. O

To O
obtain O
clues B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
normal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biological I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
DMPK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
cellular B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
ion B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
homeostasis B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
we O
have O
compared O
the O
resting B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ca2 B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O
i O
, O
the O
amplitude B_MEASURE/B_LOCATION
and O
shape B_MEASURE
of O
depolarization B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
induced O
Ca2 B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transients B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
content B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
ATP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
driven O
ion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pumps I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
cultured B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
skeletal I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
muscle I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
wild B_BIO/B_GENE
- O
type B_TIME[MEASURE]/B_BIO
and O
DMPK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
/ O
- O
] B_SPECIES[BIO]/B_GENE
knockout I_SPECIES[BIO]/I_GENE
mice I_SPECIES[BIO]/I_GENE
. O

In O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
differentiated O
DMPK B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
/ O
- O
] B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
myotubes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
exhibit O
a O
higher B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
resting B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
[ O
Ca2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O
] O
i O
than O
do O
wild B_PERSON/B_BIO
- O
type B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
myotubes B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
because O
of O
an O
altered O
open B_MEASURE
probability I_MEASURE
of O
voltage B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
dependent B_MEASURE/B_DISEASE
l I_MEASURE/I_DISEASE
- O
type B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Ca2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
Na B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
channels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
mutant B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
myotubes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
exhibit O
smaller B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
slower B_MEASURE
Ca2 I_MEASURE
+ O
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
upon O
triggering O
by O
acetylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
high B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
external I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
K I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
we O
observed O
that O
these O
Ca2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O
transients B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partially O
result O
from O
an O
influx B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
extracellular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Ca2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
the O
l B_PROTEIN[GENE]/B_DISEASE
- O
type B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
Ca2 I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
+ I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
channel I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Neither O
the O
content B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O
the O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
Na B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
/ O
K B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ATPase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
sarcoplasmic B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reticulum I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Ca2 I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
+ I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
ATPase B_ENZYME[GENE]
are O
affected O
by O
DMPK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
absence I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

In O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
DMPK B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
involved O
in O
modulating O
the O
initial B_MEASURE/B_LOCATION
events I_MEASURE/I_LOCATION
of O
excitation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
contraction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
coupling I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
skeletal B_BODY_PART_OR_ORGAN_COMPONENT
muscle I_BODY_PART_OR_ORGAN_COMPONENT
. O
. O

Constitutional O
RB1 O
- O
gene O
mutations O
in O
patients O
with O
isolated O
unilateral B_DISEASE/B_GENE
retinoblastoma I_DISEASE/I_GENE
. O

In O
most O
patients O
with O
isolated O
unilateral B_DISEASE/B_GENE
retinoblastoma I_DISEASE/I_GENE
, O
tumor B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
development O
is O
initiated O
by O
somatic O
inactivation O
of O
both O
alleles O
of O
the O
RB1 O
gene O
. O

However O
, O
some O
of O
these O
patients O
can O
transmit O
retinoblastoma B_DISEASE/B_GENE
predisposition O
to O
their O
offspring O
. O

To O
determine O
the O
frequency O
and O
nature O
of O
constitutional O
RB1 O
- O
gene O
mutations O
in O
patients O
with O
isolated O
unilateral B_DISEASE
retinoblastoma I_DISEASE
, O
we O
analyzed O
DNA O
from O
peripheral O
blood O
and O
from O
tumor B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissue O
. O

The O
analysis O
of O
tumors B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
54 O
( O
71 O
% O
) O
of O
76 O
informative O
patients O
showed O
loss O
of O
constitutional O
heterozygosity O
( O
LOH O
) O
at O
intragenic O
loci O
. O

Three B_NUMBER[MEASURE]
of O
13 B_PERSON
uninformative I_PERSON
patients I_PERSON
had O
constitutional B_DISEASE
deletions I_DISEASE
. O

For O
39 O
randomly O
selected O
tumors B_DISEASE/B_PERSON
, O
SSCP O
, O
hetero O
- O
duplex O
analysis O
, O
sequencing O
, O
and O
Southern O
blot O
analysis O
were O
used O
to O
identify O
mutations O
. O

mutations O
were O
detected O
in O
21 O
( O
91 O
% O
) O
of O
23 O
tumors B_DISEASE/B_PERSON
with O
LOH O
. O

In O
6 O
( O
38 O
% O
) O
of O
16 O
tumors B_DISEASE/B_PERSON
without O
LOH O
, O
one O
mutation O
was O
detected O
, O
and O
in O
9 O
( O
56 O
% O
) O
of O
the O
tumors B_DISEASE/B_MEASURE
without O
LOH O
, O
both O
mutations O
were O
found O
. O

Thus O
, O
a O
total O
of O
45 O
mutations O
were O
identified O
in O
tumors B_MEASURE
of O
36 O
patients O
. O

Thirty B_NUMBER[MEASURE]
- O
nine B_NUMBER[MEASURE]
of O
the O
mutations B_DISEASE/B_GENE
- O
including O
34 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
small B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutations B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
2 B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
large I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
structural I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
alterations I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
, O
and O
hypermethylation B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O
3 B_DISEASE/B_GENE
tumors B_DISEASE/I_GENE
- O
were O
not O
detected O
in O
the O
corresponding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
peripheral I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
blood I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
DNA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
. O

In O
6 B_MEASURE
( O
17 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
) O
of O
the O
36 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
, O
a O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
was O
detected O
in O
constitutional B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
1 B_NUMBER[MEASURE]/B_PERSON
of O
these O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
is O
known O
to O
be O
associated O
with O
reduced O
expressivity B_DISEASE/B_ORGANISM_FUNCTION
. O

The O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
constitutional B_DISEASE
mutation I_DISEASE
was O
not O
associated O
with O
an O
early B_DISEASE_ADJECTIVE[DISEASE]
age I_DISEASE_ADJECTIVE[DISEASE]
at O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

In O
1 B_MEASURE/B_PERSON
patient I_MEASURE/I_PERSON
, O
somatic B_DISEASE/B_GENE
mosaicism I_DISEASE/I_GENE
was O
demonstrated O
by O
molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
RNA B_GENE/B_BIO
from O
peripheral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
blood I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
. O

In O
2 O
patients O
without O
a O
detectable O
mutation O
in O
peripheral O
blood O
, O
mosaicism O
was O
suggested O
because O
1 O
of O
the O
patients O
showed O
multifocal O
tumors B_DISEASE
and O
the O
other O
later O
developed O
bilateral B_DISEASE
retinoblastoma I_DISEASE
. O

In O
conclusion O
, O
our O
results O
emphasize O
that O
the O
manifestation O
and O
transmissibility O
of O
retinoblastoma B_DISEASE/B_GENE
depend O
on O
the O
nature O
of O
the O
first O
mutation O
, O
its O
time O
in O
development O
, O
and O
the O
number O
and O
types O
of O
cells O
that O
are O
affected O
. O
. O

Hereditary B_DISEASE
deficiency I_DISEASE
of I_DISEASE
the I_DISEASE
fifth I_DISEASE
component I_DISEASE
of I_DISEASE
complement I_DISEASE
in O
man O
. O

I B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
immunochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
and O
family B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
first O
recognized O
human O
kindred O
with O
hereditary B_DISEASE/B_GENE
deficiency I_DISEASE/I_GENE
of I_DISEASE/I_GENE
the I_DISEASE/I_GENE
fifth I_DISEASE/I_GENE
component I_DISEASE/I_GENE
of I_DISEASE/I_GENE
complement I_DISEASE/I_GENE
( O
C5 O
) O
is O
described O
. O

The O
proband O
, O
a O
20 O
- O
year O
- O
old O
black O
female O
with O
systemic B_DISEASE/B_LOCATION
lupus I_DISEASE/I_LOCATION
erythematosus I_DISEASE/I_LOCATION
since O
age O
11 O
, O
lacked O
serum O
hemolytic O
complement O
activity O
, O
even O
during O
remission O
. O

C5 B_DISEASE/B_GENE
was O
undetectable B_DISEASE_ADJECTIVE[DISEASE]
in O
her O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
by O
both O
immunodiffusion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
hemolytic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assays I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Other B_PERSON
complement I_PERSON
components I_PERSON
were O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
remission B_DISEASE
of O
lupus B_DISEASE/B_LOCATION
, O
but O
C1 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
C4 B_PROTEIN[GENE]
, O
C2 B_PROTEIN[GENE]
, O
and O
C3 B_PROTEIN[GENE]
levels I_PROTEIN[GENE]
fell O
during O
exacerbations B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

A O
younger B_PERSON/B_NUMBER[MEASURE]
half B_PERSON/I_NUMBER[MEASURE]
- O
sister B_PERSON/B_BIO
, O
who O
had O
no O
underlying B_DISEASE/B_PERSON
disease I_DISEASE/I_PERSON
, O
was O
also O
found O
to O
lack O
immunochemically O
detectable B_DISEASE_ADJECTIVE[DISEASE]
C5 I_DISEASE_ADJECTIVE[DISEASE]
. O

By O
hemolytic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
she O
exhibited O
1 B_MEASURE/B_LOCATION
- O
2 B_SEQUENCE[MEASURE]
% I_SEQUENCE[MEASURE]
of O
the O
normal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
serum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
C5 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
level B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
and O
normal B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentrations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
other B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
complement B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
components B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
. O

C5 O
levels O
of O
other O
family O
members O
were O
either O
normal O
or O
approximately O
half O
- O
normal O
, O
consistent O
with O
autosomal O
codominant O
inheritance O
of O
the O
gene O
determining O
C5 B_DISEASE/B_GENE
deficiency I_DISEASE/I_GENE
. O

Normal O
hemolytic O
titers O
were O
restored O
to O
both O
homozygous O
C5 B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
deficient I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O
C5D B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
sera O
by O
addition O
of O
highly O
purified O
human O
C5 O
. O

In O
specific O
C5 O
titrations O
, O
however O
, O
it O
was O
noted O
that O
when O
limited O
amounts O
of O
C5 O
were O
assayed O
in O
the O
presence O
of O
low O
dilutions O
of O
either O
C5D B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
serum O
, O
curving O
rather O
than O
linear O
dose O
- O
response O
plots O
were O
consistently O
obtained O
, O
suggesting O
some O
inhibitory O
effect O
. O

Further O
studies O
suggested O
that O
low O
dilutions O
of O
C5D B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
serum O
contain O
a O
factor O
( O
or O
factors O
) O
interfering O
at O
some O
step O
in O
the O
hemolytic O
assay O
of O
C5 O
, O
rather O
than O
a O
true O
C5 O
inhibitor O
or O
inactivator O
. O

Of O
clinical O
interest O
are O
( O
a O
) O
the O
documentation O
of O
membranous O
glomerulonephritis B_DISEASE
, O
vasculitis B_DISEASE
, O
and O
arthritis B_DISEASE
in O
an O
individual O
lacking O
C5 O
( O
and O
its O
biologic O
functions O
) O
, O
and O
( O
b O
) O
a O
remarkable O
propensity O
to O
bacterial B_DISEASE_ADJECTIVE[DISEASE]
infections I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
proband O
, O
even O
during O
periods O
of O
low O
- O
dose O
or O
alternate O
- O
day O
corticosteroid O
therapy O
. O

Other O
observations O
indicate O
that O
the O
C5D B_DISEASE_ADJECTIVE[DISEASE]
state O
is O
compatible O
with O
normal O
coagulation O
function O
and O
the O
capacity O
to O
mount O
a O
neutrophilic O
leukocytosis O
during O
pyogenic B_DISEASE
infection I_DISEASE
. O
. O

Susceptibility O
to O
ankylosing B_DISEASE
spondylitis I_DISEASE
in O
twins O
: O
the O
role O
of O
genes O
, O
HLA O
, O
and O
the O
environment O
. O

objective O
To O
determine O
the O
relative O
effects O
of O
genetic O
and O
environmental O
factors O
in O
susceptibility O
to O
ankylosing B_DISEASE
spondylitis I_DISEASE
( O
AS B_DISEASE/B_LOCATION
) O
. O

methods O
Twins O
with O
AS B_DISEASE/B_LOCATION
were O
identified O
from O
the O
Royal O
National O
Hospital O
for O
Rheumatic B_DISEASE/B_PERSON
Diseases I_DISEASE/I_PERSON
database O
. O

Clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
radiographic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examinations I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
performed O
to O
establish O
diagnoses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
disease B_DISEASE_ADJECTIVE[DISEASE]
severity I_DISEASE_ADJECTIVE[DISEASE]
was O
assessed O
using O
a O
combination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
validated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scoring I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
systems I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

HLA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
typing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
HLA B_GENE
- O
B27 B_PROTEIN[GENE]
, O
HLA B_GENE
- O
B60 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
HLA B_GENE/B_LOCATION
- O
DR1 B_PROTEIN[GENE]
was O
performed O
by O
polymerase B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
sequence B_LOCATION/B_GENE
- O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
primers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
zygosity B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
was O
assessed O
using O
microsatellite B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
markers I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

genetic O
and O
environmental O
variance O
components O
were O
assessed O
with O
the O
program O
Mx O
, O
using O
data O
from O
this O
and O
previous O
studies O
of O
twins O
with O
AS B_DISEASE/B_LOCATION
. O

Results B_NUMBER[MEASURE]/B_SPORT[ENT]
Six I_NUMBER[MEASURE]/I_SPORT[ENT]
of O
8 B_MEASURE
monozygotic I_MEASURE
( O
MZ B_PROTEIN[GENE]/B_LOCATION
) O
twin B_PERSON/B_LOCATION
pairs I_PERSON/I_LOCATION
were O
disease B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concordant I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
compared O
with O
4 B_NUMBER[MEASURE]
of O
15 B_GENE/B_DISEASE
B27 B_GENE/I_DISEASE
- O
positive B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
dizygotic I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
DZ B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
twin B_PERSON/B_LOCATION
pairs I_PERSON/I_LOCATION
( O
27 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
4 B_NUMBER[MEASURE]
of O
32 B_MEASURE
DZ I_MEASURE
twin I_MEASURE
pairs I_MEASURE
overall I_MEASURE
( O
12 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
) O
. O

Nonsignificant B_MEASURE
increases I_MEASURE
in O
similarity B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
regard B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
age B_MEASURE/B_DISEASE
at O
disease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
onset B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
all O
of O
the O
disease B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
severity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
scores I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
assessed O
were O
noted O
in O
disease B_DISEASE/B_GENE
- O
concordant B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
MZ I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
twins I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
compared O
with O
concordant B_PERSON/B_MEASURE
DZ I_PERSON/I_MEASURE
twins I_PERSON/I_MEASURE
. O

HLA B_GENE
- O
B27 B_PROTEIN[GENE]
and O
B60 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
associated O
with O
the O
disease B_DISEASE/B_GENE
in O
probands B_PERSON/B_BIO
, O
and O
the O
rate B_MEASURE
of O
disease B_DISEASE/B_LOCATION
concordance I_DISEASE/I_LOCATION
was O
significantly O
increased O
among O
DZ B_PERSON/B_BIO
twin I_PERSON/I_BIO
pairs I_PERSON/I_BIO
in O
which O
the O
co B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
twin B_PERSON/B_MEASURE
was O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
both O
B27 B_GENE
and O
DR1 B_PROTEIN[GENE]
. O

Additive B_PERSON
genetic I_PERSON
effects I_PERSON
were O
estimated O
to O
contribute O
97 B_PERSON/B_MEASURE
% I_PERSON/I_MEASURE
of O
the O
population B_MEASURE/B_DISEASE
variance I_MEASURE/I_DISEASE
. O

conclusion O
Susceptibility O
to O
AS B_DISEASE/B_LOCATION
is O
largely O
genetically O
determined O
, O
and O
the O
environmental O
trigger O
for O
the O
disease O
is O
probably O
ubiquitous O
. O

HLA O
- O
B27 O
accounts O
for O
a O
minority O
of O
the O
overall O
genetic O
susceptibility O
to O
AS B_DISEASE/B_LOCATION
. O

Cell B_TIME[MEASURE]/B_PERSON
cycle I_TIME[MEASURE]/I_PERSON
- O
dependent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
colocalization I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
BARD1 B_GENE/B_LOCATION
and O
BRCA1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
discrete B_DISEASE
nuclear I_DISEASE
domains I_DISEASE
. O

Germ O
- O
line O
mutations O
of O
the O
BRCA1 O
gene O
predispose O
women O
to O
early O
- O
onset O
breast B_DISEASE/B_LOCATION
and I_DISEASE/I_LOCATION
ovarian I_DISEASE/I_LOCATION
cancer I_DISEASE/I_LOCATION
by O
compromising O
the O
genes O
presumptive O
function O
as O
a O
tumor B_DISEASE
suppressor O
. O

Although O
the O
biochemical B_LOCATION
properties I_LOCATION
of O
BRCA1 B_GENE/B_BIO
polypeptides I_GENE/I_BIO
are O
not O
understood O
, O
their O
expression B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pattern I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
subcellular B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
localization I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
suggest O
a O
role B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
- O
cycle B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
regulation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

When O
resting O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
are O
induced O
to O
proliferate O
, O
the O
steady B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
state B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
BRCA1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
increase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
late B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
G1 B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
reach O
a O
maximum B_MEASURE/B_LOCATION
during O
S B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANISM_FUNCTION
. O

Moreover O
, O
in O
S B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
phase I_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
BRCA1 B_GENE/B_BIO
polypeptides I_GENE/I_BIO
are O
hyperphosphorylated O
and O
accumulate O
into O
discrete B_MEASURE/B_LOCATION
subnuclear I_MEASURE/I_LOCATION
foci I_MEASURE/I_LOCATION
termed O
' O
BRCA1 B_LOCATION
nuclear I_LOCATION
dots I_LOCATION
. O

' O
BRCA1 B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
associates I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
with O
a O
structurally O
related O
protein B_BIO/B_GENE
termed O
BARD1 B_GENE
. O

Here O
we O
show O
that O
the O
steady B_MEASURE/B_GENE
- O
state B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
BARD1 B_GENE
, O
unlike O
those O
of O
BRCA1 B_GENE/B_DISEASE
, O
remain O
relatively O
constant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
during O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
cycle B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
progression B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
. O

However O
, O
immunostaining O
revealed O
that O
BARD1 B_GENE/B_DISEASE
resides O
within O
BRCA1 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
nuclear I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
dots I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
during O
S B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
phase I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
cell B_TIME[MEASURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cycle B_TIME[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
but O
not O
during O
the O
G1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

Nevertheless O
, O
BARD1 B_GENE/B_PERSON
polypeptides I_GENE/I_PERSON
are O
found O
exclusively O
in O
the O
nuclear B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
fractions I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O
both O
G1 B_MEASURE/B_LOCATION
- O
and O
S B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Therefore O
, O
progression B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O
S B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O
accompanied O
by O
the O
aggregation B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
nuclear B_GENE
BARD1 I_GENE
polypeptides I_GENE
into O
BRCA1 B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
nuclear I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
dots I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

This O
cell O
cycle O
- O
dependent O
colocalization O
of O
BARD1 O
and O
BRCA1 O
indicates O
a O
role O
for O
BARD1 O
in O
BRCA1 O
- O
mediated O
tumor B_DISEASE/B_GENE
suppression O
. O

ethnic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
differences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
the O
HFE B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
codon I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
282 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
Cys B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
/ O
Tyr B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
polymorphism B_GENE
. O

Recent O
studies O
have O
shown O
that O
hereditary B_DISEASE
hemochromatosis I_DISEASE
( O
HH B_PROTEIN[GENE]/B_DISEASE
) O
is O
likely O
to O
be O
caused O
by O
homozygosity O
for O
a O
Cys282Tyr O
mutation O
in O
the O
HFE O
gene O
located O
4 O
. O

5 B_DISEASE_ADJECTIVE[DISEASE]
Mb I_DISEASE_ADJECTIVE[DISEASE]
telomeric I_DISEASE_ADJECTIVE[DISEASE]
to O
HLA B_PROTEIN[GENE]/B_LOCATION
- O
A B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Population B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
polymorphism B_GENE/B_BIO
are O
facilitated O
by O
the O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
the O
Cys282Tyr B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
creates O
a O
Rsal B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
restriction I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
site I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O

We O
have O
studied O
the O
codon B_GENE
282 I_GENE
( O
Cys B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
/ O
Tyr B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
polymorphism B_GENE
in O
different B_BIO/B_DISEASE
ethnic I_BIO/I_DISEASE
groups I_BIO/I_DISEASE
. O

In O
agreement B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
previous B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
observations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
the O
Tyr B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
allele I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
appeared O
to O
be O
rare B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
or O
absent B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
Asiatic B_NUMBER[MEASURE]/B_PERSON
( O
Indian B_PERSON/B_LOCATION
, O
Chinese B_LOCATION/B_PERSON
) O
populations B_LOCATION/B_PERSON
. O

The O
highest B_MEASURE/B_PERSON
allele I_MEASURE/I_PERSON
frequency I_MEASURE/I_PERSON
( O
7 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
) O
was O
found O
in O
Swedes B_LOCATION/B_PERSON
. O

Saamis B_PERSON/B_LOCATION
( O
2 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
Mordvinians B_PERSON/B_LOCATION
( O
1 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
had O
significantly O
lower B_MEASURE
frequencies I_MEASURE
of O
the O
Tyr B_DISEASE/B_GENE
allele I_DISEASE/I_GENE
. O

comparisons O
with O
allele O
frequencies O
based O
on O
prevalence O
estimates O
of O
HH B_DISEASE/B_GENE
showed O
some O
disagreements O
with O
the O
RFLP O
data O
, O
particularly O
in O
Finns O
. O

The O
newly O
described O
HFE O
marker O
provides O
a O
new O
approach O
to O
the O
screening O
of O
HH B_DISEASE/B_PERSON
as O
well O
as O
studies O
of O
the O
relationship O
between O
the O
HFE O
Tyr O
allele O
and O
different O
disorders O
including O
cancer B_DISEASE
. O

Autosomal B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
dominant I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
neurohypophyseal I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
diabetes I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
insipidus I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
associated O
with O
a O
missense O
mutation O
encoding O
Gly23 O
- O
- O
> O
Val O
in O
neurophysin O
II O
. O

Autosomal B_DISEASE/B_GENE
dominant I_DISEASE/I_GENE
neurohypophyseal I_DISEASE/I_GENE
diabetes I_DISEASE/I_GENE
insipidus I_DISEASE/I_GENE
( O
ADNDI B_DISEASE
) O
is O
an O
inherited B_DISEASE
disease I_DISEASE
caused O
by O
progressive O
degeneration O
of O
the O
magnocellular O
neurons O
of O
the O
hypothalamus O
leading O
to O
decreased O
ability O
to O
produce O
the O
hormone O
arginine O
vasopressin O
( O
AVP O
) O
. O

affected O
individuals O
are O
not O
symptomatic O
at O
birth O
, O
but O
usually O
develop O
diabetes B_DISEASE_ADJECTIVE[DISEASE]
insipidus I_DISEASE_ADJECTIVE[DISEASE]
at O
1 O
- O
6 O
yr O
of O
age O
. O

The O
genetic O
locus O
of O
the O
disease O
is O
the O
AVP O
- O
neurophysin O
II O
( O
NPII O
) O
gene O
, O
and O
mutations O
that O
cause O
ADNDI B_DISEASE/B_GENE
have O
been O
found O
in O
both O
the O
signal O
peptide O
of O
the O
prepro O
- O
AVP O
- O
NPII O
precursor O
and O
within O
NPII O
itself O
. O

An O
affected O
girl B_PERSON
who O
presented O
at O
9 B_TIME[MEASURE]/B_LOCATION
months I_TIME[MEASURE]/I_LOCATION
of O
age B_TIME[MEASURE]/B_PERSON
and O
her O
similarly O
affected B_PERSON/B_DISEASE
younger I_PERSON/I_DISEASE
brother I_PERSON/I_DISEASE
and O
father B_PERSON
were O
all O
found O
to O
have O
a O
novel B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
missense B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
G1758 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
- O
> B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
T I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
) O
encoding O
the O
amino B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
acid I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
substitution I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
Gly23 I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
- O
- O
> B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
Val I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
within O
NPII B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
confirmed O
by O
restriction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
endonuclease I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

A O
T1 B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
weighted O
magnetic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
fathers B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
pituitary I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
gland I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
demonstrates O
an O
attenuated B_DISEASE
posterior I_DISEASE
pituitary I_DISEASE
bright I_DISEASE
spot I_DISEASE
. O

This O
mutation O
may O
be O
valuable O
for O
developing O
models O
of O
dominantly B_DISEASE
inherited I_DISEASE
neurodegeneration I_DISEASE
, O
as O
the O
early O
age O
of O
onset O
of O
symptoms O
suggests O
that O
this O
mutation O
may O
be O
particularly O
deleterious O
to O
the O
magnocellular O
neuron O
. O
. O

frequent O
inactivation O
of O
PTEN O
/ O
MMAC1 O
in O
primary O
prostate B_DISEASE
cancer I_DISEASE
. O

Sporadic B_DISEASE
prostate I_DISEASE
carcinoma I_DISEASE
is O
the O
most O
common O
male B_DISEASE
cancer I_DISEASE
in O
the O
Western O
world O
, O
yet O
many O
of O
the O
major O
genetic O
events O
involved O
in O
the O
progression O
of O
this O
often O
fatal O
cancer B_DISEASE
remain O
to O
be O
elucidated O
. O

Numerous O
cytogenetic O
and O
allelotype O
studies O
have O
reported O
frequent O
loss O
of O
heterozygosity O
on O
chromosomal O
arm O
10q O
in O
sporadic B_DISEASE
prostate I_DISEASE
cancer I_DISEASE
. O

Deletion B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mapping I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
unambiguously O
identified O
a O
region B_LOCATION/B_MEASURE
of O
chromosome B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
10q23 I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
to O
be O
the O
minimal B_LOCATION/B_PERSON
area I_LOCATION/I_PERSON
of O
loss B_DISEASE
. O

A O
new O
tumor B_DISEASE/B_GENE
suppressor O
gene O
, O
PTEN O
/ O
MMAC1 O
, O
was O
isolated O
recently O
at O
this O
region O
of O
chromosome O
10q23 O
and O
found O
to O
be O
inactivated O
by O
mutation O
in O
three O
prostate B_DISEASE
cancer I_DISEASE
cell O
lines O
. O

We O
screened O
80 O
prostate B_DISEASE/B_PERSON
tumors I_DISEASE/I_PERSON
by O
microsatellite O
analysis O
and O
found O
chromosome O
10q23 O
to O
be O
deleted O
in O
23 O
cases O
. O

We O
then O
proceeded O
with O
sequence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
entire B_LOCATION/B_ORGANIZATION
PTEN I_LOCATION/I_ORGANIZATION
/ O
MMAC1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
coding I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
tested O
for O
homozygous B_DISEASE
deletion I_DISEASE
with O
new B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intragenic B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markers B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
these O
23 B_PERSON/B_TIME[MEASURE]
cases I_PERSON/I_TIME[MEASURE]
with O
10q23 B_DISEASE_ADJECTIVE[DISEASE]
loss I_DISEASE_ADJECTIVE[DISEASE]
of O
heterozygosity B_GENE/B_DISEASE
. O

The O
identification O
of O
the O
second O
mutational O
event O
in O
10 O
( O
43 O
% O
) O
tumors B_DISEASE/B_PERSON
establishes O
PTEN O
/ O
MMAC1 O
as O
a O
main O
inactivation O
target O
of O
10q O
loss O
in O
sporadic B_DISEASE/B_GENE
prostate I_DISEASE/I_GENE
cancer I_DISEASE/I_GENE
. O
. O

Risk O
reversals O
in O
predictive O
testing O
for O
Huntington B_DISEASE/B_GENE
disease I_DISEASE/I_GENE
. O

The O
first O
predictive O
testing O
for O
Huntington B_DISEASE
disease I_DISEASE
( O
HD B_DISEASE/B_PROTEIN[GENE]
) O
was O
based O
on O
analysis O
of O
linked O
polymorphic O
DNA O
markers O
to O
estimate O
the O
likelihood O
of O
inheriting O
the O
mutation O
for O
HD B_DISEASE/B_PROTEIN[GENE]
. O

limits B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
accuracy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O
recombination B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
between O
the O
DNA B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
markers I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
mutation B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O
pedigree B_MEASURE/B_PERSON
structure I_MEASURE/I_PERSON
, O
and O
whether O
DNA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
samples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
family B_PERSON/B_MEASURE
members I_PERSON/I_MEASURE
. O

With O
direct O
tests O
for O
the O
HD B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation O
, O
we O
have O
assessed O
the O
accuracy O
of O
results O
obtained O
by O
linkage O
approaches O
when O
requested O
to O
do O
so O
by O
the O
test O
individuals O
. O

For O
six B_PERSON/B_MEASURE
such I_PERSON/I_MEASURE
individuals I_PERSON/I_MEASURE
, O
there O
was O
significant B_DISEASE_ADJECTIVE[DISEASE]
disparity I_DISEASE_ADJECTIVE[DISEASE]
between O
the O
tests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Three B_NUMBER[MEASURE]/B_PERSON
went O
from O
a O
decreased O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
an O
increased O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
while O
in O
another O
three B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
was O
decreased O
. O

Knowledge B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
potential B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reasons B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
these O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
impact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
risk B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reversals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
both O
patients B_PERSON
and O
the O
counseling B_PERSON/B_ORGANIZATION
team I_PERSON/I_ORGANIZATION
can O
assist O
in O
the O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
strategies B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
the O
prevention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
, O
where O
necessary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
management B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O
a O
risk B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reversal I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
any O
predictive B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testing I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
program I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
. O

A O
novel O
common O
missense O
mutation O
G301C O
in O
the O
N O
- O
acetylgalactosamine O
- O
6 O
- O
sulfate O
sulfatase O
gene O
in O
mucopolysaccharidosis B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
IVA B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

Mucopolysaccharidosis B_DISEASE/B_PROTEIN[GENE]
IVA B_DISEASE/I_PROTEIN[GENE]
( O
MPS B_LOCATION/B_PERSON
IVA I_LOCATION/I_PERSON
) O
is O
an O
autosomal B_DISEASE/B_GENE
recessive I_DISEASE/I_GENE
lysosomal I_DISEASE/I_GENE
storage I_DISEASE/I_GENE
disorder I_DISEASE/I_GENE
caused O
by O
a O
genetic B_DISEASE_ADJECTIVE[DISEASE]
defect I_DISEASE_ADJECTIVE[DISEASE]
in O
N O
- O
acetylgalactosamine O
- O
6 O
- O
sulfate O
sulfatase O
( O
GALNS O
) O
. O

In O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
we O
have O
found O
two B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
common I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
Caucasians B_PERSON/B_LOCATION
and O
Japanese B_LOCATION/B_PERSON
, O
respectively O
. O

To O
characterize O
the O
mutational O
spectrum O
in O
various O
ethnic O
groups O
, O
mutations O
in O
the O
GALNS O
gene O
in O
Colombian O
MPS B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IVA I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O
were O
investigated O
, O
and O
genetic O
backgrounds O
were O
extensively O
analyzed O
to O
identify O
racial O
origin O
, O
based O
on O
mitochondrial O
DNA O
( O
mtDNA O
) O
lineages O
. O

Three O
novel O
missense O
mutations O
never O
identified O
previously O
in O
other O
populations O
and O
found O
in O
16 O
out O
of O
19 O
Colombian O
MPS B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
IVA I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
unrelated O
alleles O
account O
for O
84 O
. O

2 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
the O
alleles B_PERSON/B_LOCATION
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

The O
G301C B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
S162F B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mutations I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
account O
for O
68 B_NUMBER[MEASURE]/B_PERSON
. O

4 B_SEQUENCE[MEASURE]/B_PERSON
% I_SEQUENCE[MEASURE]/I_PERSON
and O
10 B_MEASURE/B_LOCATION
. O

5 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
mutations B_PERSON/B_LOCATION
, O
respectively O
, O
whereas O
the O
remaining O
F69V B_MEASURE
is O
limited O
to O
a O
single B_SEQUENCE[MEASURE]/B_PERSON
allele I_SEQUENCE[MEASURE]/I_PERSON
. O

The O
skewed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevalence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
G301C B_DISEASE/B_GENE
in O
only B_PERSON/B_BIO
Colombian B_PERSON/I_BIO
patients B_PERSON/I_BIO
and O
haplotype B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
restriction B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
fragment B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
length B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
polymorphisms B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
GALNS B_PERSON/B_BIO
gene I_PERSON/I_BIO
suggest O
that O
G301C B_DISEASE/B_PERSON
originated O
from O
a O
common B_BIO/B_GENE
ancestor B_BIO/I_GENE
. O

Investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
background I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
by O
means B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
mtDNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lineages I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicate O
that O
all O
our O
patients B_PERSON/B_BIO
are O
probably O
of O
native B_DISEASE/B_GENE
American B_DISEASE/I_GENE
descent B_DISEASE/I_GENE
. O

Low O
frequency O
of O
BRCA1 O
germline O
mutations O
in O
45 O
German O
breast B_DISEASE/B_PERSON
/ I_DISEASE/I_PERSON
ovarian I_DISEASE/I_PERSON
cancer I_DISEASE/I_PERSON
families O
. O

In O
this O
study O
we O
investigated O
45 O
German O
breast B_DISEASE
/ I_DISEASE
ovarian I_DISEASE
cancer I_DISEASE
families O
for O
germline O
mutations O
in O
the O
BRCA1 O
gene O
. O

We O
identified O
four O
germline O
mutations O
in O
three O
breast B_DISEASE/B_PERSON
cancer I_DISEASE/I_PERSON
families O
and O
in O
one O
breast B_DISEASE
- I_DISEASE
ovarian I_DISEASE
cancer I_DISEASE
family O
. O
among O
these O
were O
one O
frameshift O
mutation O
, O
one O
nonsense O
mutation O
, O
one O
novel O
splice O
site O
mutation O
, O
and O
one O
missense O
mutation O
. O

The O
missense B_DISEASE_ADJECTIVE[DISEASE]
mutation I_DISEASE_ADJECTIVE[DISEASE]
was O
also O
found O
in O
2 B_NUMBER[MEASURE]/B_BIO
. O

8 B_LOCATION/B_PERSON
% I_LOCATION/I_PERSON
of O
the O
general B_PERSON/B_MEASURE
population I_PERSON/I_MEASURE
, O
suggesting O
that O
it O
is O
not O
disease B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
associated O
. O

The O
average B_MEASURE
age I_MEASURE
of O
disease B_PERSON
onset I_PERSON
in O
those O
families B_PERSON/B_SOCIAL_CIRCUMSTANCES
harbouring O
causative B_DISEASE/B_GENE
mutations I_DISEASE/I_GENE
was O
between O
32 B_NUMBER[MEASURE]/B_PERSON
. O

3 B_MEASURE
and O
37 B_NUMBER[MEASURE]/B_LOCATION
. O

4 B_MEASURE/B_LOCATION
years I_MEASURE/I_LOCATION
, O
whereas O
the O
family B_PERSON
harbouring O
the O
missense B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutation I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
had O
an O
average B_TIME[MEASURE]/B_PERSON
age I_TIME[MEASURE]/I_PERSON
of O
onset B_TIME[MEASURE]/B_PERSON
of O
51 B_TIME[MEASURE]/B_DISEASE
. O

2 B_ENT/B_TIME[MEASURE]
years I_ENT/I_TIME[MEASURE]
. O

These O
findings O
show O
that O
BRCA1 O
is O
implicated O
in O
a O
small O
fraction O
of O
breast B_DISEASE/B_GENE
/ I_DISEASE/I_GENE
ovarian I_DISEASE/I_GENE
cancer I_DISEASE/I_GENE
families O
suggesting O
the O
involvement O
of O
another O
susceptibility O
gene O
( O
s O
) O
. O

paternal O
transmission O
of O
congenital B_DISEASE
myotonic I_DISEASE
dystrophy I_DISEASE
. O

We O
report O
a O
rare O
case O
of O
paternally O
transmitted O
congenital B_DISEASE
myotonic I_DISEASE
dystrophy I_DISEASE
( O
DM B_DISEASE/B_GENE
) O
. O

The O
proband O
is O
a O
23 O
year O
old O
, O
mentally B_PERSON/B_DISEASE
retarded I_PERSON/I_DISEASE
male O
who O
suffers O
severe O
muscular B_DISEASE
weakness I_DISEASE
. O

He O
presented O
with O
respiratory B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
feeding B_DISEASE
difficulties I_DISEASE
at O
birth B_TIME[MEASURE]/B_PERSON
. O

His O
two O
sibs O
suffer O
from O
childhood O
onset O
DM B_DISEASE
. O

Their O
late O
father O
had O
the O
adult O
type O
of O
DM B_DISEASE/B_GENE
, O
with O
onset O
around O
30 O
years O
. O

Only O
six O
other O
cases O
of O
paternal O
transmission O
of O
congenital B_DISEASE
DM I_DISEASE
have O
been O
reported O
recently O
. O

We O
review O
the O
sex O
related O
effects O
on O
transmission O
of O
congenital B_DISEASE
DM I_DISEASE
. O

decreased O
fertility O
of O
males O
with O
adult O
onset O
DM B_DISEASE/B_GENE
and O
contraction O
of O
the O
repeat O
upon O
male O
transmission O
contribute O
to O
the O
almost O
absent O
occurrence O
of O
paternal O
transmission O
of O
congenital B_DISEASE/B_GENE
DM I_DISEASE/I_GENE
. O

Also O
the O
fathers O
of O
the O
reported O
congenitally O
affected O
children O
showed O
, O
on O
average O
, O
shorter O
CTG O
repeat O
lengths O
and O
hence O
less O
severe O
clinical O
symptoms O
than O
the O
mothers O
of O
children O
with O
congenital B_DISEASE/B_PERSON
DM I_DISEASE/I_PERSON
. O

We O
conclude O
that O
paternal O
transmission O
of O
congenital B_DISEASE
DM I_DISEASE
is O
rare O
and O
preferentially O
occurs O
with O
onset O
of O
DM B_DISEASE
past O
30 O
years O
in O
the O
father O
. O
. O

The O
RB1 O
gene O
mutation O
in O
a O
child O
with O
ectopic B_DISEASE
intracranial I_DISEASE
retinoblastoma I_DISEASE
. O

The O
RB1 O
gene O
mutation O
was O
investigated O
in O
a O
child O
with O
ectopic B_DISEASE
intracranial I_DISEASE
retinoblastoma I_DISEASE
using O
DNA O
obtained O
from O
both O
the O
pineal B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
and I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
retinal I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
tumours I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
of O
the O
patient O
. O

A O
nonsense O
mutation O
in O
exon O
17 O
( O
codon O
556 O
) O
of O
the O
RB1 O
gene O
was O
found O
to O
be O
present O
homozygously O
in O
both O
the O
retinal B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
the I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
pineal I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
tumours I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

The O
same B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
was O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
heterozygously O
in O
the O
DNA B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
from O
the O
constitutional B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
patient B_PERSON/B_BIO
, O
proving O
it O
to O
be O
of O
germline B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
origin I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

The O
initial B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
was O
shown O
to O
have O
occurred O
in O
the O
paternally O
derived O
RB1 B_GENE/B_PERSON
allele I_GENE/I_PERSON
. O

The O
mutation O
is O
in O
an O
area O
of O
the O
gene O
that O
encodes O
the O
protein O
- O
binding O
region O
known O
as O
the O
pocket O
region O
and O
has O
been O
detected O
in O
other O
cases O
of O
retinoblastoma B_DISEASE
. O
. O

Low B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
beta B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
hexosaminidase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
A I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
healthy B_PERSON/B_ORGANIZATION
individuals I_PERSON/I_ORGANIZATION
with O
apparent B_DISEASE_ADJECTIVE[DISEASE]
deficiency I_DISEASE_ADJECTIVE[DISEASE]
of O
this O
enzyme B_ENZYME[GENE]
. O

Appreciable O
beta O
hexosaminidase O
A O
( O
hex O
A O
) O
activity O
has O
been O
detected O
in O
cultured O
skin O
fibroblasts O
and O
melanoma B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissue O
from O
healthy O
individuals O
previously O
reported O
as O
having O
deficiency B_ENZYME[GENE]/B_DISEASE
of I_ENZYME[GENE]/I_DISEASE
hex I_ENZYME[GENE]/I_DISEASE
A I_ENZYME[GENE]/I_DISEASE
activity O
indistinguishable O
from O
that O
of O
patients O
with O
Tay B_DISEASE
- I_DISEASE
Sachs I_DISEASE
disease I_DISEASE
( O
TSD B_MEASURE/B_DISEASE
) O
. O

Identification B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
quantitation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SPECIES[BIO]
, O
amounting O
to O
3 B_NUMBER[MEASURE]
. O

5 B_MEASURE
% I_MEASURE
- O
6 B_MEASURE
. O

9 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
total B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hexosaminidase B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
has O
been O
obtained O
by O
cellulose B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gel I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
electrophoresis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
DEAE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
cellulose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
exchange B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chromatography I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
radial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunodiffusion I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
radioimmunoassay B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Previous O
family O
studies O
suggested O
that O
these O
individuals O
may O
be O
compound O
heterozygotes O
for O
the O
common O
mutant O
TSD B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O
and O
a O
rare O
( O
allelic O
) O
mutant O
gene O
. O

Thus O
, O
the O
postulated B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
rate I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutant I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
appears O
to O
code O
for O
the O
expression B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
of O
low B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
amounts B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O
hex B_GENE/B_SPECIES[BIO]
A I_GENE/I_SPECIES[BIO]
. O

Heterozygotes O
for O
the O
rare O
mutant O
may O
be O
indistinguishable O
from O
heterozygotes O
for O
the O
common O
TSD B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutant O
. O

However O
, O
direct O
visualization O
and O
quantitation O
of O
hex O
A O
by O
the O
methods O
described O
may O
prevent O
false O
- O
positive O
prenatal O
diagnosis O
of O
TSD B_DISEASE
in O
fetuses O
having O
the O
incomplete O
hex B_DISEASE/B_GENE
A I_DISEASE/I_GENE
deficiency I_DISEASE/I_GENE
of O
the O
type O
described O
in O
the O
four O
healthy O
individuals O
. O

The O
tumor B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
suppressor O
gene O
Smad4 O
/ O
Dpc4 O
is O
required O
for O
gastrulation O
and O
later O
for O
anterior O
development O
of O
the O
mouse O
embryo O
. O

mutations O
in O
the O
SMAD4 O
/ O
DPC4 O
tumor B_DISEASE/B_GENE
suppressor O
gene O
, O
a O
key O
signal O
transducer O
in O
most O
TGFbeta O
- O
related O
pathways O
, O
are O
involved O
in O
50 O
% O
of O
pancreatic B_DISEASE/B_PERSON
cancers I_DISEASE/I_PERSON
. O

Homozygous B_PERSON
Smad4 I_PERSON
mutant I_PERSON
mice I_PERSON
die O
before O
day B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
7 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O

5 B_TIME[MEASURE]/B_EDU[ORGANIZATION]
of O
embryogenesis B_LOCATION/B_PERSON
. O

mutant B_PERSON
embryos I_PERSON
have O
reduced O
size B_DISEASE/B_ORGANISM_FUNCTION
, O
fail O
to O
gastrulate O
or O
express O
a O
mesodermal B_GENE/B_BODY_PART_OR_ORGAN_COMPONENT
marker I_GENE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
show O
abnormal B_DISEASE_ADJECTIVE[DISEASE]
visceral I_DISEASE_ADJECTIVE[DISEASE]
endoderm I_DISEASE_ADJECTIVE[DISEASE]
development I_DISEASE_ADJECTIVE[DISEASE]
. O

Growth B_DISEASE_ADJECTIVE[DISEASE]
retardation I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
Smad4 O
- O
deficient O
embryos O
results O
from O
reduced O
cell O
proliferation O
rather O
than O
increased O
apoptosis O
. O

Aggregation O
of O
mutant O
Smad4 O
es O
cells O
with O
wild O
- O
type O
tetraploid O
morulae O
rescues O
the O
gastrulation B_DISEASE_ADJECTIVE[DISEASE]
defect I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
results O
indicate O
that O
Smad4 O
is O
initially O
required O
for O
the O
differentiation O
of O
the O
visceral O
endoderm O
and O
that O
the O
gastrulation B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defect B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
epiblast O
is O
secondary O
and O
non O
- O
cell O
autonomous O
. O

rescued O
embryos B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
show O
severe B_DISEASE/B_GENE
anterior I_DISEASE/I_GENE
truncations I_DISEASE/I_GENE
, O
indicating O
a O
second B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
important I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
Smad4 B_GENE
in O
anterior B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
patterning I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
during O
embryogenesis B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

prevalence O
of O
p16 O
and O
CDK4 O
germline O
mutations O
in O
48 O
melanoma B_DISEASE
- O
prone O
families O
in O
France O
. O

The O
French O
Familial B_DISEASE/B_LOCATION
Melanoma I_DISEASE/I_LOCATION
Study O
Group O
. O

Germline O
mutations O
in O
the O
p16 O
and O
CDK4 O
genes O
have O
been O
reported O
in O
a O
subset O
of O
melanoma B_DISEASE/B_LOCATION
pedigrees O
, O
but O
their O
prevalence O
is O
not O
well O
known O
. O

We O
searched O
for O
such O
germline O
mutations O
in O
48 O
French O
melanoma B_DISEASE/B_LOCATION
- O
prone O
families O
selected O
according O
to O
two O
major O
criteria O
families O
with O
at O
least O
three O
affected O
members O
( O
n O
= O
20 O
) O
or O
families O
with O
two O
affected O
members O
, O
one O
of O
them O
affected O
before O
the O
age O
of O
50 O
( O
n O
= O
28 O
) O
, O
and O
one O
additional O
minor O
criterion O
. O

Sixteen B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
different I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
p16 I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
germline I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O
found O
in O
21 B_DISEASE/B_PERSON
families I_DISEASE/I_PERSON
, O
while O
one B_SEQUENCE[MEASURE]/B_PERSON
germline I_SEQUENCE[MEASURE]/I_PERSON
mutation I_SEQUENCE[MEASURE]/I_PERSON
, O
Arg24His B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
was O
detected O
in O
the O
CDK4 B_PERSON/B_MEASURE
gene I_PERSON/I_MEASURE
. O

The O
frequency B_MEASURE
of O
p16 B_DISEASE/B_GENE
gene I_DISEASE/I_GENE
mutation I_DISEASE/I_GENE
in O
our O
sample B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
44 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
is O
among O
the O
highest B_MEASURE
rates I_MEASURE
yet O
reported O
and O
the O
CDK4 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
is O
the O
second B_SEQUENCE[MEASURE]
mutation I_SEQUENCE[MEASURE]
detected O
in O
this O
gene B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
worldwide I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

In O
summary O
, O
our O
results O
show O
frequent O
involvement O
of O
the O
p16 O
gene O
in O
familial B_DISEASE
melanoma I_DISEASE
and O
confirm O
the O
role O
of O
the O
CDK4 O
gene O
as O
a O
melanoma B_DISEASE
- O
predisposing O
gene O
. O
. O

progression O
of O
somatic O
CTG O
repeat O
length O
heterogeneity O
in O
the O
blood O
cells O
of O
myotonic B_DISEASE/B_LOCATION
dystrophy I_DISEASE/I_LOCATION
patients O
. O

The O
genetic O
basis O
of O
myotonic B_DISEASE/B_GENE
dystrophy I_DISEASE/I_GENE
( O
DM B_LOCATION
) O
is O
the O
expansion O
of O
an O
unstable O
CTG O
repeat O
in O
the O
34 O
UTR O
of O
the O
DM B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protein O
kinase O
gene O
on O
chromosome O
19 O
. O

One O
of O
the O
principal O
features O
of O
the O
DM B_DISEASE/B_GENE
mutation O
is O
an O
extraordinarily O
high O
level O
of O
somatic O
mosaicism O
, O
due O
to O
an O
extremely O
high O
degree O
of O
somatic O
instability O
both O
within O
and O
between O
different O
tissues O
. O

This O
instability B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O
to O
be O
biased O
towards O
further B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
expansion I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
continuous B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
throughout O
the O
life B_TIME[MEASURE]/B_LOCATION
of O
an O
individual B_PERSON/B_DISEASE
, O
features O
that O
could O
be O
associated O
with O
the O
progressive B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
nature I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
of O
the O
disease B_DISEASE
. O

Although O
increasing O
measured O
allele B_MEASURE
size I_MEASURE
between O
patients B_PERSON/B_BIO
clearly O
correlates O
with O
an O
increased O
severity B_MEASURE/B_LOCATION
of O
symptoms B_DISEASE
and O
an O
earlier B_TIME[MEASURE]/B_DISEASE
age I_TIME[MEASURE]/I_DISEASE
of O
onset B_DISEASE
, O
this O
correlation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
not O
precise B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
measured B_MEASURE/B_LOCATION
allele I_MEASURE/I_LOCATION
length I_MEASURE/I_LOCATION
cannot I_MEASURE/I_LOCATION
be O
used O
as O
an O
accurate B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predictor B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
age B_TIME[MEASURE]
of O
onset B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
order O
to O
further O
characterize O
the O
dynamics O
of O
DM B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
CTG O
repeat O
somatic O
instability O
, O
we O
have O
studied O
repeat O
length O
changes O
over O
time O
in O
111 O
myotonic B_DISEASE
dystrophy I_DISEASE
patients O
with O
varying O
clinical O
severity O
and O
CTG O
repeat O
size O
over O
time O
intervals O
of O
1 O
- O
7 O
years O
. O

We O
have O
found O
a O
direct B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
progression I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
size B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
heterogeneity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
over O
time B_TIME[MEASURE]/B_LOCATION
related O
to O
initial B_MEASURE/B_LOCATION
CTG I_MEASURE/I_LOCATION
repeat I_MEASURE/I_LOCATION
size I_MEASURE/I_LOCATION
and O
the O
time B_MEASURE
interval I_MEASURE
and O
always O
biased O
towards O
further B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
expansion I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

attempts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
mathematically O
model O
the O
dynamics B_DISEASE/B_EDU[ORGANIZATION]
have O
proved O
only O
partially O
successful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggesting O
that O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
/ O
or O
environmental B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
factors B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
also O
play O
a O
role B_MEASURE/B_PERSON
in O
somatic B_DISEASE/B_EDU[ORGANIZATION]
mosaicism I_DISEASE/I_EDU[ORGANIZATION]
. O
. O

Aspartylglucosaminuria B_DISEASE
among O
Palestinian O
Arabs O
. O

Aspartylglucosaminuria B_DISEASE
( O
AGU B_LOCATION/B_ORGANIZATION
) O
is O
a O
rare O
disorder B_DISEASE_ADJECTIVE[DISEASE]
of I_DISEASE_ADJECTIVE[DISEASE]
glycoprotein I_DISEASE_ADJECTIVE[DISEASE]
metabolism I_DISEASE_ADJECTIVE[DISEASE]
caused O
by O
the O
deficiency B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
of I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
the I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
lysosomal I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
enzyme I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
aspartylglucosaminidase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
AGA O
) O
. O

AGU B_DISEASE
is O
inherited O
as O
an O
autosomal O
recessive O
trait O
and O
occurs O
with O
a O
high O
frequency O
in O
Finland O
because O
of O
a O
founder O
effect O
. O

While O
very O
few O
patients O
with O
AGU B_DISEASE/B_LOCATION
have O
been O
reported O
from O
non O
- O
Finnish O
origin O
, O
we O
diagnosed O
the O
disorder O
in O
8 O
patients O
originating O
from O
3 O
unrelated O
families O
, O
all O
Palestinian O
Arabs O
from O
the O
region O
of O
Jerusalem O
. O

The O
clinical O
diagnosis O
of O
AGU B_DISEASE/B_LOCATION
is O
often O
difficult O
, O
in O
particular O
early O
in O
the O
course O
of O
the O
disease O
, O
and O
most O
of O
the O
patients O
are O
diagnosed O
after O
the O
age O
of O
5 O
years O
. O

However O
, O
since O
these O
patients B_PERSON/B_BIO
excrete O
early B_DISEASE_ADJECTIVE[DISEASE]/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
large B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amounts B_DISEASE_ADJECTIVE[DISEASE]/I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
aspartylglucosamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
urine B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
screening I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
easy B_DISEASE_ADJECTIVE[DISEASE]
by O
urine B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chromatography I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
. O

detection O
of O
heterozygous O
carriers O
of O
the O
ataxia B_DISEASE/B_GENE
- B_DISEASE/I_GENE
telangiectasia B_DISEASE/I_GENE
( O
ATM O
) O
gene O
by O
G2 O
phase O
chromosomal O
radiosensitivity O
of O
peripheral O
blood O
lymphocytes O
. O

In O
ataxia B_DISEASE/B_GENE
- B_DISEASE/I_GENE
telangiectasia B_DISEASE/I_GENE
( O
A B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
patients O
, O
mutations O
in O
a O
single O
gene O
, O
ATM O
, O
result O
in O
an O
autosomal B_DISEASE/B_GENE
recessive I_DISEASE/I_GENE
syndrome I_DISEASE/I_GENE
that O
embraces O
a O
variety O
of O
clinical O
features O
and O
manifests O
extreme O
radiosensitivity O
and O
a O
strong O
pre O
- O
disposition O
to O
malignancy B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Heterozygotes O
for O
the O
ATM O
gene O
have O
no O
clinical O
expression O
of O
A B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
may O
be O
cancer B_DISEASE/B_GENE
prone O
with O
a O
moderate O
increase O
in O
in O
vitro O
radiosensitivity O
. O

We O
performed O
a O
blind O
chromosomal O
analysis O
on O
G2 O
- O
phase O
lymphocytes O
from O
7 O
unrelated O
A B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O
, O
13 O
obligate O
A B_GENE/B_PERSON
- I_GENE/I_PERSON
T I_GENE/I_PERSON
heterozygotes O
( O
parents O
of O
the O
patients O
) O
, O
and O
14 O
normal O
controls O
following O
X O
- O
irradiation O
with O
1 O
Gy O
in O
order O
to O
evaluate O
this O
cytogenetic O
method O
as O
a O
tool O
for O
detection O
of O
ATM O
carriers O
. O

Both O
A B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homozygotes O
and O
heterozygotes O
showed O
significantly O
increased O
levels O
of O
radiation O
- O
induced O
chromatid O
damage O
relative O
to O
that O
of O
normal O
controls O
. O

These O
results O
show O
that O
the O
G2 O
- O
phase O
chromosomal O
radiosensitivity O
assay O
can O
be O
used O
for O
the O
detection O
of O
A B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heterozygotes O
. O

In O
combination O
with O
molecular O
genetic O
analyses O
, O
this O
test O
may O
be O
of O
value O
in O
studies O
of O
familial B_DISEASE/B_LOCATION
and I_DISEASE/I_LOCATION
sporadic I_DISEASE/I_LOCATION
cancers I_DISEASE/I_LOCATION
aimed O
at O
determination O
of O
the O
potential O
involvement O
of O
ATM O
mutations O
in O
tumor B_DISEASE/B_LOCATION
risk O
or O
development O
. O
. O

Ataxia B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
telangiectasia B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
identification O
and O
detection O
of O
founder O
- O
effect O
mutations O
in O
the O
ATM O
gene O
in O
ethnic O
populations O
. O

To O
facilitate O
the O
evaluation O
of O
ATM O
heterozygotes O
for O
susceptibility O
to O
other O
diseases O
, O
such O
as O
breast B_DISEASE
cancer I_DISEASE
, O
we O
have O
attempted O
to O
define O
the O
most O
common O
mutations O
and O
their O
frequencies O
in O
ataxia B_DISEASE/B_GENE
- B_DISEASE/I_GENE
telangiectasia B_DISEASE/I_GENE
( O
A B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
homozygotes O
from O
10 O
ethnic O
populations O
. O

Both O
genomic B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mutations I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
their O
effects B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O
cDNA B_GENE/B_DISEASE
were O
characterized O
. O

Protein B_GENE/B_MEASURE
- O
truncation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
testing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
entire B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ATM I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detected O
92 B_MEASURE
( O
66 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
truncating O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O
140 B_GENE/B_BIO
mutant I_GENE/I_BIO
alleles I_GENE/I_BIO
screened O
. O

The O
haplotyping B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
patients B_PERSON/B_BIO
with O
identical B_DISEASE/B_GENE
mutations I_DISEASE/I_GENE
indicates O
that O
almost O
all O
of O
these O
represent B_PERSON/B_MEASURE
common I_PERSON/I_MEASURE
ancestry I_PERSON/I_MEASURE
and O
that O
very O
few B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spontaneously O
recurring O
ATM B_DISEASE/B_GENE
mutations I_DISEASE/I_GENE
exist O
. O

assays B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
requiring O
minimal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amounts I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
genomic B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
designed O
to O
allow O
rapid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
screening I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
common B_DISEASE_ADJECTIVE[DISEASE]
ethnic I_DISEASE_ADJECTIVE[DISEASE]
mutations I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
rapid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assays I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
detected O
mutations B_DISEASE
in O
76 B_PERSON/B_MEASURE
% B_PERSON/I_MEASURE
of O
Costa B_PERSON/B_LOCATION
Rican I_PERSON/I_LOCATION
patients I_PERSON/I_LOCATION
( O
3 B_MEASURE
) O
, O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
Norwegian B_PERSON/B_LOCATION
patients I_PERSON/I_LOCATION
( O
1 B_MEASURE
) O
, O
25 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
Polish B_PERSON/B_LOCATION
patients I_PERSON/I_LOCATION
( O
4 B_NUMBER[MEASURE]
) O
, O
and O
14 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
Italian B_PERSON/B_LOCATION
patients I_PERSON/I_LOCATION
( O
1 B_MEASURE
) O
, O
as O
well O
as O
in O
patients B_PERSON/B_LOCATION
of O
Amish B_PERSON/B_LOCATION
/ O
Mennonite B_LOCATION/B_PERSON
and O
Irish B_PERSON/B_LOCATION
English I_PERSON/I_LOCATION
backgrounds I_PERSON/I_LOCATION
. O

Additional B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O
observed O
in O
Japanese B_LOCATION/B_PERSON
, O
Utah B_PERSON/B_LOCATION
Mormon I_PERSON/I_LOCATION
, O
and O
African B_PERSON/B_LOCATION
American B_PERSON/I_LOCATION
patients B_PERSON/I_LOCATION
. O

These O
assays O
should O
facilitate O
screening O
for O
A B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heterozygotes O
in O
the O
populations O
studied O
. O
. O

The O
von B_DISEASE/B_GENE
Hippel I_DISEASE/I_GENE
- I_DISEASE/I_GENE
Lindau I_DISEASE/I_GENE
tumor I_DISEASE/I_GENE
suppressor O
gene O
is O
required O
for O
cell O
cycle O
exit O
upon O
serum O
withdrawal O
. O

The O
inactivation O
of O
the O
von B_DISEASE/B_GENE
Hippel I_DISEASE/I_GENE
- I_DISEASE/I_GENE
Lindau I_DISEASE/I_GENE
( I_DISEASE/I_GENE
VHL I_DISEASE/I_GENE
) I_DISEASE/I_GENE
tumor I_DISEASE/I_GENE
suppressor O
gene O
predisposes O
affected O
individuals O
to O
the O
human O
VHL B_DISEASE/B_GENE
cancer I_DISEASE/I_GENE
syndrome I_DISEASE/I_GENE
and O
is O
associated O
with O
sporadic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
renal I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cell I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
carcinomas I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
RCC B_LOCATION/B_ORGANIZATION
) O
and O
brain B_DISEASE
hemangioblastomas I_DISEASE
. O

VHL O
- O
negative O
786 O
- O
0 O
RCC B_DISEASE
cells O
are O
tumorigenic O
in O
nude O
mice O
which O
is O
suppressed O
by O
the O
reintroduction O
of O
VHL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

remarkably O
, O
this O
occurs O
without O
affecting O
the O
growth B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
rate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
cell B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cycle B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
profile B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
these O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
in O
culture B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
786 O
- O
0 O
cell O
line O
, O
like O
many O
cancer B_DISEASE
cells O
, O
fails O
to O
exit O
the O
cell O
cycle O
upon O
serum O
withdrawal O
. O

Here O
, O
it O
is O
shown O
that O
reintroduction O
of O
the O
wild O
- O
type O
VHL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O
restores O
the O
ability O
of O
VHL O
- O
negative O
RCC B_DISEASE
cancer I_DISEASE
cells O
to O
exit O
the O
cell O
cycle O
and O
enter O
G0 O
/ O
quiescence O
in O
low O
serum O
. O

Both O
VHL O
- O
positive O
and O
VHL O
- O
negative O
RCC B_DISEASE
cells O
exit O
the O
cell O
cycle O
by O
contact O
inhibition O
. O

The O
cyclin O
- O
dependent O
kinase O
inhibitor O
, O
p27 O
, O
accumulates O
upon O
serum O
withdrawal O
, O
only O
in O
the O
presence O
of O
VHL B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
a O
result O
of O
the O
stabilization O
of O
the O
protein O
. O

We O
propose O
that O
the O
loss O
of O
wild O
- O
type O
VHL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O
results O
in O
a O
specific O
cellular O
defect O
in O
serum O
- O
dependent O
growth O
control O
, O
which O
may O
initiate O
tumor B_DISEASE
formation O
. O

This O
is O
corrected O
by O
the O
reintroduction O
of O
wild O
- O
type O
VHL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
implicating O
VHL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
as O
the O
first O
tumor B_DISEASE/B_GENE
suppressor O
involved O
in O
the O
regulation O
of O
cell O
cycle O
exit O
, O
which O
is O
consistent O
with O
its O
gatekeeper O
function O
in O
the O
kidney O
. O
. O

Piebaldism B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
with O
deafness B_DISEASE
: O
molecular O
evidence O
for O
an O
expanded O
syndrome O
. O

In O
a O
South O
African O
girl O
of O
Xhosa O
stock O
with O
severe O
piebaldism B_DISEASE
and O
profound O
congenital O
sensorineural B_DISEASE
deafness I_DISEASE
we O
identified O
a O
novel O
missense O
substitution O
at O
a O
highly O
conserved O
residue O
in O
the O
intracellular O
kinase O
domain O
of O
the O
Kit O
Proto O
- O
oncogene O
, O
R796G O
. O

Though O
auditory B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anomalies I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
observed O
in O
mice O
with O
dominant O
white O
spotting O
( O
W O
) O
due O
to O
Kit O
mutations O
, O
deafness B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
typical O
in O
human O
piebaldism B_DISEASE/B_PERSON
. O

Thus O
, O
the O
occurrence O
of O
sensorineural B_DISEASE/B_GENE
deafness I_DISEASE/I_GENE
in O
this O
patient O
extends O
considerably O
the O
phenotypic O
range O
of O
piebaldism B_DISEASE/B_MEASURE
due O
to O
Kit O
gene O
mutation O
in O
humans O
and O
tightens O
the O
clinical O
similarity O
between O
piebaldism B_DISEASE/B_PERSON
and O
the O
various O
forms O
of O
Waardenburg B_DISEASE/B_GENE
syndrome I_DISEASE/I_GENE
. O
. O

Cycloheximide O
facilitates O
the O
identification O
of O
aberrant O
transcripts O
resulting O
from O
a O
novel O
splice O
- O
site O
mutation O
in O
COL17A1 O
in O
a O
patient O
with O
generalized O
atrophic B_DISEASE
benign I_DISEASE
epidermolysis I_DISEASE
bullosa I_DISEASE
. O

patients O
with O
generalized O
atrophic B_DISEASE
benign I_DISEASE
epidermolysis I_DISEASE
bullosa I_DISEASE
often O
show O
decreased O
expression O
of O
type O
XVII O
collagen O
, O
a O
transmembrane O
hemidesmosomal O
protein O
encoded O
by O
COL17A1 O
. O

This O
report O
documents O
a O
novel O
splice O
- O
site O
mutation O
in O
COL17A1 O
in O
a O
patient O
with O
generalized O
atrophic B_DISEASE
benign I_DISEASE
epidermolysis I_DISEASE
bullosa I_DISEASE
, O
and O
applies O
a O
new O
methodology O
to O
define O
and O
characterize O
the O
resulting O
mRNA O
splice O
variants O
. O

mutational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
COL17A1 B_GENE/B_BIO
identified O
a O
maternally O
inherited O
G B_PROTEIN[GENE]/B_LOCATION
- O
to O
- O
T B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
transversion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
at O
the O
- O
1 B_LOCATION/B_MEASURE
position I_LOCATION/I_MEASURE
of O
exon B_GENE
32 I_GENE
. O

This O
acceptor B_NUMBER[MEASURE]/B_GENE
splice I_NUMBER[MEASURE]/I_GENE
- O
site B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
led O
to O
the O
formation B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
aberrant B_GENE/B_DISEASE
transcripts I_GENE/I_DISEASE
present I_GENE/I_DISEASE
at O
extremely O
low B_MEASURE/B_LOCATION
levels I_MEASURE/I_LOCATION
. O

Based O
on O
our O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
finding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
cycloheximide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
stabilized O
mutant B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
COL17A1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
keratinocytes B_BIO/B_PERSON
homozygous I_BIO/I_PERSON
for O
a O
frameshift B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
, O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
splice B_GENE/B_MEASURE
- O
site B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
on O
splicing B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
COL17A1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
determined O
using O
reverse B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transcriptase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
polymerase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
chain I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
total B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
from O
keratinocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
incubated O
for O
2 B_TIME[MEASURE]/B_BIO
. O

5 B_MEASURE
h O
in O
the O
presence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
or O
absence B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycloheximide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
per O
ml B_TIME[MEASURE]/B_PERSON
. O

Using O
this O
approach B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
an O
abnormally O
spliced O
transcript B_GENE/B_LOCATION
was O
identified O
that O
contains O
an O
extra B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
264 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
bases B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
upstream O
from O
exon B_GENE
32 I_GENE
, O
resulting O
in O
a O
premature B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
termination B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
codon B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
27 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
bp B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
downstream B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
from O
the O
cryptic B_GENE/B_TIME[MEASURE]
splice I_GENE/I_TIME[MEASURE]
site I_GENE/I_TIME[MEASURE]
. O

Three B_NUMBER[MEASURE]/B_PERSON
other I_NUMBER[MEASURE]/I_PERSON
splice I_NUMBER[MEASURE]/I_PERSON
variants I_NUMBER[MEASURE]/I_PERSON
, O
including O
one B_NUMBER[MEASURE]/B_PERSON
derived O
from O
the O
skipping B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
exon B_GENE
32 I_GENE
, O
were O
also O
identified O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O
the O
usefulness B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
cycloheximide B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
evaluating O
the O
abnormal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processing B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
mRNA B_GENE
due O
to O
splice B_MEASURE/B_GENE
- O
site B_DISEASE_ADJECTIVE[DISEASE]
mutations I_DISEASE_ADJECTIVE[DISEASE]
, O
because O
( O
i O
) O
aberrant B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
splicing B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
often O
generates O
a O
premature B_GENE/B_DISEASE
termination I_GENE/I_DISEASE
codon I_GENE/I_DISEASE
, O
( O
ii B_TIME[MEASURE]/B_PROTEIN[GENE]
) O
transcripts B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O
premature B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
termination I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
codons I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
can O
occur O
at O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
undetectable B_MEASURE
levels I_MEASURE
due O
to O
nonsense B_GENE
- O
mediated O
mRNA B_DISEASE/B_GENE
decay I_DISEASE/I_GENE
, O
and O
( O
III B_NUMBER[MEASURE]/B_PROTEIN[GENE]
) O
the O
levels B_MEASURE/B_GENE
of O
these O
transcripts B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
can O
be O
increased O
by O
cycloheximide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

A O
deletion O
mutation O
in O
COL17A1 O
in O
five O
Austrian O
families O
with O
generalized O
atrophic B_DISEASE/B_GENE
benign I_DISEASE/I_GENE
epidermolysis I_DISEASE/I_GENE
bullosa I_DISEASE/I_GENE
represents O
propagation O
of O
an O
ancestral O
allele O
. O

patients O
with O
generalized O
atrophic B_DISEASE
benign I_DISEASE
epidermolysis I_DISEASE
bullosa I_DISEASE
, O
a O
usually O
nonlethal O
form O
of O
junctional B_DISEASE/B_GENE
epidermolysis I_DISEASE/I_GENE
bullosa I_DISEASE/I_GENE
, O
have O
generalized O
blistering B_DISEASE
, O
nail B_DISEASE
dystrophy I_DISEASE
, O
patchy B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
alopecia I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
dental B_DISEASE
abnormalities I_DISEASE
. O

Skin B_DISEASE/B_GENE
fragility I_DISEASE/I_GENE
in O
most O
cases O
is O
due O
to O
mutations O
in O
the O
gene O
encoding O
type O
XVII O
collagen O
( O
COL17A1 O
) O
. O

Recently O
, O
we O
reported O
five O
Austrian O
families O
with O
generalized O
atrophic B_DISEASE/B_GENE
benign I_DISEASE/I_GENE
epidermolysis I_DISEASE/I_GENE
bullosa I_DISEASE/I_GENE
who O
share O
the O
same O
COL17A1 O
mutation O
. O

affected O
individuals B_PERSON/B_BIO
in O
three B_NUMBER[MEASURE]/B_ENT
families I_NUMBER[MEASURE]/I_ENT
are O
homozygous B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O
4003delTC B_GENE/B_LOCATION
, O
whereas O
those O
in O
two B_NUMBER[MEASURE]/B_PERSON
others I_NUMBER[MEASURE]/I_PERSON
are O
compound B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
heterozygotes I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

To O
determine O
if O
the O
occurrence B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
4003delTC B_DISEASE/B_GENE
in O
these O
unrelated B_PERSON/B_BIO
families I_PERSON/I_BIO
signifies O
propagation B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
an O
ancestral B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
allele B_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O
a O
mutational B_DISEASE/B_MEASURE
hot I_DISEASE/I_MEASURE
spot I_DISEASE/I_MEASURE
, O
haplotypes B_PERSON/B_MEASURE
were O
determined O
for O
polymorphisms B_GENE
both O
within O
and O
flanking O
COL17A1 B_GENE/B_PERSON
. O

Five B_PERSON/B_ENT
intragenic I_PERSON/I_ENT
polymorphisms I_PERSON/I_ENT
were O
chosen O
based O
on O
their O
informativeness B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

One B_NUMBER[MEASURE]/B_PERSON
of O
these O
, O
not O
previously O
reported O
, O
was O
2988 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
C B_MEASURE/B_GENE
that O
introduces O
a O
new B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
restriction B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
site B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
Eco0109 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I O
. O

All O
the O
4003delTC B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
alleles I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
showed O
the O
same B_GENE
haplotype I_GENE
for O
these O
five B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
polymorphic I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
markers I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

Fourteen B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
microsatellite I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
polymorphisms I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O
selected O
based O
on O
their O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
heterozygosity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
their O
location B_LOCATION/B_MEASURE
within O
10q23 B_GENE/B_MEASURE
- O
q25 B_MEASURE/B_LOCATION
near O
COL17A1 B_GENE
. O

Three B_NUMBER[MEASURE]/B_ENT
families I_NUMBER[MEASURE]/I_ENT
shared O
microsatellite B_LOCATION
polymorphisms I_LOCATION
covering O
at O
most O
19 B_TIME[MEASURE]/B_LOCATION
cm B_TIME[MEASURE]/I_LOCATION
, O
whereas O
the O
others B_PERSON/B_SEQUENCE[MEASURE]
shared O
smaller B_DISEASE/B_MEASURE
regions I_DISEASE/I_MEASURE
consistent I_DISEASE/I_MEASURE
with O
cross O
- O
over O
events B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
during O
passage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
this O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_BIO
through O
several B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
generations I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
indicate O
that O
4003delTC B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurs O
on O
a O
single B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
ancestral I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
allele I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O
. O

The O
haptoglobin O
- O
gene O
deletion O
responsible O
for O
anhaptoglobinemia B_DISEASE
. O

We O
have O
found O
an O
allelic O
deletion O
of O
the O
haptoglobin O
( O
HP O
) O
gene O
from O
an O
individual O
with O
anhaptoglobinemia B_DISEASE/B_LOCATION
. O

The O
Hp B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
cluster I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
consists O
of O
coding B_GENE/B_LOCATION
regions I_GENE/I_LOCATION
of O
the O
alpha B_PROTEIN[GENE]
chain I_PROTEIN[GENE]
and O
beta B_PROTEIN[GENE]/B_LOCATION
chain I_PROTEIN[GENE]/I_LOCATION
of O
the O
haptoglobin B_GENE
gene I_GENE
( O
Hp B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O
and O
of O
the O
alpha B_PROTEIN[GENE]
chain I_PROTEIN[GENE]
and O
beta B_GENE/B_LOCATION
chain I_GENE/I_LOCATION
of O
the O
haptoglobin B_GENE/B_DISEASE
- O
related O
gene B_GENE/B_LOCATION
( O
Hpr B_GENE/B_LOCATION
) O
, O
in O
tandem B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
5 B_GENE/B_MEASURE
side I_GENE/I_MEASURE
. O

Southern O
blot O
and O
PCR O
analyses O
have O
indicated O
that O
the O
individual O
with O
anhaptoglobinemia B_DISEASE
was O
homozygous O
for O
the O
gene O
deletion O
and O
that O
the O
gene O
deletion O
was O
included O
at O
least O
from O
the O
promoter O
region O
of O
HP O
to O
Hpr O
alpha O
but O
not O
to O
Hpr O
beta O
( O
Hpdel O
) O
. O

In O
addition O
, O
we O
found O
seven O
individuals O
with O
hypohaptoglobinemia B_DISEASE
in O
three O
families O
, O
and O
the O
genotypes O
of O
six O
of O
the O
seven O
individuals O
were O
found O
to O
be O
Hp2 O
/ O
Hpdel O
. O

The O
phenotypes O
and O
genotypes O
in O
one O
of O
these O
three O
families O
showed O
the O
father O
to O
be O
hypohaptoglobinemic B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
( O
Hp2 O
) O
and O
Hp2 O
/ O
Hpdel O
, O
the O
mother O
to O
be O
Hp2 O
- O
1 O
and O
Hp1 O
/ O
Hp2 O
, O
one O
of O
the O
two O
children O
to O
be O
hypohaptoglobinemic B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
( O
Hp2 O
) O
and O
Hp2 O
/ O
Hpdel O
, O
and O
the O
other O
child O
to O
be O
Hp1 O
and O
Hp1 O
/ O
Hpdel O
, O
showing O
an O
anomalous O
inheritance O
of O
HP O
phenotypes O
in O
the O
child O
with O
Hp1 O
. O

The O
Hp2 B_PROTEIN[GENE]/B_BACTERIUM[BIO]
/ O
Hpdel B_PERSON/B_LOCATION
individuals I_PERSON/I_LOCATION
had O
an O
extremely O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
level B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
Hp B_PROTEIN[GENE]/B_BACTERIUM[BIO]
( O
mean B_MEASURE
+ I_MEASURE
/ O
- O
SD B_DISEASE/B_MEASURE
= O
0 B_MEASURE
. O
049 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
043 B_MEASURE
mg I_MEASURE
/ O
ml B_MEASURE/B_PERSON
; O
n O
= O
6 B_MEASURE
) O
, O
compared O
with O
the O
level B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_MEASURE/B_LOCATION
. O
64 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
. O
07 B_MEASURE/B_PERSON
mg I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
) O
obtained O
from O
52 B_PERSON
healthy I_PERSON
volunteers I_PERSON
having O
phenotype B_DISEASE/B_GENE
Hp2 I_DISEASE/I_GENE
, O
whereas O
the O
serum B_MEASURE/B_DISEASE
HP I_MEASURE/I_DISEASE
level I_MEASURE/I_DISEASE
of O
an O
individual B_PERSON/B_DISEASE
with O
Hp1 B_PROTEIN[GENE]/B_MEASURE
/ O
Hpdel B_GENE/B_MEASURE
was O
0 B_MEASURE
. O

50 B_MEASURE/B_ORGANIZATION
mg I_MEASURE/I_ORGANIZATION
/ O
ml B_TIME[MEASURE]/B_PERSON
, O
which O
was O
approximately O
half O
the O
level B_MEASURE/B_DISEASE
of O
Hp B_GENE/B_BACTERIUM[BIO]
in O
control B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
sera I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
from O
the O
Hp1 B_PERSON/B_BIO
phenotype I_PERSON/I_BIO
( O
1 B_MEASURE/B_LOCATION
. O
26 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
33 B_MEASURE
mg I_MEASURE
/ O
ml B_MEASURE/B_PERSON
; O
n B_OTHER/B_MEASURE
= O
9 B_MEASURE
) O
, O
showing O
a O
gene B_PERSON/B_MEASURE
- O
dosage B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
other B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
allele I_GENE/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
( O
Hp2 B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O
of O
individuals B_PERSON/B_BIO
with O
Hp2 B_PROTEIN[GENE]/B_BACTERIUM[BIO]
/ O
Hpdel B_MEASURE/B_GENE
was O
found O
to O
have O
, O
in O
all O
exons B_PERSON/B_LOCATION
, O
no O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
, O
by O
DNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

On O
the O
basis O
of O
the O
present O
study O
, O
the O
mechanism O
of O
anhaptoglobinemia B_DISEASE/B_GENE
and O
the O
mechanism O
of O
anomalous O
inheritance O
of O
HP O
phenotypes O
were O
well O
explained O
. O

However O
, O
the O
mechanism O
of O
hypohaptoglobinemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
remains O
unknown O
. O

ATM O
mutations O
and O
phenotypes O
in O
ataxia B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
- B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
telangiectasia B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
families O
in O
the O
British O
Isles O
: O
expression O
of O
mutant O
ATM O
and O
the O
risk O
of O
leukemia B_DISEASE
, O
lymphoma B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
breast B_DISEASE
cancer I_DISEASE
. O

We O
report O
the O
spectrum O
of O
59 O
ATM O
mutations O
observed O
in O
ataxia B_DISEASE/B_GENE
- B_DISEASE/I_GENE
telangiectasia B_DISEASE/I_GENE
( O
A B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
patients O
in O
the O
British O
Isles O
. O

Of O
51 O
ATM O
mutations O
identified O
in O
families O
native O
to O
the O
British O
Isles O
, O
11 O
were O
founder O
mutations O
, O
and O
2 O
of O
these O
11 O
conferred O
a O
milder O
clinical O
phenotype O
with O
respect O
to O
both O
cerebellar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
degeneration B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cellular O
features O
. O

We O
report O
, O
in O
two O
A B_LOCATION/B_MEASURE
- I_LOCATION/I_MEASURE
T I_LOCATION/I_MEASURE
families O
, O
an O
ATM O
mutation O
( O
7271T O
- O
- O
> O
G O
) O
that O
may O
be O
associated O
with O
an O
increased O
risk O
of O
breast B_DISEASE
cancer I_DISEASE
in O
both O
homozygotes O
and O
heterozygotes O
( O
relative O
risk O
12 O
. O
7 O
; O
P O
= O
. O
0025 O
) O
, O
although O
there O
is O
a O
less O
severe O
A B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenotype O
in O
terms O
of O
the O
degree O
of O
cerebellar B_DISEASE/B_GENE
degeneration I_DISEASE/I_GENE
. O

This O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
( O
7271T B_PROTEIN[GENE]/B_LOCATION
- O
- O
> B_MEASURE/B_DISEASE
G I_MEASURE/I_DISEASE
) O
also O
allows O
expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
full B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
length B_GENE/B_MEASURE
ATM I_GENE/I_MEASURE
protein I_GENE/I_MEASURE
at O
a O
level B_MEASURE/B_LOCATION
comparable I_MEASURE/I_LOCATION
with O
that O
in O
unaffected B_PERSON/B_BIO
individuals I_PERSON/I_BIO
. O

In O
addition O
, O
we O
have O
studied O
18 O
A B_DISEASE/B_MEASURE
- I_DISEASE/I_MEASURE
T I_DISEASE/I_MEASURE
patients O
, O
in O
15 O
families O
, O
who O
developed O
leukemia B_DISEASE
, O
lymphoma B_DISEASE
, O
preleukemic O
T O
- O
cell O
proliferation O
, O
or O
Hodgkin B_DISEASE
lymphoma I_DISEASE
, O
mostly O
in O
childhood O
. O

A O
wide B_MEASURE
variety I_MEASURE
of O
ATM B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
types I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
including O
missense B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutations I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
and O
in O
- O
frame B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
deletions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
were O
seen O
in O
these O
patients B_PERSON/B_BIO
. O

We O
also O
show O
that O
25 O
% O
of O
all O
A B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O
carried O
in O
- O
frame O
deletions O
or O
missense O
mutations O
, O
many O
of O
which O
were O
also O
associated O
with O
expression O
of O
mutant O
ATM O
protein O
. O

The O
DMPK O
gene O
of O
severely O
affected O
myotonic B_DISEASE/B_GENE
dystrophy I_DISEASE/I_GENE
patients O
is O
hypermethylated O
proximal O
to O
the O
largely O
expanded O
CTG O
repeat O
. O

Using O
methylation O
- O
sensitive O
restriction O
enzymes O
, O
we O
characterized O
the O
methylation O
pattern O
on O
the O
5 O
side O
of O
the O
CTG O
repeat O
in O
the O
DMPK O
gene O
of O
normal O
individuals O
and O
of O
patients O
affected O
with O
myotonic B_DISEASE/B_GENE
dystrophy I_DISEASE/I_GENE
, O
showing O
expansions O
of O
the O
repetitive O
sequence O
. O

The O
gene B_GENE/B_LOCATION
segment I_GENE/I_LOCATION
analyzed O
corresponds B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
to O
the O
genomic B_PROTEIN[GENE]/B_BACTERIUM[BIO]
SacI I_PROTEIN[GENE]/I_BACTERIUM[BIO]
- O
HindIII B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fragment I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
carrying O
exons B_GENE/B_LOCATION
11 I_GENE/I_LOCATION
- O
15 B_MEASURE
. O

There O
is O
constitutive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methylation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
intron B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
12 B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
at O
restriction B_LOCATION/B_MEASURE
sites I_LOCATION/I_MEASURE
of O
SacII B_PROTEIN[GENE]/B_SPECIES[BIO]
and O
HhaI B_PROTEIN[GENE]/B_BACTERIUM[BIO]
, O
localized B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
, O
159 B_MEASURE
- O
1 B_MEASURE
, O
232 B_MEASURE
BP I_MEASURE
upstream O
of O
the O
CTG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
repeat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
whereas O
most B_NUMBER[MEASURE]/B_PERSON
, O
if O
not O
all O
, O
of O
the O
other B_GENE/B_LOCATION
sites I_GENE/I_LOCATION
of O
SacII B_GENE/B_SPECIES[BIO]
, O
HhaI B_GENE/B_BACTERIUM[BIO]
, O
and O
HpaII B_GENE/B_BIO
in O
this O
region B_LOCATION/B_PERSON
are O
unmethylated O
, O
in O
normal B_PERSON
individuals I_PERSON
and O
most B_NUMBER[MEASURE]/B_LOCATION
of O
the O
patients B_PERSON/B_DISEASE
. O

In O
a O
number B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
young B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
and O
severely O
affected B_PERSON/B_DISEASE
patients I_PERSON/I_DISEASE
, O
however O
, O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
methylation B_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
of O
these O
restriction B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
found O
in O
the O
mutated B_GENE/B_PERSON
allele I_GENE/I_PERSON
. O

In O
most B_NUMBER[MEASURE]/B_PERSON
of O
these O
patients B_PERSON/B_LOCATION
, O
the O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O
the O
disease B_DISEASE
was O
congenital B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Preliminary B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
footprinting I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
gave O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
protein B_GENE/B_BACTERIUM[BIO]
- O
DNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
contact I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
normal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
genes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
at O
an O
Sp1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
consensus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding O
site B_LOCATION/B_MEASURE
upstream O
of O
the O
CTG B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
for O
a O
significant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
this O
interaction B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O
a O
hypermethylated B_DISEASE/B_GENE
DMPK I_DISEASE/I_GENE
gene I_DISEASE/I_GENE
. O
. O

The O
hemochromatosis B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
gene O
product O
complexes O
with O
the O
transferrin O
receptor O
and O
lowers O
its O
affinity O
for O
ligand O
binding O
. O

We O
recently O
reported O
the O
positional O
cloning O
of O
a O
candidate O
gene O
for O
hereditary B_DISEASE
hemochromatosis I_DISEASE
called O
HFE O
. O

The O
gene B_PERSON/B_ORGANIZATION
product I_PERSON/I_ORGANIZATION
, O
a O
member B_PERSON/B_MEASURE
of O
the O
major B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
histocompatibility I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
complex I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
class I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
I O
- O
like B_PROTEIN[GENE]/B_LOCATION
family I_PROTEIN[GENE]/I_LOCATION
, O
was O
found O
to O
have O
a O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Cys B_LOCATION/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
- O
282 B_MEASURE/B_LOCATION
- O
- O
> B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
Tyr I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
( O
C282Y B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
in O
85 B_NUMBER[MEASURE]
% I_NUMBER[MEASURE]
of O
patient B_PERSON/B_BIO
chromosomes I_PERSON/I_BIO
. O

This O
mutation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
eliminates O
the O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
HFE B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
to O
associate B_PERSON/B_TIME[MEASURE]
with O
beta2 B_PROTEIN[GENE]/B_MEASURE
- O
microglobulin B_GENE
( O
beta2m B_LOCATION/B_ORGANIZATION
) O
and O
prevents O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
surface B_DISEASE_ADJECTIVE[DISEASE]
expression I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
second B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O
has O
no O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
beta2m B_GENE/B_DISEASE
association B_GENE/I_DISEASE
, O
H63D B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O
was O
found O
in O
eight B_NUMBER[MEASURE]
out O
of O
nine B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
heterozygous I_NUMBER[MEASURE]
for O
the O
C282Y B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutant I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O

In O
this O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
we O
demonstrate O
in O
cultured B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
293 I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
overexpressing O
wild B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O
type B_MEASURE/B_LOCATION
or O
mutant B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
HFE I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
proteins I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
that O
both O
the O
wild B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
- O
type B_DISEASE/B_MEASURE
and O
H63D B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
HFE B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
proteins B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
form O
stable B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
complexes I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
with O
the O
transferrin B_GENE/B_BIO
receptor I_GENE/I_BIO
( O
TfR B_PROTEIN[GENE]/B_LOCATION
) O
. O

The O
C282Y B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nearly O
completely O
prevents O
the O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
mutant B_GENE/B_DISEASE
HFE I_GENE/I_DISEASE
protein I_GENE/I_DISEASE
with O
the O
TfR B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

Studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
associated O
transferrin B_PROTEIN[GENE]
at O
37 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
degrees I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
C I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
suggest O
that O
the O
overexpressed O
wild B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
type B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
HFE I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
decreases O
the O
affinity B_MEASURE/B_GENE
of O
the O
TfR B_GENE
for O
transferrin B_GENE
. O

The O
overexpressed B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
H63D I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
protein I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
does O
not O
have O
this O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
providing O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
direct I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
a O
functional B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consequence B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
H63D B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O

Addition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
soluble B_PROTEIN[GENE]
wild I_PROTEIN[GENE]
- O
type B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
HFE B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
/ O
beta2m B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
heterodimers I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
cultured B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
also O
decreased O
the O
apparent B_MEASURE
affinity I_MEASURE
of O
the O
TfR B_GENE
for O
its O
ligand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
under O
steady B_DISEASE_ADJECTIVE[DISEASE]
- O
state B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
conditions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O
both O
in O
293 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
in O
HeLa B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Furthermore O
, O
at O
4 B_TIME[MEASURE]/B_LOCATION
degrees I_TIME[MEASURE]/I_LOCATION
C I_TIME[MEASURE]/I_LOCATION
, O
the O
added O
soluble B_MEASURE/B_PROTEIN[GENE]
complex I_MEASURE/I_PROTEIN[GENE]
of O
HFE B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
/ O
beta2m B_GENE/B_LOCATION
inhibited O
binding B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
transferrin B_GENE
to O
HeLa B_GENE
cell I_GENE
TfR I_GENE
in O
a O
concentration B_MEASURE/B_LOCATION
- O
dependent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
manner B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Scatchard B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
plots B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
of O
these O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
the O
added O
heterodimer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
substantially O
reduced O
the O
affinity B_MEASURE/B_GENE
of O
TfR B_GENE
for O
transferrin B_GENE
. O

These O
results O
establish O
a O
molecular O
link O
between O
HFE O
and O
a O
key O
protein O
involved O
in O
iron O
transport O
, O
the O
TfR O
, O
and O
raise O
the O
possibility O
that O
alterations O
in O
this O
regulatory O
mechanism O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
hereditary B_DISEASE
hemochromatosis I_DISEASE
. O
. O

Genomic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
organization I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
the O
UBE3A B_GENE
/ O
E6 B_PROTEIN[GENE]/B_LOCATION
- O
AP B_GENE/B_DISEASE
gene I_GENE/I_DISEASE
and O
related O
pseudogenes B_BACTERIUM[BIO]/B_GENE
. O

The O
UBE3A O
gene O
encodes O
the O
E6 O
- O
AP O
ubiquitin O
- O
protein O
ligase O
and O
has O
recently O
been O
shown O
to O
be O
mutated O
in O
Angelman B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
syndrome B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
patients O
who O
lack O
15q11 O
- O
q13 O
deletions O
or O
chromosome O
15 O
paternal O
uniparental B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
disomy I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O

Previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
UBE3A I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cDNA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
has O
shown O
a O
coding B_LOCATION/B_MEASURE
region B_LOCATION/I_MEASURE
of O
approximately O
2 B_NUMBER[MEASURE]
. O

6 B_GENE/B_MEASURE
kb I_GENE/I_MEASURE
and O
a O
3 B_TIME[MEASURE]/B_LOCATION
- O
untranslated B_GENE/B_LOCATION
region I_GENE/I_LOCATION
( O
UTR B_GENE/B_LOCATION
) O
of O
< B_GENE/B_DISEASE
50 I_GENE/I_DISEASE
bp I_GENE/I_DISEASE
, O
whereas O
Northern B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
has O
indicated O
mRNA B_MEASURE/B_LOCATION
sizes I_MEASURE/I_LOCATION
of O
5 B_NUMBER[MEASURE]/B_LOCATION
- O
8 B_MEASURE
kb I_MEASURE
. O

We O
have O
analyzed O
additional B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cDNA I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clones I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
provide O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
an O
additional B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

5 B_MEASURE/B_LOCATION
kb I_MEASURE/I_LOCATION
of O
5 B_MEASURE/B_LOCATION
- O
UTR B_GENE/B_LOCATION
and O
> B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
kb I_MEASURE/I_LOCATION
of O
3 B_MEASURE/B_LOCATION
- O
UTR B_GENE/B_LOCATION
. O

We O
have O
established O
the O
genomic B_LOCATION/B_ORGANIZATION
organization I_LOCATION/I_ORGANIZATION
of O
UBE3A B_GENE
and O
the O
sequence B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
intron B_GENE/B_DISEASE
- O
exon B_NUMBER[MEASURE]/B_PERSON
borders I_NUMBER[MEASURE]/I_PERSON
. O

We O
have O
also O
mapped O
two B_NUMBER[MEASURE]/B_PERSON
highly O
homologous B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processed O
pseudogenes B_GENE/B_BACTERIUM[BIO]
, O
UBE3AP1 B_GENE
and O
UBE3AP2 B_GENE
, O
to O
chromosomes B_MEASURE
2 I_MEASURE
and O
21 B_NUMBER[MEASURE]
, O
respectively O
, O
and O
determined O
their O
genomic B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
organization I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
will O
form O
the O
basis B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
mutation B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
imprinting B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O
UBE3A B_GENE/B_SPECIES[BIO]
. O

mutation O
spectrum O
and O
genotype O
- O
phenotype O
analyses O
in O
Cowden B_DISEASE/B_GENE
disease I_DISEASE/I_GENE
and O
Bannayan B_DISEASE/B_GENE
- I_DISEASE/I_GENE
Zonana I_DISEASE/I_GENE
syndrome I_DISEASE/I_GENE
, O
two O
hamartoma B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
syndromes I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O
germline O
PTEN O
mutation O
. O

The O
tumour B_DISEASE/B_GENE
suppressor O
gene O
PTEN O
, O
which O
maps O
to O
10q23 O
. O

3 O
and O
encodes O
a O
403 O
amino O
acid O
dual O
specificity O
phosphatase O
( O
protein O
tyrosine O
phosphatase O
; O
PTPase O
) O
, O
was O
shown O
recently O
to O
play O
a O
broad O
role O
in O
human O
malignancy B_DISEASE
. O

Somatic O
PTEN O
deletions O
and O
mutations O
were O
observed O
in O
sporadic B_DISEASE
breast I_DISEASE
, I_DISEASE
brain I_DISEASE
, I_DISEASE
prostate I_DISEASE
and I_DISEASE
kidney I_DISEASE
cancer I_DISEASE
cell O
lines O
and O
in O
several O
primary O
tumours B_DISEASE/B_LOCATION
such O
as O
endometrial B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
carcinomas I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
malignant B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
melanoma I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
thyroid B_DISEASE
tumours I_DISEASE
. O

In O
addition O
, O
PTEN O
was O
identified O
as O
the O
susceptibility O
gene O
for O
two O
hamartoma B_DISEASE
syndromes I_DISEASE
Cowden I_DISEASE
disease I_DISEASE
( O
CD B_LOCATION/B_DISEASE
; O
MIM O
158350 O
) O
and O
Bannayan B_DISEASE/B_GENE
- I_DISEASE/I_GENE
Zonana I_DISEASE/I_GENE
( I_DISEASE/I_GENE
BZS I_DISEASE/I_GENE
) I_DISEASE/I_GENE
or I_DISEASE/I_GENE
Ruvalcaba I_DISEASE/I_GENE
- I_DISEASE/I_GENE
Riley I_DISEASE/I_GENE
- I_DISEASE/I_GENE
Smith I_DISEASE/I_GENE
syndrome I_DISEASE/I_GENE
( O
MIM O
153480 O
) O
. O

Constitutive O
DNA O
from O
37 O
CD B_DISEASE
families O
and O
seven O
BZS B_DISEASE/B_LOCATION
families O
was O
screened O
for O
germline O
PTEN O
mutations O
. O

PTEN O
mutations O
were O
identified O
in O
30 O
of O
37 O
( O
81 O
% O
) O
CD B_DISEASE
families O
, O
including O
missense O
and O
nonsense O
point O
mutations O
, O
deletions O
, O
insertions O
, O
a O
deletion O
/ O
insertion O
and O
splice O
site O
mutations O
. O

These O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
were O
scattered O
over O
the O
entire B_MEASURE/B_LOCATION
length I_MEASURE/I_LOCATION
of O
PTEN B_GENE
, O
with O
the O
exception B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
first B_SEQUENCE[MEASURE]
, O
fourth B_SEQUENCE[MEASURE]
and O
last B_SEQUENCE[MEASURE]/B_ENT
exons I_SEQUENCE[MEASURE]/I_ENT
. O

A O
hot O
spot O
for O
PTEN O
mutation O
in O
CD B_DISEASE/B_LOCATION
was O
identified O
in O
exon O
5 O
that O
contains O
the O
PTPase O
core O
motif O
, O
with O
13 O
of O
30 O
( O
43 O
% O
) O
CD B_DISEASE/B_GENE
mutations O
identified O
in O
this O
exon O
. O

Seven B_NUMBER[MEASURE]
of O
30 B_NUMBER[MEASURE]/B_PERSON
( O
23 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
were O
within O
the O
core B_GENE/B_LOCATION
motif I_GENE/I_LOCATION
, O
the O
majority B_PERSON/B_MEASURE
( O
five B_NUMBER[MEASURE]/B_LOCATION
of O
seven B_NUMBER[MEASURE]/B_PERSON
) O
of O
which O
were O
missense B_DISEASE_ADJECTIVE[DISEASE]
mutations I_DISEASE_ADJECTIVE[DISEASE]
, O
possibly O
pointing O
to O
the O
functional B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significance I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
region B_LOCATION
. O

Germline O
PTEN O
mutations O
were O
identified O
in O
four O
of O
seven O
( O
57 O
% O
) O
BZS B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
families O
studied O
. O

Interestingly O
, O
none B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LOCATION
was O
observed O
in O
the O
PTPase B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
core I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
motif I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

It O
is O
also O
worthy O
of O
note O
that O
a O
single O
nonsense O
point O
mutation O
, O
R233X O
, O
was O
observed O
in O
the O
germline O
DNA O
from O
two O
unrelated O
CD B_DISEASE/B_LOCATION
families O
and O
one O
BZS B_LOCATION/B_DISEASE
family O
. O

Genotype O
- O
phenotype O
studies O
were O
not O
performed O
on O
this O
small O
group O
of O
BZS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
families O
. O

However O
, O
genotype O
- O
phenotype O
analysis O
inthe O
group O
of O
CD B_DISEASE/B_NUMBER[MEASURE]
families O
revealed O
two O
possible O
associations O
worthy O
of O
follow O
- O
up O
in O
independent O
analyses O
. O

The O
first O
was O
an O
association O
noted O
in O
the O
group O
of O
CD B_NUMBER[MEASURE]/B_LOCATION
families O
with O
breast B_DISEASE
disease I_DISEASE
. O

A O
correlation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
between O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
absence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
a O
PTEN B_DISEASE/B_MEASURE
mutation I_DISEASE/I_MEASURE
and O
the O
type B_MEASURE
of O
breast B_DISEASE
involvement I_DISEASE
( O
unaffected B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benign I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
malignant I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Specifically O
and O
more O
directly O
, O
an O
association O
was O
also O
observed O
between O
the O
presence O
of O
a O
PTEN O
mutation O
and O
malignant B_DISEASE/B_GENE
breast I_DISEASE/I_GENE
disease I_DISEASE/I_GENE
. O

secondly O
, O
there O
appeared O
to O
be O
an O
interdependent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
association I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
between O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
upstream O
and O
within O
the O
PTPase B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
core I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motif I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
core B_LOCATION
motif I_LOCATION
containing O
the O
majority B_MEASURE/B_LOCATION
of O
missense B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutations I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
, O
and O
the O
involvement B_DISEASE/B_GENE
of O
all O
major B_DISEASE/B_LOCATION
organ B_DISEASE/I_LOCATION
systems B_DISEASE/I_LOCATION
( O
central B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nervous I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
thyroid B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
breast B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
skin B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
gastrointestinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

However O
, O
these O
observations O
would O
need O
to O
be O
confirmed O
by O
studying O
a O
larger O
number O
of O
CD B_DISEASE/B_LOCATION
families O
. O

Molecular O
defects O
leading O
to O
human O
complement B_DISEASE
component I_DISEASE
C6 I_DISEASE
deficiency I_DISEASE
in O
an O
African O
- O
American O
family O
. O

Complement B_DISEASE
component I_DISEASE
C6 I_DISEASE
deficiency I_DISEASE
( O
C6D B_DISEASE/B_LOCATION
) O
was O
diagnosed O
in O
a O
16 O
- O
year O
- O
old O
African O
- O
American O
male O
with O
meningococcal B_DISEASE/B_GENE
meningitis I_DISEASE/I_GENE
. O

The O
patients O
father O
and O
two O
brothers O
also O
had O
C6D B_DISEASE
, O
but O
gave O
no O
history O
of O
meningitis B_DISEASE
or O
other O
neisserial B_DISEASE_ADJECTIVE[DISEASE]
infection I_DISEASE_ADJECTIVE[DISEASE]
. O

By O
using O
exon B_GENE
- O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
polymerase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
chain I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
/ O
single B_NUMBER[MEASURE]
- O
strand B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conformation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphism B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
screening B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
step I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
nucleotide B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
target B_GENE/B_BIO
exons I_GENE/I_BIO
, O
we O
determined O
that O
the O
proband B_PERSON/B_BIO
was O
a O
compound B_PERSON/B_LOCATION
heterozygote I_PERSON/I_LOCATION
for O
two B_DISEASE/B_GENE
C6 I_DISEASE/I_GENE
gene I_DISEASE/I_GENE
mutations I_DISEASE/I_GENE
. O

The O
first O
, O
1195delC O
located O
in O
exon O
7 O
, O
is O
a O
novel O
mutation O
, O
while O
the O
second O
, O
1936delG O
in O
exon O
12 O
, O
has O
been O
described O
before O
to O
cause O
C6D B_DISEASE/B_GENE
in O
an O
unrelated O
African O
- O
American O
individual O
. O

Both O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
result O
in O
premature B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
termination I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
codons I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
C6 B_DISEASE/B_GENE
null I_DISEASE/I_GENE
alleles I_DISEASE/I_GENE
. O

Allele B_PERSON/B_GENE
- O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
PCR I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicated O
that O
the O
probands B_PERSON/B_ENT
two I_PERSON/I_ENT
brothers I_PERSON/I_ENT
also O
inherited O
the O
1195delC B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
from O
their O
heterozygous B_PERSON
mother I_PERSON
and O
the O
1936delG B_DISEASE_ADJECTIVE[DISEASE]/B_SEQUENCE[MEASURE]
mutation I_DISEASE_ADJECTIVE[DISEASE]/I_SEQUENCE[MEASURE]
from O
their O
homozygous B_PERSON
father I_PERSON
. O
. O

PAX6 B_PERSON/B_LOCATION
mutations I_PERSON/I_LOCATION
reviewed O
. O

mutations O
in O
PAX6 O
are O
responsible O
for O
human O
aniridia B_DISEASE/B_SPECIES[BIO]
and O
have O
also O
been O
found O
in O
patients O
with O
Peters B_DISEASE
anomaly I_DISEASE
, O
with O
congenital B_DISEASE
cataracts I_DISEASE
, O
with O
autosomal B_DISEASE
dominant I_DISEASE
keratitis I_DISEASE
, O
and O
with O
isolated B_DISEASE
foveal I_DISEASE
hypoplasia I_DISEASE
. O

No O
locus O
other O
than O
chromosome O
11p13 O
has O
been O
implicated O
in O
aniridia B_DISEASE/B_SPECIES[BIO]
, O
and O
PAX6 O
is O
clearly O
the O
major O
, O
if O
not O
only O
, O
gene O
responsible O
. O

Twenty B_NUMBER[MEASURE]
- O
eight B_NUMBER[MEASURE]
percent I_NUMBER[MEASURE]
of O
identified O
PAX6 B_DISEASE_ADJECTIVE[DISEASE]
mutations I_DISEASE_ADJECTIVE[DISEASE]
are O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
T B_MEASURE/B_LOCATION
changes B_MEASURE/I_LOCATION
at O
CpG B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
dinucleotides I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
20 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
are O
splicing O
errors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
more B_MEASURE/B_PERSON
than O
30 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
are O
deletion B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
insertion B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
events I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

There O
is O
a O
noticeably O
elevated B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
level B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O
the O
paired B_GENE/B_BIO
domain I_GENE/I_BIO
compared O
with O
the O
rest B_LOCATION/B_MEASURE
of O
the O
gene B_GENE/B_LOCATION
. O

increased O
mutation B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
in O
the O
homeodomain B_GENE/B_BIO
is O
accounted O
for O
by O
the O
hypermutable B_DISEASE_ADJECTIVE[DISEASE]
CpG I_DISEASE_ADJECTIVE[DISEASE]
dinucleotide I_DISEASE_ADJECTIVE[DISEASE]
in O
codon B_GENE
240 I_GENE
. O

Very O
nearly O
all O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
appear O
to O
cause O
loss B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
function B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
the O
mutant B_GENE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
allele I_GENE/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
, O
and O
more B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
80 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
of O
exonic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substitutions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
result O
in O
nonsense B_DISEASE/B_GENE
codons I_DISEASE/I_GENE
. O

In O
a O
gene B_PERSON/B_GENE
with O
such B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
extraordinarily O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sequence I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
conservation I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
throughout O
evolution B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
, O
there O
are O
presumed O
undiscovered B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
missense I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
these O
are O
hypothesized O
to O
exist O
in O
as O
- O
yet O
unidentified B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
phenotypes I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O
. O

genetic O
heterogeneity O
and O
penetrance O
analysis O
of O
the O
BRCA1 O
and O
BRCA2 O
genes O
in O
breast B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
cancer I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
families O
. O

The O
Breast B_PERSON/B_ORGANIZATION
Cancer B_PERSON/I_ORGANIZATION
Linkage O
Consortium O
. O

The O
contribution O
of O
BRCA1 O
and O
BRCA2 O
to O
inherited B_DISEASE/B_GENE
breast I_DISEASE/I_GENE
cancer I_DISEASE/I_GENE
was O
assessed O
by O
linkage O
and O
mutation O
analysis O
in O
237 O
families O
, O
each O
with O
at O
least O
four O
cases O
of O
breast B_DISEASE/B_GENE
cancer I_DISEASE/I_GENE
, O
collected O
by O
the O
Breast B_DISEASE/B_LOCATION
Cancer B_DISEASE/I_LOCATION
Linkage O
Consortium O
. O

Families O
were O
included O
without O
regard O
to O
the O
occurrence O
of O
ovarian B_DISEASE
or I_DISEASE
other I_DISEASE
cancers I_DISEASE
. O

Overall O
, O
disease B_DISEASE/B_GENE
was O
linked O
to O
BRCA1 B_GENE/B_DISEASE
in O
an O
estimated O
52 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
families B_PERSON/B_SOCIAL_CIRCUMSTANCES
, O
to O
BRCA2 B_GENE/B_DISEASE
in O
32 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
families B_PERSON/B_SOCIAL_CIRCUMSTANCES
, O
and O
to O
neither O
gene B_GENE
in O
16 B_PERSON/B_NUMBER[MEASURE]
% I_PERSON/I_NUMBER[MEASURE]
( O
95 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
confidence I_MEASURE/I_LOCATION
interval I_MEASURE/I_LOCATION
[ O
CI B_MEASURE/B_LOCATION
] O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
- O
28 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
suggesting O
other B_DISEASE/B_GENE
predisposition I_DISEASE/I_GENE
genes I_DISEASE/I_GENE
. O

The O
majority O
( O
81 O
% O
) O
of O
the O
breast B_DISEASE_ADJECTIVE[DISEASE]
- I_DISEASE_ADJECTIVE[DISEASE]
ovarian I_DISEASE_ADJECTIVE[DISEASE]
cancer I_DISEASE_ADJECTIVE[DISEASE]
families O
were O
due O
to O
BRCA1 O
, O
with O
most O
others O
( O
14 O
% O
) O
due O
to O
BRCA2 O
. O

Conversely O
, O
the O
majority O
of O
families O
with O
male B_DISEASE/B_LOCATION
and I_DISEASE/I_LOCATION
female I_DISEASE/I_LOCATION
breast I_DISEASE/I_LOCATION
cancer I_DISEASE/I_LOCATION
were O
due O
to O
BRCA2 O
( O
76 O
% O
) O
. O

The O
largest O
proportion O
( O
67 O
% O
) O
of O
families O
due O
to O
other O
genes O
was O
found O
in O
families O
with O
four O
or O
five O
cases O
of O
female O
breast B_DISEASE/B_PERSON
cancer I_DISEASE/I_PERSON
only O
. O

These O
estimates B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
not O
substantially O
affected O
either O
by O
changing O
the O
assumed O
penetrance B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
BRCA1 B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
by O
including O
or O
excluding O
BRCA1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
mutation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Among O
those O
families B_PERSON/B_SOCIAL_CIRCUMSTANCES
with O
disease B_DISEASE/B_GENE
due O
to O
BRCA1 B_DISEASE/B_GENE
that O
were O
tested O
by O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
standard B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
screening I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
mutations B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
were O
detected O
in O
the O
coding B_GENE
sequence I_GENE
or O
splice B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
an O
estimated B_MEASURE/B_PERSON
63 B_MEASURE/I_PERSON
% B_MEASURE/I_PERSON
( O
95 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
CI I_MEASURE/I_LOCATION
51 I_MEASURE/I_LOCATION
% I_MEASURE/I_LOCATION
- O
77 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
. O

The O
estimated O
sensitivity B_MEASURE
was O
identical B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O
direct B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
and O
other B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
techniques I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
penetrance B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
BRCA2 B_DISEASE/B_GENE
was O
estimated O
by O
maximizing O
the O
LOD B_MEASURE
score I_MEASURE
in O
BRCA2 B_GENE/B_NUMBER[MEASURE]
- O
mutation B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
families I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
over O
all O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
penetrance I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
functions I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

The O
estimated O
cumulative O
risk O
of O
breast B_DISEASE
cancer I_DISEASE
reached O
28 O
% O
( O
95 O
% O
CI O
9 O
% O
- O
44 O
% O
) O
by O
age O
50 O
years O
and O
84 O
% O
( O
95 O
% O
CI O
43 O
% O
- O
95 O
% O
) O
by O
age O
70 O
years O
. O

The O
corresponding O
ovarian B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cancer B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
risks O
were O
0 O
. O

4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
95 B_MEASURE
% I_MEASURE
CI I_MEASURE
0 I_MEASURE
% I_MEASURE
- O
1 B_MEASURE
% I_MEASURE
) O
by O
age B_PERSON
50 I_PERSON
years I_PERSON
and O
27 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
95 B_MEASURE
% I_MEASURE
CI I_MEASURE
0 I_MEASURE
% I_MEASURE
- O
47 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
) O
by O
age B_PERSON
70 I_PERSON
years I_PERSON
. O

The O
lifetime O
risk O
of O
breast B_DISEASE
cancer I_DISEASE
appears O
similar O
to O
the O
risk O
in O
BRCA1 O
carriers O
, O
but O
there O
was O
some O
suggestion O
of O
a O
lower O
risk O
in O
BRCA2 O
carriers O
< O
50 O
years O
of O
age O
. O

Eye B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
movement I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
abnormalities I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
correlate O
with O
genotype O
in O
autosomal O
dominant O
cerebellar B_DISEASE/B_PERSON
ataxia I_DISEASE/I_PERSON
type I_DISEASE/I_PERSON
I I_DISEASE/I_PERSON
. O

We O
compared O
horizontal O
eye O
movements O
( O
visually O
guided O
saccades O
, O
antisaccades O
, O
and O
smooth O
pursuit O
) O
in O
control O
subjects O
( O
n O
= O
14 O
) O
and O
patients O
with O
three O
forms O
of O
autosomal O
dominant O
cerebellar B_DISEASE/B_GENE
ataxias I_DISEASE/I_GENE
type I_DISEASE/I_GENE
I I_DISEASE/I_GENE
spinocerebellar I_DISEASE/I_GENE
ataxias I_DISEASE/I_GENE
1 I_DISEASE/I_GENE
and I_DISEASE/I_GENE
2 I_DISEASE/I_GENE
( O
SCA1 B_DISEASE/B_GENE
, O
n O
= O
11 O
; O
SCA2 B_DISEASE/B_GENE
, O
n O
= O
10 O
) O
and O
SCA3 B_PERSON
/ O
Machado B_MEASURE
- I_MEASURE
Joseph I_MEASURE
disease I_MEASURE
( O
MJD B_DISEASE/B_GENE
) O
( O
n O
= O
16 O
) O
. O

In O
SCA1 B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, O
saccade O
amplitude O
was O
significantly O
increased O
, O
resulting O
in O
hypermetria B_DISEASE
. O

The O
smooth B_DISEASE/B_MEASURE
pursuit I_DISEASE/I_MEASURE
gain I_DISEASE/I_MEASURE
was O
decreased O
. O

In O
SCA2 B_DISEASE/B_TIME[MEASURE]
, O
saccade O
velocity O
was O
markedly O
decreased O
. O

The O
percentage B_MEASURE
of O
errors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
antisaccades B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
greatly O
increased O
and O
was O
significantly O
correlated O
with O
age B_TIME[MEASURE]/B_DISEASE
at O
disease B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
onset I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
addition B_MEASURE/B_LOCATION
, O
a O
correlation B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
smooth B_DISEASE/B_GENE
pursuit I_DISEASE/I_GENE
gain I_DISEASE/I_GENE
and O
the O
number B_MEASURE/B_LOCATION
of O
trinucleotide B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
repeats B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
found O
. O

In O
SCA3 B_PERSON/B_BIO
, O
gaze B_DISEASE
- I_DISEASE
evoked I_DISEASE
nystagmus I_DISEASE
was O
often O
present O
as O
was O
saccade O
hypometria O
and O
smooth O
pursuit O
gain O
was O
markedly O
decreased O
. O

Three O
major O
criteria O
, O
saccade O
amplitude O
, O
saccade O
velocity O
, O
and O
presence O
of O
gaze B_DISEASE
- I_DISEASE
evoked I_DISEASE
nystagmus I_DISEASE
, O
permitted O
the O
correct O
assignment O
of O
90 O
% O
of O
the O
SCA1 B_DISEASE/B_PERSON
, O
90 O
% O
of O
the O
SCA2 B_DISEASE/B_PERSON
, O
and O
93 O
% O
of O
the O
patients O
with O
SCA3 B_DISEASE/B_GENE
to O
their O
genetically O
confirmed O
patient O
group O
and O
, O
therefore O
, O
may O
help O
Orient O
diagnoses O
of O
SCA1 B_DISEASE/B_GENE
, O
SCA2 B_DISEASE/B_GENE
, O
and O
SCA3 B_DISEASE/B_PERSON
at O
early O
clinical O
stages O
of O
the O
diseases O
. O
. O

genetic O
basis O
and O
molecular O
mechanism O
for O
idiopathic B_DISEASE
ventricular I_DISEASE
fibrillation I_DISEASE
. O

Ventricular B_DISEASE
fibrillation I_DISEASE
causes O
more O
than O
300 O
, O
000 O
sudden O
deaths O
each O
year O
in O
the O
USA O
alone O
. O

In O
approximately O
5 O
- O
12 O
% O
of O
these O
cases O
, O
there O
are O
no O
demonstrable O
cardiac O
or O
non O
- O
cardiac O
causes O
to O
account O
for O
the O
episode O
, O
which O
is O
therefore O
classified O
as O
idiopathic B_DISEASE/B_ORGANISM_FUNCTION
ventricular I_DISEASE/I_ORGANISM_FUNCTION
fibrillation I_DISEASE/I_ORGANISM_FUNCTION
( O
IVF B_LOCATION/B_ORGANIZATION
) O
. O

A O
distinct O
group O
of O
IVF B_DISEASE/B_PERSON
patients O
has O
been O
found O
to O
present O
with O
a O
characteristic O
electrocardiographic O
pattern O
. O

Because O
of O
the O
small O
size O
of O
most O
pedigrees O
and O
the O
high O
incidence O
of O
sudden B_DISEASE
death I_DISEASE
, O
however O
, O
molecular O
genetic O
studies O
of O
IVF B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
have O
not O
yet O
been O
done O
. O

Because O
IVF B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
causes O
cardiac O
rhythm O
disturbance O
, O
we O
investigated O
whether O
malfunction O
of O
ion O
channels O
could O
cause O
the O
disorder O
by O
studying O
mutations O
in O
the O
cardiac O
sodium O
channel O
gene O
SCN5A O
. O

We O
have O
now O
identified O
a O
missense O
mutation O
, O
a O
splice O
- O
donor O
mutation O
, O
and O
a O
frameshift O
mutation O
in O
the O
coding O
region O
of O
SCN5A O
in O
three O
IVF B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
families O
. O

We O
show O
that O
sodium B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
channels I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
with O
the O
missense B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
recover O
from O
inactivation B_DISEASE
more O
rapidly O
than O
normal B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
that O
the O
frameshift B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
causes O
the O
sodium B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
channel B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
to O
be O
non B_DISEASE
- O
functional B_DISEASE_ADJECTIVE[DISEASE]
. O

Our O
results O
indicate O
that O
mutations O
in O
cardiac O
ion O
- O
channel O
genes O
contribute O
to O
the O
risk O
of O
developing O
IVF B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O
. O

Molecular O
heterogeneity O
in O
mucopolysaccharidosis B_DISEASE/B_LOCATION
IVA I_DISEASE/I_LOCATION
in O
Australia O
and O
Northern O
Ireland O
: O
nine O
novel O
mutations O
including O
T312S O
, O
a O
common O
allele O
that O
confers O
a O
mild O
phenotype O
. O

Mucopolysaccharidosis B_DISEASE/B_PROTEIN[GENE]
IVA B_DISEASE/I_PROTEIN[GENE]
( O
MPS B_LOCATION/B_PERSON
IVA I_LOCATION/I_PERSON
) O
is O
an O
autosomal B_DISEASE/B_GENE
recessive I_DISEASE/I_GENE
lysosomal I_DISEASE/I_GENE
storage I_DISEASE/I_GENE
disorder I_DISEASE/I_GENE
caused O
by O
a O
genetic B_DISEASE_ADJECTIVE[DISEASE]
defect I_DISEASE_ADJECTIVE[DISEASE]
in O
N O
- O
acetylgalactosamine O
- O
6 O
- O
sulfate O
sulfatase O
( O
GALNS O
) O
. O

Previous O
studies O
of O
patients O
from O
a O
British O
- O
Irish O
population O
showed O
that O
the O
I113F O
mutation O
is O
the O
most O
common O
single O
mutation O
among O
MPS B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IVA I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O
and O
produces O
a O
severe O
clinical O
phenotype O
. O

We O
studied O
mutations O
in O
the O
GALNS O
gene O
from O
23 O
additional O
MPS B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IVA I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O
( O
15 O
from O
Australia O
, O
8 O
from O
Northern O
Ireland O
) O
, O
with O
various O
clinical O
phenotypes O
( O
severe O
, O
16 O
cases O
; O
intermediate O
, O
4 O
cases O
; O
mild O
, O
3 O
cases O
) O
. O

We O
found O
two B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
common I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
that O
together O
accounted O
for O
32 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
44 B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
unrelated I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
alleles I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O
these O
patients B_PERSON/B_BIO
. O

One B_SEQUENCE[MEASURE]/B_PERSON
is O
the O
T312S B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
a O
novel B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
found O
exclusively O
in O
milder B_PERSON/B_BIO
patients B_PERSON/I_BIO
. O

The O
other B_SEQUENCE[MEASURE]/B_DISEASE
is O
the O
previously O
described O
I113F B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O
produces O
a O
severe B_DISEASE_ADJECTIVE[DISEASE]
phenotype I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
I113F B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
T312S B_DISEASE/B_PROTEIN[GENE]
mutations B_DISEASE/I_PROTEIN[GENE]
accounted O
for O
8 B_MEASURE
( O
18 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
6 B_MEASURE
( O
14 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
of O
44 B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
unrelated I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
alleles I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
respectively O
. O

The O
relatively O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
residual I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
GALNS I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
activity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
seen O
when O
the O
T312S B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
mutant I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
cDNA I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
overexpressed O
in O
mutant B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
provides O
an O
explanation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
the O
mild B_DISEASE_ADJECTIVE[DISEASE]
phenotype I_DISEASE_ADJECTIVE[DISEASE]
in O
patients B_PERSON/B_BIO
with O
this O
mutation B_DISEASE/B_GENE
. O

The O
distribution B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
relative B_MEASURE/B_LOCATION
frequencies I_MEASURE/I_LOCATION
of O
the O
I113F B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
T312S B_DISEASE/B_GENE
mutations B_DISEASE/I_GENE
in O
Australia B_LOCATION/B_PERSON
corresponded O
to O
those O
observed O
in O
Northern B_LOCATION
Ireland I_LOCATION
and O
are O
unique B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
these O
two B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
populations I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
suggesting O
that O
both O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
were O
probably O
introduced O
to O
Australia B_LOCATION
by O
Irish B_PERSON/B_LOCATION
migrants I_PERSON/I_LOCATION
during O
the O
19th B_TIME[MEASURE]/B_LOCATION
century I_TIME[MEASURE]/I_LOCATION
. O

haplotype B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
6 B_GENE
RFLPs I_GENE
provides O
additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
that O
the O
I113F B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
originated O
from O
a O
common B_PERSON/B_GENE
ancestor I_PERSON/I_GENE
. O

The O
other B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
9 I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
novel I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
identified O
in O
these O
23 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
were O
each O
limited O
to O
a O
single B_MEASURE/B_PERSON
family I_MEASURE/I_PERSON
. O

These O
data O
provide O
further O
evidence O
for O
extensive O
allelic O
heterogeneity O
in O
MPS B_DISEASE/B_GENE
IVA B_DISEASE/I_GENE
in O
British O
- O
Irish O
patients O
and O
provide O
evidence O
for O
their O
transmission O
to O
Australia O
by O
British O
- O
Irish O
migrants O
. O
. O

identification O
of O
constitutional O
WT1 O
mutations O
, O
in O
patients O
with O
isolated O
diffuse B_DISEASE/B_GENE
mesangial I_DISEASE/I_GENE
sclerosis I_DISEASE/I_GENE
, O
and O
analysis O
of O
genotype O
/ O
phenotype O
correlations O
by O
use O
of O
a O
computerized O
mutation O
database O
. O

Constitutional O
mutations O
of O
the O
WT1 O
gene O
, O
encoding O
a O
zinc O
- O
finger O
transcription O
factor O
involved O
in O
renal O
and O
gonadal O
development O
, O
are O
found O
in O
most O
patients O
with O
Denys B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
Drash I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
syndrome I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
DDS B_DISEASE
) O
, O
or O
diffuse B_DISEASE
mesangial I_DISEASE
sclerosis I_DISEASE
( O
DMS B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
associated O
with O
pseudohermaphroditism B_DISEASE/B_BIO
and O
/ O
or O
Wilms B_DISEASE/B_GENE
tumor I_DISEASE/I_GENE
( O
WT B_PROTEIN[GENE]/B_LOCATION
) O
. O

Most O
mutations O
in O
DDS B_DISEASE/B_PERSON
patients O
lie O
in O
exon O
8 O
or O
exon O
9 O
, O
encoding O
zinc O
finger O
2 O
or O
zinc O
finger O
3 O
, O
respectively O
, O
with O
a O
hot O
spot O
( O
R394W O
) O
in O
exon O
9 O
. O

We O
analyzed O
a O
series O
of O
24 O
patients O
, O
10 O
with O
isolated B_DISEASE/B_GENE
DMS I_DISEASE/I_GENE
( O
IDMS B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
10 O
with O
DDS B_DISEASE/B_LOCATION
, O
and O
4 O
with O
urogenital B_DISEASE/B_PROTEIN[GENE]
abnormalities B_DISEASE/I_PROTEIN[GENE]
and O
/ O
or O
WT B_DISEASE/B_GENE
. O

We O
report O
WT1 O
heterozygous O
mutations O
in O
16 O
patients O
, O
4 O
of O
whom O
presented O
with O
IDMS B_DISEASE
. O

One O
male O
and O
two O
female O
IDMS B_DISEASE/B_PERSON
patients O
with O
WT1 O
mutations O
underwent O
normal O
puberty O
. O

Two O
mutations O
associated O
with O
IDMS B_DISEASE
are O
different O
from O
those O
described O
in O
DDS B_DISEASE/B_MEASURE
patients O
. O

No O
WT1 O
mutations O
were O
detected O
in O
the O
six O
other O
IDMS B_DISEASE/B_NUMBER[MEASURE]
patients O
, O
suggesting O
genetic O
heterogeneity O
of O
this O
disease O
. O

We O
analyzed O
genotype B_GENE/B_DISEASE
/ O
phenotype B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlations I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
on O
the O
basis B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
constitution B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
WT1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mutation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
84 B_SEQUENCE[MEASURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
germ I_SEQUENCE[MEASURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
line B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
to O
compare O
the O
distribution B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
type B_DISEASE/B_MEASURE
of O
mutations B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
, O
according O
to O
the O
different B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
symptoms I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
demonstrated O
( O
1 O
) O
the O
association O
between O
mutations O
in O
exons O
8 O
and O
9 O
and O
DMS B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
( O
2 O
) O
among O
patients O
with O
DMS B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
higher O
frequency O
of O
exon O
8 O
mutations O
among O
46 O
, O
XY O
patients O
with O
female O
phenotype O
than O
among O
46 O
, O
XY O
patients O
with O
sexual O
ambiguity O
or O
male O
phenotype O
; O
and O
( O
3 O
) O
statistically O
significant O
evidence O
that O
mutations O
in O
exons O
8 O
and O
9 O
preferentially O
affect O
amino O
acids O
with O
different O
functions O
. O
. O

The O
185delAG B_DISEASE/B_MEASURE
BRCA1 I_DISEASE/I_MEASURE
mutation I_DISEASE/I_MEASURE
originated O
before O
the O
dispersion B_TIME[MEASURE]/B_PERSON
of O
Jews B_PERSON/B_LOCATION
in O
the O
diaspora B_LOCATION/B_PERSON
and O
is O
not O
limited O
to O
Ashkenazim B_PERSON/B_LOCATION
. O

The O
185delAG O
mutation O
in O
BRCA1 O
is O
detected O
in O
Ashkenazi O
Jews O
both O
in O
familial B_PERSON/B_LOCATION
breast I_PERSON/I_LOCATION
and I_PERSON/I_LOCATION
ovarian I_PERSON/I_LOCATION
cancer I_PERSON/I_LOCATION
and O
in O
the O
general O
population O
. O

All O
tested O
Ashkenazi B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutation I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
carriers I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
share O
the O
same B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
allelic I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
pattern I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
at O
the O
BRCA1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
locus I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Our O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
that O
this O
Ashkenazi B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
also O
occurs O
in O
Iraqi B_PERSON/B_LOCATION
Jews I_PERSON/I_LOCATION
with O
a O
similar B_DISEASE/B_PERSON
allelic I_DISEASE/I_PERSON
pattern I_DISEASE/I_PERSON
. O

We O
extended O
our O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
other B_PERSON/B_DISEASE
non I_PERSON/I_DISEASE
- O
Ashkenazi B_PERSON
subsets I_PERSON
354 I_PERSON
of O
Moroccan B_MEASURE/B_PERSON
origin I_MEASURE/I_PERSON
, O
200 B_MEASURE/B_PERSON
Yemenites I_MEASURE/I_PERSON
and O
150 B_PERSON
Iranian I_PERSON
Jews I_PERSON
. O

Heteroduplex B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
complemented O
by O
direct B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequencing I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
abnormally O
migrating O
bands B_LOCATION/B_GENE
were O
employed O
. O

Four B_NUMBER[MEASURE]/B_PERSON
of O
Moroccan B_PERSON/B_LOCATION
origin I_PERSON/I_LOCATION
( O
1 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
) O
and O
none B_PERSON/B_NUMBER[MEASURE]
of O
the O
Yemenites B_PERSON/B_LOCATION
or O
Iranians B_PERSON/B_LOCATION
was O
a O
carrier B_PERSON/B_MEASURE
of O
the O
185delAG B_DISEASE_ADJECTIVE[DISEASE]
mutation I_DISEASE_ADJECTIVE[DISEASE]
. O

BRCA1 O
allelic O
patterns O
were O
determined O
for O
four O
of O
these O
individuals O
and O
for O
12 O
additional O
non O
- O
Ashkenazi O
185delAG O
mutation O
carriers O
who O
had O
breast B_DISEASE
/ I_DISEASE
ovarian I_DISEASE
cancer I_DISEASE
. O

Six B_NUMBER[MEASURE]/B_DISEASE
non I_NUMBER[MEASURE]/I_DISEASE
- O
Ashkenazi B_PERSON
individuals I_PERSON
shared O
the O
common B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
Ashkenazi B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
haplotype B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
four B_NUMBER[MEASURE]
had O
a O
closely O
related O
pattern B_DISEASE/B_GENE
, O
and O
the O
rest B_SEQUENCE[MEASURE]/B_LOCATION
( O
n B_OTHER/B_LOCATION
= O
6 B_MEASURE
) O
displayed O
a O
distinct B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
BRCA1 I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
allelic I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
pattern I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O

We O
conclude O
that O
the O
185delAG B_DISEASE_ADJECTIVE[DISEASE]
BRCA1 I_DISEASE_ADJECTIVE[DISEASE]
mutation I_DISEASE_ADJECTIVE[DISEASE]
occurs O
in O
some O
non B_LOCATION/B_PERSON
- O
Ashkenazi B_PERSON/B_LOCATION
populations I_PERSON/I_LOCATION
at O
rates B_MEASURE/B_LOCATION
comparable I_MEASURE/I_LOCATION
with O
that O
of O
Ashkenazim B_PERSON/B_LOCATION
. O

The O
majority B_PERSON/B_LOCATION
of O
Jewish B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
185delAG I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
mutation I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
carriers I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
have O
a O
common B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
allelic B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
pattern B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
supporting O
the O
founder B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
notion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
but O
dating O
the O
mutations B_DISEASE_ADJECTIVE[DISEASE]
origin I_DISEASE_ADJECTIVE[DISEASE]
to O
an O
earlier B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
date I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
currently O
estimated O
. O

However O
, O
the O
different B_DISEASE_ADJECTIVE[DISEASE]
allelic I_DISEASE_ADJECTIVE[DISEASE]
pattern I_DISEASE_ADJECTIVE[DISEASE]
at O
the O
BRCA1 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
locus B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
even O
in O
some O
Jewish B_DISEASE/B_PERSON
mutation I_DISEASE/I_PERSON
carriers I_DISEASE/I_PERSON
, O
might O
suggest O
that O
the O
mutation B_DISEASE/B_GENE
arose O
independently O
. O
. O

Crystal O
structure O
of O
the O
hemochromatosis B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
protein O
HFE O
and O
characterization O
of O
its O
interaction O
with O
transferrin O
receptor O
. O

HFE O
is O
an O
MHC O
- O
related O
protein O
that O
is O
mutated O
in O
the O
iron B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
- I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
overload I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
hereditary I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
hemochromatosis I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

HFE B_DISEASE/B_PROTEIN[GENE]
binds O
to O
transferrin O
receptor B_PROTEIN[GENE]/B_DISEASE
( O
TfR B_PROTEIN[GENE]/B_LOCATION
) O
and O
reduces O
its O
affinity B_MEASURE/B_GENE
for O
iron B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
loaded O
transferrin B_PROTEIN[GENE]
, O
implicating O
HFE B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
iron B_DISEASE
metabolism I_DISEASE
. O

The O
2 B_TIME[MEASURE]/B_PERSON
. O

6 O
A O
crystal O
structure O
of O
HFE O
reveals O
the O
locations O
of O
hemochromatosis B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
mutations O
and O
a O
patch O
of O
histidines O
that O
could O
be O
involved O
in O
pH O
- O
dependent O
interactions O
. O

We O
also O
demonstrate O
that O
soluble B_PROTEIN[GENE]/B_LOCATION
TfR I_PROTEIN[GENE]/I_LOCATION
and O
HFE B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
bind O
tightly O
at O
the O
basic B_LOCATION/B_MEASURE
pH I_LOCATION/I_MEASURE
of O
the O
cell B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
surface I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
, O
but O
not O
at O
the O
acidic B_MEASURE/B_LOCATION
pH B_MEASURE/I_LOCATION
of O
intracellular B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
vesicles I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

TfR B_GENE/B_MEASURE
HFE B_GENE/I_MEASURE
stoichiometry B_GENE/I_MEASURE
( O
2 B_MEASURE
1 I_MEASURE
) O
differs O
from O
TfR B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transferrin I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stoichiometry I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 B_MEASURE
2 I_MEASURE
) O
, O
implying O
a O
different B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mode I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
binding B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
HFE B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
transferrin B_GENE
to O
TfR B_GENE
, O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
our O
demonstration B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
HFE B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
transferrin B_GENE
, O
and O
TfR B_GENE
form O
a O
ternary B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
complex I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

identification O
of O
three O
novel O
mutations O
and O
a O
high O
frequency O
of O
the O
Arg778Leu O
mutation O
in O
Korean O
patients O
with O
Wilson B_DISEASE/B_GENE
disease I_DISEASE/I_GENE
. O

Four O
mutations O
- O
- O
R778L O
, O
A874V O
, O
L1083F O
, O
and O
2304delC O
- O
- O
in O
the O
copper O
- O
transporting O
enzyme O
, O
P O
- O
type O
ATPase O
( O
ATP7B O
) O
, O
were O
identified O
in O
Korean O
patients O
with O
Wilson B_DISEASE
disease I_DISEASE
. O

Arg778Leu B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
most O
frequently O
reported O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
of O
this O
enzyme B_BIO/B_GENE
, O
was O
found O
in O
six B_NUMBER[MEASURE]
of O
eight B_NUMBER[MEASURE]/B_PERSON
unrelated I_NUMBER[MEASURE]/I_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
studied O
, O
an O
allele B_MEASURE
frequency I_MEASURE
of O
37 B_NUMBER[MEASURE]
. O

5 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
, O
which O
is O
considerably O
higher B_MEASURE
than O
those O
in O
other B_LOCATION
Asian I_LOCATION
populations I_LOCATION
. O

The O
novel B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
single I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
nucleotide I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
deletion I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
, O
2304delC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
was O
found O
in O
one B_PERSON/B_BIO
patient B_PERSON/I_BIO
. O

Since O
a O
mutation O
at O
cDNA O
nucleotide O
2302 O
( O
2302insC O
) O
had O
been O
previously O
described O
, O
this O
region O
of O
the O
ATP7B O
gene O
may O
be O
susceptible O
to O
gene O
rearrangements O
causing O
Wilson B_DISEASE
disease I_DISEASE
. O

disruption O
of O
splicing O
regulated O
by O
a O
CUG O
- O
binding O
protein O
in O
myotonic B_DISEASE/B_BIO
dystrophy I_DISEASE/I_BIO
. O

Myotonic B_DISEASE
dystrophy I_DISEASE
( O
DM B_LOCATION
) O
is O
caused O
by O
a O
CTG O
expansion O
in O
the O
3 O
untranslated O
region O
of O
the O
DM B_GENE/B_DISEASE
gene O
. O

One O
model O
of O
DM B_DISEASE
pathogenesis O
suggests O
that O
RNAs O
from O
the O
expanded O
allele O
create O
a O
gain O
- O
of O
- O
function O
mutation O
by O
the O
inappropriate O
binding O
of O
proteins O
to O
the O
CUG O
repeats O
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
presented O
here O
indicate O
that O
the O
conserved B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
heterogeneous I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
nuclear I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
ribonucleoprotein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
CUG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
binding O
protein B_PROTEIN[GENE]/B_BACTERIUM[BIO]
( O
CUG B_PROTEIN[GENE]/B_LOCATION
- O
BP B_PROTEIN[GENE]/B_LOCATION
) O
, O
may O
mediate O
the O
trans B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dominant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
the O
RNA B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

CUG B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
BP B_MEASURE
was O
found O
to O
bind O
to O
the O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cardiac I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
troponin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
T I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
cTNT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
messenger B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
RNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
regulate O
its O
alternative B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Splicing O
of O
cTNT O
was O
disrupted O
in O
DM B_DISEASE/B_MEASURE
striated O
muscle O
and O
in O
normal O
cells O
expressing O
transcripts O
that O
contain O
CUG O
repeats O
. O

altered O
expression O
of O
genes O
regulated O
posttranscriptionally O
by O
CUG O
- O
BP O
therefore O
may O
contribute O
to O
DM B_DISEASE/B_LOCATION
pathogenesis O
. O
. O

identification O
of O
a O
novel O
nonsense O
mutation O
and O
a O
missense O
substitution O
in O
the O
vasopressin O
- O
neurophysin O
II O
gene O
in O
two O
Spanish O
kindreds O
with O
familial B_DISEASE
neurohypophyseal I_DISEASE
diabetes I_DISEASE
insipidus I_DISEASE
. O

Familial B_DISEASE/B_PERSON
neurohypophyseal I_DISEASE/I_PERSON
diabetes I_DISEASE/I_PERSON
insipidus I_DISEASE/I_PERSON
( O
FNDI B_DISEASE
) O
is O
an O
autosomal B_DISEASE
dominant I_DISEASE
disease I_DISEASE
caused O
by O
deficiency O
in O
the O
antidiuretic O
hormone O
arginine O
vasopressin O
( O
AVP O
) O
encoded O
by O
the O
AVP O
- O
neurophysin O
II O
( O
AVP O
- O
NPII O
) O
gene O
on O
chromosome O
20p13 O
. O

In O
this O
study O
, O
we O
analyzed O
two O
families O
with O
FNDI B_DISEASE
using O
direct O
automated O
fluorescent O
, O
solid O
phase O
, O
single O
- O
stranded O
DNA O
sequencing O
of O
PCR O
- O
amplified O
AVP O
- O
NPII O
DNA O
. O

In O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
families B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
affected B_PERSON
individuals I_PERSON
presented O
a O
novel B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
nonsense I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
mutation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O
exon B_GENE/B_LOCATION
3 B_GENE/I_LOCATION
of O
the O
gene B_GENE/B_DISEASE
, O
consisting O
in O
a O
G B_OTHER/B_LOCATION
to O
T B_MEASURE/B_DISEASE
transition I_MEASURE/I_DISEASE
at O
nucleotide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
2101 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
, O
which O
produces O
a O
stop B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
signal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
codon B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
82 I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
( O
Glu B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O
of O
NPII B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
. O

The O
premature B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
termination I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
eliminates O
part B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
terminal B_LOCATION/B_MEASURE
domain I_LOCATION/I_MEASURE
of O
NPII B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
including O
a O
cysteine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
residue I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
position B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
85 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
, O
which O
could O
be O
involved O
in O
the O
correct B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
folding B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
the O
prohormone B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
second B_PERSON/B_TIME[MEASURE]
family I_PERSON/I_TIME[MEASURE]
, O
a O
G279A B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
substitution B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
position B_LOCATION
- O
1 B_MEASURE
of O
the O
signal B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peptide I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
in O
all O
affected O
individuals B_PERSON/B_BIO
. O

This O
missense O
mutation O
, O
which O
replaces O
Ala O
with O
Thr O
, O
is O
frequent O
among O
FNDI B_DISEASE/B_LOCATION
patients O
and O
is O
thought O
to O
reduce O
the O
efficiency O
of O
cleavage O
by O
signal O
peptidases O
. O
. O

genetic O
heterogeneity O
of O
Saethre B_DISEASE/B_GENE
- I_DISEASE/I_GENE
Chotzen I_DISEASE/I_GENE
syndrome I_DISEASE/I_GENE
, O
due O
to O
twist O
and O
FGFR O
mutations O
. O

Thirty O
- O
two O
unrelated O
patients O
with O
features O
of O
Saethre B_DISEASE
- I_DISEASE
Chotzen I_DISEASE
syndrome I_DISEASE
, O
a O
common O
autosomal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dominant I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
condition I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
craniosynostosis B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
limb B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
anomalies I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
were O
screened O
for O
mutations O
in O
twist O
, O
FGFR2 O
, O
and O
FGFR3 O
. O

Nine B_NUMBER[MEASURE]/B_ENT
novel I_NUMBER[MEASURE]/I_ENT
and O
three B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
recurrent I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
twist I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
were O
found O
in O
12 B_PERSON/B_ENT
families I_PERSON/I_ENT
. O

Seven B_NUMBER[MEASURE]/B_ENT
families I_NUMBER[MEASURE]/I_ENT
were O
found O
to O
have O
the O
FGFR3 B_DISEASE_ADJECTIVE[DISEASE]
P250R I_DISEASE_ADJECTIVE[DISEASE]
mutation I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
one B_NUMBER[MEASURE]/B_PERSON
individual I_NUMBER[MEASURE]/I_PERSON
was O
found O
to O
have O
an O
FGFR2 B_LOCATION/B_GENE
VV269 I_LOCATION/I_GENE
- O
270 B_DISEASE_ADJECTIVE[DISEASE]
deletion I_DISEASE_ADJECTIVE[DISEASE]
. O

To O
date O
, O
our O
detection O
rate O
for O
twist O
or O
FGFR O
mutations O
is O
68 O
% O
in O
our O
Saethre B_NUMBER[MEASURE]
- I_NUMBER[MEASURE]
Chotzen I_NUMBER[MEASURE]
syndrome I_NUMBER[MEASURE]
patients O
, O
including O
our O
five O
patients O
elsewhere O
reported O
with O
twist O
mutations O
. O

More B_MEASURE/B_PERSON
than O
35 B_NUMBER[MEASURE]
different I_NUMBER[MEASURE]
twist I_NUMBER[MEASURE]
mutations I_NUMBER[MEASURE]
are O
now O
known O
in O
the O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
most O
common O
phenotypic O
features O
, O
present O
in O
more O
than O
a O
third O
of O
our O
patients O
with O
twist O
mutations O
, O
are O
coronal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
synostosis I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
brachycephaly B_DISEASE
, O
low B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
frontal I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
hairline I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
facial B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
asymmetry I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
ptosis B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
hypertelorism B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
broad B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
great I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
toes I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
clinodactyly B_DISEASE
. O

Significant B_DISEASE/B_MEASURE
intra I_DISEASE/I_MEASURE
- O
and O
interfamilial B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
phenotypic B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
variability B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
is O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
either O
twist B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutations I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
or O
FGFR B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

The O
overlap O
in O
clinical O
features O
and O
the O
presence O
, O
in O
the O
same O
genes O
, O
of O
mutations O
for O
more O
than O
one O
craniosynostotic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
condition B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- O
such O
as O
Saethre B_DISEASE/B_LOCATION
- I_DISEASE/I_LOCATION
Chotzen I_DISEASE/I_LOCATION
, I_DISEASE/I_LOCATION
Crouzon I_DISEASE/I_LOCATION
, I_DISEASE/I_LOCATION
and I_DISEASE/I_LOCATION
Pfeiffer I_DISEASE/I_LOCATION
syndromes I_DISEASE/I_LOCATION
- O
support O
the O
hypothesis O
that O
twist O
and O
FGFRs O
are O
components O
of O
the O
same O
molecular O
pathway O
involved O
in O
the O
modulation O
of O
craniofacial O
and O
limb O
development O
in O
humans O
. O
. O

mutation O
analysis O
of O
UBE3A O
in O
Angelman B_DISEASE/B_NUMBER[MEASURE]
syndrome I_DISEASE/I_NUMBER[MEASURE]
patients O
. O

Angelman B_DISEASE/B_PERSON
syndrome I_DISEASE/I_PERSON
( O
AS B_DISEASE/B_PROTEIN[GENE]
) O
is O
caused O
by O
chromosome O
15q11 O
- O
q13 O
deletions O
of O
maternal O
origin O
, O
by O
paternal O
uniparental B_DISEASE/B_GENE
disomy I_DISEASE/I_GENE
( O
UPD B_LOCATION
) O
15 O
, O
by O
imprinting O
defects O
, O
and O
by O
mutations O
in O
the O
UBE3A O
gene O
. O

UBE3A B_GENE
encodes O
a O
ubiquitin B_GENE
- O
protein B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
ligase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
shows O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imprinting B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Here O
we O
describe O
UBE3A O
coding O
- O
region O
mutations O
detected O
by O
SSCP O
analysis O
in O
13 O
AS B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
individuals O
or O
families O
. O

Two B_MEASURE/B_LOCATION
identical B_MEASURE/I_LOCATION
de B_MEASURE/I_LOCATION
novo B_MEASURE/I_LOCATION
5 B_MEASURE/I_LOCATION
- O
bp B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
duplications B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
exon B_GENE
16 I_GENE
were O
found O
. O

Among O
the O
other B_DISEASE_ADJECTIVE[DISEASE]
11 I_DISEASE_ADJECTIVE[DISEASE]
unique I_DISEASE_ADJECTIVE[DISEASE]
mutations I_DISEASE_ADJECTIVE[DISEASE]
, O
8 B_NUMBER[MEASURE]
were O
small B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
deletions I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
or O
insertions B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
predicted O
to O
cause O
frameshifts B_DISEASE/B_GENE
, O
1 B_NUMBER[MEASURE]
was O
a O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
to O
a O
stop B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
codon B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
1 B_MEASURE
was O
a O
missense B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mutation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
1 B_NUMBER[MEASURE]
was O
predicted O
to O
cause O
insertion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
an O
isoleucine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
hect B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
domain I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
UBE3A B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
protein I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
functions O
in O
E2 B_GENE
binding I_GENE
and O
ubiquitin B_GENE
transfer I_GENE
. O

Eight B_NUMBER[MEASURE]
of O
the O
cases B_PERSON/B_DISEASE
were O
familial B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
, O
and O
five B_NUMBER[MEASURE]/B_PERSON
were O
sporadic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O

In O
two O
familial O
cases O
and O
one O
sporadic O
case O
, O
mosaicism O
for O
UBE3A O
mutations O
was O
detected O
in O
the O
mother O
of O
three O
AS B_DISEASE
sons O
, O
in O
the O
maternal O
grandfather O
of O
two O
AS B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
first O
cousins O
, O
and O
in O
the O
mother O
of O
an O
AS B_LOCATION/B_DISEASE
daughter O
. O

The O
frequencies B_MEASURE/B_ORGANIZATION
with O
which O
we O
detected O
mutations B_DISEASE/B_GENE
were O
5 B_MEASURE
( O
14 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
of O
35 B_NUMBER[MEASURE]
in O
sporadic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cases I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O
8 B_MEASURE
( O
80 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
of O
10 B_MEASURE
in O
familial B_DISEASE/B_PERSON
cases I_DISEASE/I_PERSON
. O
. O

The O
hemochromatosis B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
845 O
G O
- O
- O
> O
A O
and O
187 O
C O
- O
- O
> O
G O
mutations O
: O
prevalence O
in O
non O
- O
Caucasian O
populations O
. O

Hemochromatosis B_DISEASE
, O
the O
inherited B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
disorder I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
iron I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
metabolism I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
leads O
, O
if O
untreated O
, O
to O
progressive O
iron B_DISEASE
overload I_DISEASE
and O
premature B_DISEASE
death I_DISEASE
. O

The O
hemochromatosis B_DISEASE_ADJECTIVE[DISEASE]/B_SEQUENCE[MEASURE]
gene O
, O
HFE O
, O
recently O
has O
been O
identified O
, O
and O
characterization O
of O
this O
gene O
has O
shown O
that O
it O
contains O
two O
mutations O
that O
result O
in O
amino O
acid O
substitutions O
- O
cDNA O
nucleotides O
845 O
G O
- O
- O
> O
A O
( O
C282Y O
) O
and O
187 O
C O
- O
- O
> O
G O
( O
H63D O
) O
. O

Although O
hemochromatosis B_DISEASE/B_LOCATION
is O
common O
in O
Caucasians O
, O
affecting O
> O
= O
1 O
/ O
300 O
individuals O
of O
northern O
European O
origin O
, O
it O
has O
not O
been O
recognized O
in O
other O
populations O
. O

The O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
used O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
restriction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
enzyme B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
digestion B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
analyze O
the O
frequency B_MEASURE
of O
the O
845 B_PROTEIN[GENE]/B_LOCATION
G I_PROTEIN[GENE]/I_LOCATION
- O
- O
> B_PERSON/B_PROTEIN[GENE]
A B_PERSON/I_PROTEIN[GENE]
and O
187 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
- O
> B_GENE
G I_GENE
mutations I_GENE
in O
HLA B_GENE/B_MEASURE
- O
typed O
samples B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
non B_LOCATION/B_MEASURE
- O
Caucasian B_PERSON/B_LOCATION
populations I_PERSON/I_LOCATION
, O
comprising O
Australian B_PERSON/B_LOCATION
Aboriginal I_PERSON/I_LOCATION
, O
Chinese B_LOCATION/B_PERSON
, O
and O
Pacific B_PERSON/B_ORGANIZATION
Islanders I_PERSON/I_ORGANIZATION
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O
that O
the O
845 B_PROTEIN[GENE]/B_LOCATION
G I_PROTEIN[GENE]/I_LOCATION
- O
- O
> B_GENE/B_DISEASE
A I_GENE/I_DISEASE
mutation I_GENE/I_DISEASE
was O
present B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
these O
populations B_LOCATION/B_PERSON
( O
allele B_MEASURE
frequency I_MEASURE
0 I_MEASURE
. O
32 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
and O
, O
Furthermore O
, O
it O
was O
always O
seen O
in O
conjunction B_PERSON/B_LOCATION
with O
HLA B_DISEASE/B_PERSON
haplotypes I_DISEASE/I_PERSON
common I_DISEASE/I_PERSON
in O
Caucasians B_LOCATION/B_PERSON
, O
suggesting O
that O
845 B_PROTEIN[GENE]/B_LOCATION
G I_PROTEIN[GENE]/I_LOCATION
- O
- O
> B_PERSON/B_PROTEIN[GENE]
A B_PERSON/I_PROTEIN[GENE]
may O
have O
been O
introduced O
into O
these O
populations B_LOCATION/B_PERSON
by O
Caucasian B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
admixture I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

187 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
- O
> B_DISEASE/B_GENE
G B_DISEASE/I_GENE
was O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
an O
allele B_MEASURE/B_PERSON
frequency I_MEASURE/I_PERSON
of O
2 B_NUMBER[MEASURE]
. O

68 B_PERSON/B_MEASURE
% B_PERSON/I_MEASURE
in O
the O
two B_LOCATION/B_MEASURE
populations I_LOCATION/I_MEASURE
analyzed O
( O
Australian B_PERSON/B_LOCATION
Aboriginal I_PERSON/I_LOCATION
and O
Chinese B_LOCATION/B_PERSON
) O
. O

In O
the O
Australian B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
Aboriginal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
samples I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
187 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
- O
> B_PROTEIN[GENE]/B_DISEASE
G I_PROTEIN[GENE]/I_DISEASE
was O
found O
to O
be O
associated O
with O
HLA B_DISEASE/B_LOCATION
haplotypes I_DISEASE/I_LOCATION
common I_DISEASE/I_LOCATION
in O
Caucasians B_LOCATION/B_PERSON
, O
suggesting O
that O
it O
was O
introduced O
by O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
admixture I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

In O
the O
Chinese B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analyzed O
, O
187 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
- O
> B_DISEASE/B_PROTEIN[GENE]
G B_DISEASE/I_PROTEIN[GENE]
was O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
association B_ORGANIZATION/B_PERSON
with O
a O
wide B_MEASURE/B_ENT
variety I_MEASURE/I_ENT
of O
HLA B_DISEASE/B_GENE
haplotypes I_DISEASE/I_GENE
, O
showing O
this O
mutation B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
be O
widespread B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
likely B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
to O
predate O
the O
more O
genetically O
restricted B_PROTEIN[GENE]/B_LOCATION
845 I_PROTEIN[GENE]/I_LOCATION
G I_PROTEIN[GENE]/I_LOCATION
- O
- O
> B_GENE/B_DISEASE
A I_GENE/I_DISEASE
mutation I_GENE/I_DISEASE
. O

Genotype O
- O
phenotype O
correlations O
in O
attenuated B_DISEASE/B_BIO
adenomatous I_DISEASE/I_BIO
polyposis I_DISEASE/I_BIO
coli I_DISEASE/I_BIO
. O

Germ O
- O
line O
mutations O
of O
the O
tumor B_DISEASE/B_GENE
suppressor O
APC O
are O
implicated O
in O
attenuated B_DISEASE/B_GENE
adenomatous I_DISEASE/I_GENE
polyposis I_DISEASE/I_GENE
coli I_DISEASE/I_GENE
( O
AAPC B_LOCATION/B_PERSON
) O
, O
a O
variant O
of O
familial B_DISEASE/B_GENE
adenomatous I_DISEASE/I_GENE
polyposis I_DISEASE/I_GENE
( O
FAP B_DISEASE/B_GENE
) O
. O

AAPC B_DISEASE/B_PERSON
is O
recognized O
by O
the O
occurrence O
of O
< O
100 O
colonic B_DISEASE/B_PERSON
adenomas I_DISEASE/I_PERSON
and O
a O
later O
onset O
of O
colorectal B_DISEASE
cancer I_DISEASE
( O
age O
> O
40 O
years O
) O
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
genotype O
- O
phenotype O
correlations O
in O
AAPC B_PERSON/B_LOCATION
families O
. O

By O
protein O
- O
truncation O
test O
( O
PTT O
) O
assay O
, O
the O
entire O
coding O
region O
of O
the O
APC B_GENE/B_BACTERIUM[BIO]
gene O
was O
screened O
in O
affected O
individuals O
from O
11 O
AAPC B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
kindreds O
, O
and O
their O
phenotypic O
differences O
were O
examined O
. O

Five O
novel O
germ O
- O
line O
APC B_GENE/B_BACTERIUM[BIO]
mutations O
were O
identified O
in O
seven O
kindreds O
. O

mutations O
were O
located O
in O
three O
different O
regions O
of O
the O
APC B_GENE/B_BACTERIUM[BIO]
gene O
( O
1 O
) O
at O
the O
5 O
end O
spanning O
exons O
4 O
and O
5 O
, O
( O
2 O
) O
within O
exon O
9 O
, O
and O
( O
3 O
) O
at O
the O
3 O
distal O
end O
of O
the O
gene O
. O

Variability O
in O
the O
number O
of O
colorectal B_DISEASE/B_PERSON
adenomas I_DISEASE/I_PERSON
was O
most O
apparent O
in O
individuals O
with O
mutations O
in O
region O
1 O
, O
and O
upper O
- O
gastrointestinal O
manifestations O
were O
more O
severe O
in O
them O
. O

In O
individuals O
with O
mutations O
in O
either O
region O
2 O
or O
region O
3 O
, O
the O
average O
number O
of O
adenomas B_DISEASE/B_BIO
tended O
to O
be O
lower O
than O
those O
in O
individuals O
with O
mutations O
in O
region O
1 O
, O
although O
age O
at O
diagnosis O
was O
similar O
. O

In O
all O
AAPC B_NUMBER[MEASURE]/B_PERSON
kindreds O
, O
a O
predominance O
of O
right O
- O
sided O
colorectal B_DISEASE
adenomas I_DISEASE
and O
rectal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
polyp I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
sparing O
was O
observed O
. O

No O
desmoid B_DISEASE/B_GENE
tumors I_DISEASE/I_GENE
were O
found O
in O
these O
kindreds O
. O

Our O
data O
suggest O
that O
, O
in O
AAPC B_DISEASE/B_NUMBER[MEASURE]
families O
, O
the O
location O
of O
the O
APC B_GENE/B_BACTERIUM[BIO]
mutation O
may O
partially O
predict O
specific O
phenotypic O
expression O
. O

This O
should O
help O
in O
the O
design O
of O
tailored O
clinical O
- O
management O
protocols O
in O
this O
subset O
of O
FAP B_DISEASE/B_PERSON
patients O
. O
. O

Wilms B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
' B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
tumor B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 O
and O
Dax O
- O
1 O
modulate O
the O
orphan O
nuclear O
receptor O
SF O
- O
1 O
in O
sex O
- O
specific O
gene O
expression O
. O

Products O
of O
steroidogenic O
factor O
1 O
( O
SF O
- O
1 O
) O
and O
Wilms B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
tumor B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1 O
( O
WT1 O
) O
genes O
are O
essential O
for O
mammalian O
gonadogenesis O
prior O
to O
sexual O
differentiation O
. O

In O
males B_PERSON/B_BIO
, O
SF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_NUMBER[MEASURE]
participates O
in O
sexual B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
development B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
by O
regulating O
expression B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
polypeptide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
Mullerian B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
inhibiting O
substance B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
MIS B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Here O
, O
we O
show O
that O
WT1 B_PROTEIN[GENE]/B_LOCATION
- O
KTS B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
isoforms O
associate B_PERSON/B_TIME[MEASURE]
and O
synergize O
with O
SF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_MEASURE/B_LOCATION
to O
promote O
MIS B_DISEASE
expression I_DISEASE
. O

In O
contrast O
, O
WT1 O
missense O
mutations O
, O
associated O
with O
male B_DISEASE/B_GENE
pseudohermaphroditism I_DISEASE/I_GENE
in O
Denys B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
- I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
Drash I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
syndrome I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
fail O
to O
synergize O
with O
SF O
- O
1 O
. O

Additionally O
, O
the O
X B_OTHER/B_DISEASE
- O
linked O
, O
candidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dosage I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
sensitive B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sex B_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
reversal B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Dax B_PERSON/B_LOCATION
- O
1 B_NUMBER[MEASURE]
, O
antagonizes O
synergy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
between O
SF B_LOCATION
- O
1 B_NUMBER[MEASURE]
and O
WT1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
most O
likely B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
through O
a O
direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
with O
SF B_LOCATION/B_GENE
- O
1 B_NUMBER[MEASURE]
. O

We O
propose O
that O
WT1 B_GENE
and O
Dax B_PERSON/B_LOCATION
- O
1 B_MEASURE
functionally O
oppose O
each O
other B_NUMBER[MEASURE]/B_DISEASE
in O
testis B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
development I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
by O
modulating O
SF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
1 B_NUMBER[MEASURE]
- O
mediated O
transactivation B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
. O

A O
mouse O
model O
for O
Prader B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
- B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
Willi B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
syndrome B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
imprinting O
- O
centre O
mutations O
. O

Imprinting O
in O
the O
15q11 B_GENE/B_MEASURE
- O
q13 B_MEASURE/B_GENE
region I_MEASURE/I_GENE
involves O
an O
imprinting O
centre B_LOCATION/B_MEASURE
( O
IC B_DISEASE/B_PROTEIN[GENE]
) O
, O
mapping B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
part B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
the O
promoter B_GENE
and O
first B_GENE
exon I_GENE
of O
SNRPN B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Deletion O
of O
this O
IC O
abolishes O
local O
paternally O
derived O
gene O
expression O
and O
results O
in O
Prader B_DISEASE/B_ORGANISM_FUNCTION
- I_DISEASE/I_ORGANISM_FUNCTION
Willi I_DISEASE/I_ORGANISM_FUNCTION
syndrome I_DISEASE/I_ORGANISM_FUNCTION
( O
PWS B_MEASURE/B_DISEASE
) O
. O

We O
have O
created O
two O
deletion O
mutations O
in O
mice O
to O
understand O
PWS B_DISEASE_ADJECTIVE[DISEASE]
and O
the O
mechanism O
of O
this O
IC O
. O

mice O
harbouring O
an O
intragenic O
deletion O
in O
Snrpn O
are O
phenotypically O
normal O
, O
suggesting O
that O
mutations O
of O
SNRPN O
are O
not O
sufficient O
to O
induce O
PWS B_DISEASE
. O

mice O
with O
a O
larger O
deletion O
involving O
both O
Snrpn O
and O
the O
putative O
PWS O
- O
IC O
lack O
expression O
of O
the O
imprinted O
genes O
Zfp127 O
( O
mouse O
homologue O
of O
ZNF127 O
) O
, O
Ndn O
and O
Ipw O
, O
and O
manifest O
several O
phenotypes O
common O
to O
PWS B_PERSON
infants O
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrate O
that O
both O
the O
position B_LOCATION/B_MEASURE
of O
the O
IC B_GENE/B_DISEASE
and O
its O
role B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
coordinate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
conserved O
between O
mouse B_SPECIES[BIO]/B_DISEASE
and O
human B_SPECIES[BIO]
, O
and O
indicate O
that O
the O
mouse B_SPECIES[BIO]/B_DISEASE
is O
a O
suitable B_LOCATION/B_PERSON
model I_LOCATION/I_PERSON
system I_LOCATION/I_PERSON
in O
which O
to O
investigate O
the O
molecular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
imprinting O
in O
this O
region B_LOCATION/B_MEASURE
of O
the O
genome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O
. O

mutations O
of O
the O
ATM O
gene O
detected O
in O
Japanese O
ataxia B_DISEASE
- I_DISEASE
telangiectasia I_DISEASE
patients O
: O
possible O
preponderance O
of O
the O
two O
founder O
mutations O
4612del165 O
and O
7883del5 O
. O

The O
ATM B_GENE/B_DISEASE
( O
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
T B_GENE/B_LOCATION
, O
mutated O
) O
gene B_LOCATION/B_GENE
on O
human B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
chromosome I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
11q22 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

3 O
has O
recently O
been O
identified O
as O
the O
gene O
responsible O
for O
the O
human O
recessive B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
disease B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
ataxia B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
- B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
telangiectasia B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
A B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

In O
order O
to O
define O
the O
types O
of O
disease O
- O
causing O
ATM O
mutations O
in O
Japanese O
A B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O
as O
well O
as O
to O
look O
for O
possible O
mutational O
hotspots O
, O
reverse O
- O
transcribed O
RNA O
derived O
from O
ten O
patients O
belonging O
to O
eight O
unrelated O
Japanese O
A B_DISEASE/B_PERSON
- I_DISEASE/I_PERSON
T I_DISEASE/I_PERSON
families O
was O
analyzed O
for O
mutations O
by O
the O
restriction O
endonuclease O
fingerprinting O
method O
. O

As O
has O
been O
reported O
by O
others B_PERSON
, O
mutations B_DISEASE_ADJECTIVE[DISEASE]
that O
lead O
to O
exon B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
skipping I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
or O
premature B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
protein I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
truncation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
also O
predominant B_DISEASE_ADJECTIVE[DISEASE]
in O
our O
mutants B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

Six B_PERSON
different I_PERSON
mutations I_PERSON
were O
identified O
on O
12 B_NUMBER[MEASURE]
of O
the O
16 B_GENE/B_PERSON
alleles I_GENE/I_PERSON
examined O
. O

Four B_NUMBER[MEASURE]/B_PERSON
were O
deletions B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
involving O
a O
loss B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LOCATION
of O
a O
single B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
exon B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
exon B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
7 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
exon B_MEASURE
16 I_MEASURE
, O
exon B_MEASURE
33 I_MEASURE
or O
exon B_MEASURE
35 I_MEASURE
. O

The O
others B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
were O
minute B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
deletions I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
4649delA B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
exon B_GENE/B_MEASURE
33 I_GENE/I_MEASURE
and O
7883del5 B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
exon B_GENE/B_PERSON
55 I_GENE/I_PERSON
. O

The O
mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
4612del165 I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
and O
7883del5 B_MEASURE/B_GENE
were O
found O
in O
more B_MEASURE/B_PERSON
than O
two B_NUMBER[MEASURE]
unrelated I_NUMBER[MEASURE]
families I_NUMBER[MEASURE]
; O
44 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
( O
7 B_TIME[MEASURE]/B_LOCATION
of O
16 B_NUMBER[MEASURE]
) O
of O
the O
mutant B_PERSON/B_BIO
alleles I_PERSON/I_BIO
had O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
the O
two B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
. O

The O
4612del165 B_DISEASE_ADJECTIVE[DISEASE]
mutations I_DISEASE_ADJECTIVE[DISEASE]
in O
three B_PERSON/B_ENT
different I_PERSON/I_ENT
families I_PERSON/I_ENT
were O
all O
ascribed O
to O
the O
same B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
T I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_LOCATION
- O
- O
> B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
A B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
substitution B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
at O
the O
splice B_LOCATION/B_GENE
donor I_LOCATION/I_GENE
site I_LOCATION/I_GENE
in O
intron B_GENE/B_BIO
33 I_GENE/I_BIO
. O

microsatellite B_GENE
genotyping I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
around O
the O
ATM B_GENE/B_BIO
locus I_GENE/I_BIO
also O
indicated O
that O
a O
common B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
haplotype I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
shared O
by O
the O
mutant B_PERSON/B_BIO
alleles B_PERSON/I_BIO
in O
both O
mutations B_PERSON/B_DISEASE
. O

This O
suggests O
that O
these O
two B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
founder I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
may O
be O
predominant B_DISEASE_ADJECTIVE[DISEASE]
among O
Japanese B_PERSON/B_BIO
ATM I_PERSON/I_BIO
mutant I_PERSON/I_BIO
alleles I_PERSON/I_BIO
. O

W474C O
amino O
acid O
substitution O
affects O
early O
processing O
of O
the O
alpha O
- O
subunit O
of O
beta O
- O
hexosaminidase O
A O
and O
is O
associated O
with O
subacute O
G B_DISEASE
( I_DISEASE
M2 I_DISEASE
) I_DISEASE
gangliosidosis I_DISEASE
. O

mutations O
in O
the O
HEXA O
gene O
, O
encoding O
the O
alpha O
- O
subunit O
of O
beta O
- O
hexosaminidase O
A O
( O
Hex O
A O
) O
, O
that O
abolish O
Hex O
A O
enzyme O
activity O
cause O
Tay B_DISEASE/B_GENE
- I_DISEASE/I_GENE
Sachs I_DISEASE/I_GENE
disease I_DISEASE/I_GENE
( O
TSD B_DISEASE/B_LOCATION
) O
, O
the O
fatal O
infantile B_DISEASE_ADJECTIVE[DISEASE]
form I_DISEASE_ADJECTIVE[DISEASE]
of I_DISEASE_ADJECTIVE[DISEASE]
G I_DISEASE_ADJECTIVE[DISEASE]
( I_DISEASE_ADJECTIVE[DISEASE]
M2 I_DISEASE_ADJECTIVE[DISEASE]
) I_DISEASE_ADJECTIVE[DISEASE]
gangliosidosis I_DISEASE_ADJECTIVE[DISEASE]
, I_DISEASE_ADJECTIVE[DISEASE]
Type I_DISEASE_ADJECTIVE[DISEASE]
1 I_DISEASE_ADJECTIVE[DISEASE]
. O

Less O
severe B_DISEASE_ADJECTIVE[DISEASE]
, O
subacute B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
( O
juvenile B_PERSON
- O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
) O
and O
chronic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
( O
adult B_PERSON
- O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
) O
variants B_DISEASE
are O
characterized O
by O
a O
broad B_DISEASE/B_MEASURE
spectrum B_DISEASE/I_MEASURE
of O
clinical B_DISEASE_ADJECTIVE[DISEASE]
manifestations I_DISEASE_ADJECTIVE[DISEASE]
and O
are O
associated O
with O
residual B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
levels I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Hex B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzyme I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
identified O
a O
1422 O
G O
- O
- O
> O
C O
( O
amino O
acid O
W474C O
) O
substitution O
in O
the O
first O
position O
of O
exon O
13 O
of O
HEXA O
of O
a O
non O
- O
Jewish O
proband O
who O
manifested O
a O
subacute O
variant O
of O
G B_DISEASE/B_GENE
( I_DISEASE/I_GENE
M2 I_DISEASE/I_GENE
) I_DISEASE/I_GENE
gangliosidosis I_DISEASE/I_GENE
. O

On O
the O
second B_SEQUENCE[MEASURE]
maternally O
inherited O
allele B_GENE/B_PERSON
, O
we O
identified O
the O
common B_DISEASE/B_GENE
infantile I_DISEASE/I_GENE
disease I_DISEASE/I_GENE
- O
causing O
4 B_MEASURE/B_LOCATION
- O
bp B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
insertion I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
+ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TATC B_MEASURE/B_PERSON
1278 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
in O
exon B_GENE/B_PERSON
11 I_GENE/I_PERSON
. O

pulse B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
chase B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
proband B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
fibroblasts I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
revealed O
that O
the O
W474C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
containing O
alpha B_PROTEIN[GENE]/B_MEASURE
- O
subunit B_GENE
precursor I_GENE
was O
normally O
synthesized O
, O
but O
not O
phosphorylated O
or O
secreted O
, O
and O
the O
mature B_PROTEIN[GENE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
lysosomal I_PROTEIN[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
alpha I_PROTEIN[GENE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
subunit B_GENE
was O
not O
detected O
. O

When O
the O
W474C O
- O
containing O
alpha O
- O
subunit O
was O
transiently O
co O
- O
expressed O
with O
the O
beta O
- O
subunit O
to O
produce O
Hex O
A O
( O
alphabeta O
) O
in O
COS O
- O
7 O
cells O
, O
the O
mature O
alpha O
- O
subunit O
was O
present O
, O
but O
its O
level O
was O
much O
lower O
than O
that O
from O
normal O
alpha O
- O
subunit O
transfections O
, O
although O
higher O
than O
in O
those O
cells O
transfected O
with O
an O
alpha O
- O
subunit O
associated O
with O
infantile O
TSD B_DISEASE
. O

Furthermore O
, O
the O
precursor B_GENE/B_DISEASE
level I_GENE/I_DISEASE
of O
the O
W474C B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
subunit B_GENE
was O
found O
to O
accumulate O
in O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
normal B_PROTEIN[GENE]/B_MEASURE
alpha I_PROTEIN[GENE]/I_MEASURE
- O
subunit B_GENE
precursor I_GENE
levels I_GENE
. O

We O
conclude O
that O
the O
1422 O
G O
- O
- O
> O
C O
mutation O
is O
the O
cause O
of O
Hex B_DISEASE/B_GENE
A I_DISEASE/I_GENE
enzyme I_DISEASE/I_GENE
deficiency I_DISEASE/I_GENE
in O
the O
proband O
. O

The O
resulting O
W474C O
substitution O
clearly O
interferes O
with O
alpha O
- O
subunit O
processing O
, O
but O
because O
the O
base O
substitution O
falls O
at O
the O
first O
position O
of O
exon O
13 O
, O
aberrant O
splicing O
may O
also O
contribute O
to O
Hex B_DISEASE
A I_DISEASE
deficiency I_DISEASE
in O
this O
proband O
. O
. O

Two O
frequent O
missense O
mutations O
in O
Pendred B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
syndrome B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

Pendred B_DISEASE/B_LOCATION
syndrome I_DISEASE/I_LOCATION
is O
an O
autosomal B_DISEASE_ADJECTIVE[DISEASE]
recessive I_DISEASE_ADJECTIVE[DISEASE]
disorder I_DISEASE_ADJECTIVE[DISEASE]
characterized O
by O
early O
childhood O
deafness B_DISEASE
and O
goiter B_DISEASE
. O

A O
century B_TIME[MEASURE]
after O
its O
recognition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
as O
a O
syndrome B_DISEASE/B_PERSON
by O
Vaughan B_PERSON
Pendred I_PERSON
, O
the O
disease B_DISEASE/B_GENE
gene I_DISEASE/I_GENE
( O
PDS B_LOCATION/B_DISEASE
) O
was O
mapped O
to O
chromosome B_GENE/B_MEASURE
7q22 B_GENE/I_MEASURE
- O
q31 B_MEASURE
. O

1 B_TIME[MEASURE]
and O
, O
recently O
, O
found O
to O
encode O
a O
putative B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfate I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
transporter I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
performed O
mutation O
analysis O
of O
the O
PDS B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene O
in O
patients O
from O
14 O
Pendred B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
families O
originating O
from O
seven O
countries O
and O
identified O
all O
mutations O
. O

The O
mutations B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
include O
three B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
single I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
base I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
deletions I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
one B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
splice I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
site I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
mutation I_NUMBER[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
10 B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
missense I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
. O

One B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
missense I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mutation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
L236P B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
was O
found O
in O
a O
homozygous B_PERSON/B_LOCATION
state I_PERSON/I_LOCATION
in O
two B_NUMBER[MEASURE]/B_PERSON
consanguineous I_NUMBER[MEASURE]/I_PERSON
families I_NUMBER[MEASURE]/I_PERSON
and O
in O
a O
heterozygous B_MEASURE/B_PERSON
state I_MEASURE/I_PERSON
in O
five B_NUMBER[MEASURE]/B_LOCATION
additional I_NUMBER[MEASURE]/I_LOCATION
non I_NUMBER[MEASURE]/I_LOCATION
- O
consanguineous B_PERSON/B_BIO
families I_PERSON/I_BIO
. O

Another O
missense B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
( O
T416P B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O
was O
found O
in O
a O
homozygous B_PERSON/B_LOCATION
state I_PERSON/I_LOCATION
in O
one B_NUMBER[MEASURE]
family I_NUMBER[MEASURE]
and O
in O
a O
heterozygous B_MEASURE/B_PERSON
state I_MEASURE/I_PERSON
in O
four B_NUMBER[MEASURE]/B_ENT
families I_NUMBER[MEASURE]/I_ENT
. O

Pendred B_NUMBER[MEASURE]/B_LOCATION
patients O
in O
three O
non O
- O
consanguineous O
families O
were O
shown O
to O
be O
compound O
heterozygotes O
for O
L236P O
and O
T416P O
. O

In O
total B_MEASURE
, O
one B_NUMBER[MEASURE]/B_PERSON
or O
both O
of O
these O
mutations B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
were O
found O
in O
nine B_NUMBER[MEASURE]
of O
the O
14 B_PERSON/B_BIO
families I_PERSON/I_BIO
analyzed O
. O

The O
identification O
of O
two O
frequent O
PDS B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations O
will O
facilitate O
the O
molecular O
diagnosis O
of O
Pendred B_DISEASE
syndrome I_DISEASE
. O

Insertional O
mutation O
by O
transposable O
element O
, O
L1 O
, O
in O
the O
DMD B_DISEASE/B_GENE
gene O
results O
in O
X B_DISEASE/B_GENE
- I_DISEASE/I_GENE
linked I_DISEASE/I_GENE
dilated I_DISEASE/I_GENE
cardiomyopathy I_DISEASE/I_GENE
. O

X B_DISEASE
- I_DISEASE
linked I_DISEASE
dilated I_DISEASE
cardiomyopathy I_DISEASE
( O
XLDCM B_DISEASE/B_LOCATION
) O
is O
a O
clinical O
phenotype O
of O
dystrophinopathy B_DISEASE
which O
is O
characterized O
by O
preferential O
myocardial B_DISEASE/B_ORGANISM_FUNCTION
involvement I_DISEASE/I_ORGANISM_FUNCTION
without O
any O
overt O
clinical O
signs O
of O
skeletal B_DISEASE
myopathy I_DISEASE
. O

To O
date O
, O
several O
mutations O
in O
the O
Duchenne B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
muscular I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
dystrophy I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
gene O
, O
DMD O
, O
have O
been O
identified O
in O
patients O
with O
XLDCM B_DISEASE
, O
but O
a O
pathogenic O
correlation O
of O
these O
cardiospecific O
mutations O
in O
DMD O
with O
the O
XLDCM B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
phenotype O
has O
remained O
to O
be O
elucidated O
. O

We O
report O
here O
the O
identification O
of O
a O
unique O
de O
novo O
L1 O
insertion O
in O
the O
muscle O
exon O
1 O
in O
DMD O
in O
three O
XLDCM B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
patients O
from O
two O
unrelated O
Japanese O
families O
. O

The O
insertion B_SEQUENCE[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
a O
5 B_NUMBER[MEASURE]
- O
truncated B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
human B_GENE/B_DISEASE
L1 I_GENE/I_DISEASE
inversely O
integrated O
in O
the O
5 B_TIME[MEASURE]/B_LOCATION
- O
untranslated O
region B_LOCATION/B_MEASURE
in O
the O
muscle B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
exon I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
affected O
the O
transcription B_GENE/B_MEASURE
or O
the O
stability B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
muscle B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
dystrophin B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
transcripts I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
but O
not O
that O
of O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
or O
Purkinje B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cell I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
form I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
probably O
due O
to O
its O
unique B_LOCATION/B_MEASURE
site B_LOCATION/I_MEASURE
of O
integration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE_EXPRESSION_ADJECTIVE[GENE]
. O

We O
speculate O
that O
this O
insertion O
of O
an O
L1 O
sequence O
in O
DMD O
is O
responsible O
for O
some O
of O
the O
population O
of O
Japanese O
patients O
with O
XLDCM B_DISEASE
. O
. O

severe O
early O
- O
onset O
obesity B_DISEASE
, O
adrenal B_DISEASE/B_COLOR
insufficiency I_DISEASE/I_COLOR
and O
red O
hair O
pigmentation O
caused O
by O
POMC O
mutations O
in O
humans O
. O

Sequential B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cleavage B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
precursor B_GENE
protein I_GENE
pre I_GENE
- O
pro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
opiomelanocortin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
( O
POMC B_LOCATION/B_GENE
) O
generates O
the O
melanocortin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peptides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
adrenocorticotrophin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
ACTH B_LOCATION/B_PERSON
) O
, O
melanocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
- O
stimulating O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MSH B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
alpha B_PROTEIN[GENE]
, O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
gamma B_PROTEIN[GENE]
as O
well O
as O
the O
opioid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
receptor B_PROTEIN[GENE]/B_DISEASE
ligand I_PROTEIN[GENE]/I_DISEASE
beta I_PROTEIN[GENE]/I_DISEASE
- O
endorphin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

While O
a O
few O
cases O
of O
isolated O
ACTH B_DISEASE
deficiency I_DISEASE
have O
been O
reported O
( O
OMIM O
201400 O
) O
, O
an O
inherited O
POMC O
defect O
has O
not O
been O
described O
so O
far O
. O

Recent O
studies O
in O
animal O
models O
elucidated O
a O
central O
role O
of O
alpha O
- O
MSH O
in O
the O
regulation O
of O
food O
intake O
by O
activation O
of O
the O
brain O
melanocortin O
- O
4 O
- O
receptor O
( O
MC4 O
- O
R O
; O
refs O
3 O
- O
5 O
) O
and O
the O
linkage O
of O
human O
obesity B_DISEASE/B_GENE
to O
chromosome O
2 O
in O
close O
proximity O
to O
the O
POMC O
locus O
, O
led O
to O
the O
proposal O
of O
an O
association O
of O
POMC O
with O
human O
obesity B_DISEASE/B_ORGANISM_FUNCTION
. O

The O
dual O
role O
of O
alpha O
- O
MSH O
in O
regulating O
food O
intake O
and O
influencing O
hair O
pigmentation O
predicts O
that O
the O
phenotype O
associated O
with O
a O
defect O
in O
POMC O
function O
would O
include O
obesity B_DISEASE
, O
alteration O
in O
pigmentation O
and O
ACTH B_DISEASE/B_ORGANISM_FUNCTION
deficiency I_DISEASE/I_ORGANISM_FUNCTION
. O

The O
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
symptoms B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O
two B_PERSON/B_BIO
probands I_PERSON/I_BIO
prompted O
us O
to O
search O
for O
mutations B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
within O
their O
POMC B_GENE/B_BIO
genes I_GENE/I_BIO
. O

patient B_PERSON/B_LOCATION
1 I_PERSON/I_LOCATION
was O
found O
to O
be O
a O
compound B_PERSON/B_GENE
heterozygote I_PERSON/I_GENE
for O
two B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutations I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O
exon B_GENE
3 I_GENE
( O
G7013T B_GENE/B_DISEASE
, O
C7133delta B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O
which O
interfere O
with O
appropriate B_DISEASE_ADJECTIVE[DISEASE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
synthesis B_DISEASE_ADJECTIVE[DISEASE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
ACTH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
alpha B_PROTEIN[GENE]/B_LOCATION
- O
MSH B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

patient B_PERSON/B_LOCATION
2 I_PERSON/I_LOCATION
was O
homozygous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
a O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
exon B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
C3804A B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
which O
abolishes O
POMC B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
translation I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
findings O
represent O
the O
first O
examples O
of O
a O
genetic B_DISEASE/B_GENE
defect I_DISEASE/I_GENE
within O
the O
POMC O
gene O
and O
define O
a O
new O
monogenic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
endocrine I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
disorder I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
resulting O
in O
early O
- O
onset O
obesity B_DISEASE
, O
adrenal B_DISEASE
insufficiency I_DISEASE
and O
red O
hair O
pigmentation O
. O
. O

A O
European O
multicenter O
study O
of O
phenylalanine B_DISEASE/B_LOCATION
hydroxylase I_DISEASE/I_LOCATION
deficiency I_DISEASE/I_LOCATION
: O
classification O
of O
105 O
mutations O
and O
a O
general O
system O
for O
genotype O
- O
based O
prediction O
of O
metabolic O
phenotype O
. O

Phenylketonuria B_DISEASE/B_GENE
( O
PKU B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
mild B_DISEASE
hyperphenylalaninemia I_DISEASE
( O
MHP B_LOCATION
) O
are O
allelic B_DISEASE_ADJECTIVE[DISEASE]
disorders I_DISEASE_ADJECTIVE[DISEASE]
caused O
by O
mutations O
in O
the O
gene O
encoding O
phenylalanine O
hydroxylase O
( O
PAH O
) O
. O

Previous O
studies O
have O
suggested O
that O
the O
highly O
variable O
metabolic O
phenotypes O
of O
PAH B_DISEASE/B_BIO
deficiency I_DISEASE/I_BIO
correlate O
with O
PAH O
genotypes O
. O

We O
identified O
both O
causative B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
686 B_PERSON/B_BIO
patients I_PERSON/I_BIO
from O
seven B_LOCATION/B_ORGANIZATION
European I_LOCATION/I_ORGANIZATION
centers I_LOCATION/I_ORGANIZATION
. O

On O
the O
basis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
phenotypic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
characteristics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
297 B_NUMBER[MEASURE]/B_PERSON
functionally O
hemizygous B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
105 B_NUMBER[MEASURE]
of O
the O
mutations B_PERSON/B_DISEASE
were O
assigned O
to O
one B_NUMBER[MEASURE]/B_LOCATION
of O
four B_NUMBER[MEASURE]/B_PERSON
arbitrary I_NUMBER[MEASURE]/I_PERSON
phenotype I_NUMBER[MEASURE]/I_PERSON
categories I_NUMBER[MEASURE]/I_PERSON
. O

We O
proposed O
and O
tested O
a O
simple B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
correlation B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
genotype B_GENE
and O
phenotypic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
outcome I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
observed B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenotype B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
matched O
the O
predicted B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
phenotype I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
79 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
the O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
in O
only O
5 B_NUMBER[MEASURE]
of O
184 B_NUMBER[MEASURE]/B_PERSON
patients B_NUMBER[MEASURE]/I_PERSON
was O
the O
observed B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
phenotype I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
more I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
than O
one B_TIME[MEASURE]/B_LOCATION
category I_TIME[MEASURE]/I_LOCATION
away O
from O
that O
expected O
. O

Among O
the O
seven B_NUMBER[MEASURE]
contributing O
centers B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
proportion B_MEASURE/B_DISEASE
of O
patients B_PERSON
for O
whom O
the O
observed O
phenotype B_GENE/B_DISEASE
did O
not O
match O
the O
predicted O
phenotype B_GENE/B_DISEASE
was O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
- O
23 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
P B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
. O
0001 B_MEASURE
) O
, O
suggesting O
that O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
methods B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
for O
mutation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
detection B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O
phenotype B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
classification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
account O
for O
a O
considerable B_MEASURE/B_LOCATION
proportion I_MEASURE/I_LOCATION
of O
genotype B_GENE/B_MEASURE
- O
phenotype B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inconsistencies I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
data O
indicate O
that O
the O
PAH O
- O
mutation O
genotype O
is O
the O
main O
determinant O
of O
metabolic O
phenotype O
in O
most O
patients O
with O
PAH B_DISEASE/B_LOCATION
deficiency I_DISEASE/I_LOCATION
. O

In O
the O
present O
study O
, O
the O
classification O
of O
105 O
PAH O
mutations O
may O
allow O
the O
prediction O
of O
the O
biochemical O
phenotype O
in O
> O
10 O
, O
000 O
genotypes O
, O
which O
may O
be O
useful O
for O
the O
management O
of O
hyperphenylalaninemia B_DISEASE
in O
newborns O
. O

Somatic O
instability O
of O
the O
CTG O
repeat O
in O
mice O
transgenic O
for O
the O
myotonic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
dystrophy B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
region O
is O
age O
dependent O
but O
not O
correlated O
to O
the O
relative O
intertissue O
transcription O
levels O
and O
proliferative O
capacities O
. O

A O
( O
CTG O
) O
nexpansion O
in O
the O
3 O
- O
untranslated O
region O
( O
UTR O
) O
of O
the O
DM O
protein O
kinase O
gene O
( O
DMPK O
) O
is O
responsible O
for O
causing O
myotonic B_DISEASE
dystrophy I_DISEASE
( O
DM B_DISEASE/B_PROTEIN[GENE]
) O
. O

Major B_DISEASE_ADJECTIVE[DISEASE]
instability I_DISEASE_ADJECTIVE[DISEASE]
, O
with O
very O
large B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expansions I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
generations B_MEASURE/B_DISEASE
and O
high B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
levels I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
somatic B_DISEASE/B_GENE
mosaicism I_DISEASE/I_GENE
, O
is O
observed O
in O
patients B_PERSON/B_BIO
. O

There O
is O
a O
good B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correlation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
repeat B_MEASURE/B_DISEASE
size I_MEASURE/I_DISEASE
( O
at O
least O
in O
leucocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
) O
, O
clinical B_MEASURE/B_LOCATION
severity I_MEASURE/I_LOCATION
and O
age B_TIME[MEASURE]/B_LOCATION
of O
onset B_DISEASE/B_PERSON
. O

The O
trinucleotide O
repeat O
instability O
mechanisms O
involved O
in O
DM B_DISEASE/B_LOCATION
and O
other O
human O
genetic B_DISEASE/B_GENE
diseases I_DISEASE/I_GENE
are O
unknown O
. O

We O
studied O
somatic O
instability O
by O
measuring O
the O
CTG O
repeat O
length O
at O
several O
ages O
in O
various O
tissues O
of O
transgenic O
mice O
carrying O
a O
( O
CTG O
) O
55expansion O
surrounded O
by O
45 O
kb O
of O
the O
human O
DM B_DISEASE/B_GENE
region O
, O
using O
small O
- O
pool O
PCR O
. O

These O
mice B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
have O
been O
shown O
to O
reproduce O
the O
intergenerational B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
somatic B_DISEASE_ADJECTIVE[DISEASE]
instability I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
55 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CTG I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repeat I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggesting O
that O
surrounding O
sequences B_DISEASE/B_GENE
and O
the O
chromatin B_GENE
environment I_GENE
are O
involved O
in O
instability B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

As O
observed O
in O
some O
of O
the O
tissues O
of O
DM B_DISEASE/B_PERSON
patients O
, O
there O
is O
a O
tendency O
for O
repeat O
length O
and O
somatic O
mosaicism O
to O
increase O
with O
the O
age O
of O
the O
mouse O
. O

Furthermore O
, O
we O
observed O
no O
correlation B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
somatic B_MEASURE/B_DISEASE
mutation I_MEASURE/I_DISEASE
rate I_MEASURE/I_DISEASE
and O
tissue B_DISEASE/B_GENE
proliferation I_DISEASE/I_GENE
capacity I_DISEASE/I_GENE
. O

The O
somatic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mutation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
rates I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
different B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
tissues B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O
also O
not O
correlated O
to O
the O
relative B_MEASURE/B_BIO
inter B_MEASURE/I_BIO
- O
tissue B_MEASURE
difference I_MEASURE
in O
transcriptional B_MEASURE
levels I_MEASURE
of O
the O
three B_GENE
genes I_GENE
( O
DMAHP B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
DMPK B_MEASURE/B_ORGANIZATION
and O
59 B_MEASURE/B_LOCATION
) O
surrounding O
the O
repeat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O
. O

A O
novel O
missense O
mutation O
in O
patients O
from O
a O
retinoblastoma B_DISEASE/B_LOCATION
pedigree O
showing O
only O
mild O
expression O
of O
the O
tumor B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
phenotype O
. O

We O
have O
used O
single O
strand O
conformation O
polymorphism O
analysis O
to O
study O
the O
27 O
exons O
of O
the O
RB1 O
gene O
in O
individuals O
from O
a O
family O
showing O
mild O
expression O
of O
the O
retinoblastoma B_DISEASE
phenotype O
. O

In O
this O
family O
affected O
individuals O
developed O
unilateral B_DISEASE
tumors I_DISEASE
and O
, O
as O
a O
result O
of O
linkage O
analysis O
, O
unaffected O
mutation O
carriers O
were O
also O
identified O
within O
the O
pedigree O
. O

A O
single B_LOCATION/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
band B_LOCATION/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
shift B_LOCATION/I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
using O
SSCP B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
identified O
in O
exon B_MEASURE
21 I_MEASURE
which O
resulted O
in O
a O
missense B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
converting O
a O
cys B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O
- O
> B_GENE
arg I_GENE
at O
nucleotide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
position B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
28 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
exon B_GENE/B_PERSON
. O

The O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
destroyed O
an O
NdeI B_GENE
restriction I_GENE
enzyme I_GENE
site I_GENE
. O

Analysis O
of O
all O
family O
members O
demonstrated O
that O
the O
missense O
mutation O
co O
- O
segregated O
with O
patients O
with O
tumors B_DISEASE/B_GENE
or O
who O
, O
as O
a O
result O
of O
linkage O
analysis O
had O
been O
predicted O
to O
carry O
the O
predisposing O
mutation O
. O

These O
observations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
point O
to O
another O
region B_LOCATION/B_MEASURE
of O
the O
RB1 B_GENE
gene I_GENE
where O
mutations B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
only O
modify O
the O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
the O
gene B_GENE/B_LOCATION
and O
raise O
important B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
questions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
genetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
counseling I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
families B_PERSON/B_SOCIAL_CIRCUMSTANCES
with O
these O
distinctive B_DISEASE/B_PERSON
phenotypes I_DISEASE/I_PERSON
. O
. O

Maternal B_PERSON
disomy I_PERSON
and O
Prader B_DISEASE_ADJECTIVE[DISEASE]
- I_DISEASE_ADJECTIVE[DISEASE]
Willi I_DISEASE_ADJECTIVE[DISEASE]
syndrome I_DISEASE_ADJECTIVE[DISEASE]
consistent O
with O
gamete O
complementation O
in O
a O
case O
of O
familial O
translocation O
( O
3 O
; O
15 O
) O
( O
p25 O
; O
q11 O
. O
2 O
) O
. O

Maternal B_DISEASE
uniparental I_DISEASE
disomy I_DISEASE
( I_DISEASE
UPD I_DISEASE
) I_DISEASE
for I_DISEASE
chromosome I_DISEASE
15 I_DISEASE
is O
responsible O
for O
an O
estimated O
30 O
% O
of O
cases O
of O
Prader B_DISEASE/B_ORGANISM_FUNCTION
- I_DISEASE/I_ORGANISM_FUNCTION
Willi I_DISEASE/I_ORGANISM_FUNCTION
syndrome I_DISEASE/I_ORGANISM_FUNCTION
( O
PWS B_DISEASE
) O
. O

We O
report O
on O
an O
unusual O
case O
of O
maternal B_DISEASE
disomy I_DISEASE
15 I_DISEASE
in O
PWS B_DISEASE/B_PERSON
that O
is O
most O
consistent O
with O
adjacent O
- O
1 O
segregation O
of O
a O
paternal O
t O
( O
3 O
; O
15 O
) O
( O
p25 O
; O
q11 O
. O
2 O
) O
with O
simultaneous O
maternal O
meiotic O
nondisjunction O
for O
chromosome O
15 O
. O

The O
patient O
( O
J O
. O
B O
. O
) O
, O
a O
17 O
- O
year O
- O
old O
white O
male O
with O
PWS B_DISEASE/B_GENE
, O
was O
found O
to O
have O
47 O
chromosomes O
with O
a O
supernumerary O
, O
paternal O
der O
( O
15 O
) O
consisting O
of O
the O
short O
arm O
and O
the O
proximal O
long O
arm O
of O
chromosome O
15 O
, O
and O
distal O
chromosome O
arm O
3p O
. O

The O
t B_OTHER/B_DISEASE
( O
3 B_MEASURE
; O
15 B_MEASURE
) O
was O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
balanced B_LOCATION/B_PERSON
state I_LOCATION/I_PERSON
in O
the O
patients B_PERSON/B_SEQUENCE[MEASURE]
father B_PERSON/I_SEQUENCE[MEASURE]
and O
a O
sister B_PERSON
. O

fluorescent O
in O
situ O
hybridization O
analysis O
demonstrated O
that O
the O
PWS B_DISEASE/B_PROTEIN[GENE]
critical O
region O
resided O
on O
the O
derivative O
chromosome O
3 O
and O
that O
there O
was O
no O
deletion O
of O
the O
PWS B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
region O
on O
the O
normal O
pair O
of O
15s O
present O
in O
J O
. O

B B_OTHER/B_DISEASE
. O

methylation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O
exon B_GENE/B_MEASURE
alpha B_GENE/I_MEASURE
of O
the O
small B_DISEASE
nuclear I_DISEASE
ribonucleoprotein I_DISEASE
- O
associated O
polypeptide B_PROTEIN[GENE]
N I_PROTEIN[GENE]
( O
SNRPN B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
gene B_GENE/B_LOCATION
showed O
a O
pattern B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
characteristic I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
only O
the O
maternal B_GENE/B_DISEASE
chromosome B_GENE/I_DISEASE
15 B_GENE/I_DISEASE
in O
J B_OTHER/B_PERSON
. O

B B_OTHER/B_DISEASE
. O

Maternal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disomy B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
confirmed O
by O
polymerase O
chain O
reaction O
analysis O
of O
microsatellite O
repeats O
at O
the O
gamma O
- O
aminobutyric O
acid O
receptor O
beta3 O
subunit O
( O
GABRB3 O
) O
locus O
. O

A O
niece B_PERSON/B_BIO
( O
B B_PROTEIN[GENE]/B_DISEASE
. O
B B_OTHER/B_LOCATION
. O
) O
with O
45 B_DISEASE/B_GENE
chromosomes I_DISEASE/I_GENE
and O
the O
derivative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
but O
without O
the O
der B_PERSON/B_DISEASE
( O
15 B_MEASURE/B_LOCATION
) O
demonstrated O
a O
phenotype B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consistent B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
that O
reported O
for O
haploinsufficiency B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O
distal B_GENE
3 I_GENE
p I_GENE
. O

Uniparental B_DISEASE/B_GENE
disomy I_DISEASE/I_GENE
associated O
with O
unbalanced O
segregation O
of O
non O
- O
Robertsonian O
translocations O
has O
been O
reported O
previously O
but O
has O
not O
, O
to O
our O
knowledge O
, O
been O
observed O
in O
a O
case O
of O
PWS B_DISEASE/B_GENE
. O

Furthermore O
, O
our O
findings O
are O
best O
interpreted O
as O
true O
gamete O
complementation O
resulting O
in O
maternal B_PROTEIN[GENE]/B_DISEASE
UPD B_PROTEIN[GENE]/I_DISEASE
15 B_PROTEIN[GENE]/I_DISEASE
and O
PWS B_MEASURE/B_LOCATION
. O

Schwartz B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
Jampel I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
syndrome I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
type I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
2 I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
Stuve B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
- I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
Wiedemann I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
syndrome I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
: O
a O
case O
for O
' O
lumping O
' O
. O

Recent O
studies O
demonstrated O
the O
existence O
of O
a O
genetically O
distinct O
, O
usually O
lethal O
form O
of O
the O
Schwartz B_DISEASE/B_GENE
- I_DISEASE/I_GENE
Jampel I_DISEASE/I_GENE
syndrome I_DISEASE/I_GENE
( O
SJS B_DISEASE/B_LOCATION
) O
of O
myotonia B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
skeletal B_DISEASE
dysplasia I_DISEASE
, O
which O
we O
called O
SJS B_DISEASE/B_PERSON
type I_DISEASE/I_PERSON
2 I_DISEASE/I_PERSON
. O

This O
disorder O
is O
reminiscent O
of O
another O
rare O
condition O
, O
the O
Stuve B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
Wiedemann I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
syndrome I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
SWS B_DISEASE/B_PROTEIN[GENE]
) O
, O
which O
comprises O
campomelia B_DISEASE/B_BIO
at O
birth O
with O
skeletal B_DISEASE
dysplasia I_DISEASE
, O
contractures B_DISEASE
, O
and O
early B_DISEASE
death I_DISEASE
. O

To O
test O
for O
possible O
nosologic O
identity O
between O
these O
disorders O
, O
we O
reviewed O
the O
literature O
and O
obtained O
a O
follow O
- O
up O
of O
the O
only O
two O
surviving O
patients O
, O
one O
with O
SJS B_DISEASE
type I_DISEASE
2 I_DISEASE
at O
age O
10 O
years O
and O
another O
with O
SWS B_DISEASE
at O
age O
7 O
years O
. O

patients O
reported O
as O
having O
either O
neonatal O
SJS B_DISEASE
or O
SWS B_DISEASE
presented O
a O
combination O
of O
a O
severe O
, O
prenatal O
- O
onset O
neuromuscular B_DISEASE
disorder I_DISEASE
( O
with O
congenital B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
joint I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
contractures I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
respiratory O
and O
feeding O
difficulties O
, O
tendency O
to O
hyperthermia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
and O
frequent O
death O
in O
infancy O
) O
with O
a O
distinct O
campomelic B_DISEASE_ADJECTIVE[DISEASE]
- I_DISEASE_ADJECTIVE[DISEASE]
metaphyseal I_DISEASE_ADJECTIVE[DISEASE]
skeletal I_DISEASE_ADJECTIVE[DISEASE]
dysplasia I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
similarity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
radiographic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
so O
extensive B_DISEASE_ADJECTIVE[DISEASE]
that O
these O
disorders B_DISEASE
appear O
to O
be O
a O
single B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
entity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

The O
follow O
- O
up O
observation O
of O
an O
identical O
and O
unique O
pattern O
of O
progressive O
bone B_DISEASE
dysplasia I_DISEASE
in O
the O
two O
patients O
( O
one O
with O
SJS B_DISEASE/B_GENE
type I_DISEASE/I_GENE
2 I_DISEASE/I_GENE
, O
one O
with O
SWS B_DISEASE/B_GENE
) O
surviving O
beyond O
infancy O
adds O
to O
the O
evidence O
in O
favor O
of O
identity O
. O

The O
hypothesis O
that O
SWS B_DISEASE/B_GENE
and O
SJS B_LOCATION
type I_LOCATION
2 I_LOCATION
are O
the O
same O
disorder O
should O
be O
testable O
by O
molecular O
methods O
. O
. O

A O
mouse O
model O
of O
severe O
von B_DISEASE
Willebrand I_DISEASE
disease I_DISEASE
: O
defects O
in O
hemostasis O
and O
thrombosis B_DISEASE
. O

von B_DISEASE/B_LOCATION
Willebrand I_DISEASE/I_LOCATION
factor I_DISEASE/I_LOCATION
( I_DISEASE/I_LOCATION
vWf I_DISEASE/I_LOCATION
) I_DISEASE/I_LOCATION
deficiency I_DISEASE/I_LOCATION
causes O
severe O
von B_DISEASE
Willebrand I_DISEASE
disease I_DISEASE
in O
humans O
. O

We O
generated O
a O
mouse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
this O
disease B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
using O
gene B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
targeting B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

vWf B_PERSON/B_LOCATION
- I_PERSON/I_LOCATION
deficient I_PERSON/I_LOCATION
mice O
appeared O
normal O
at O
birth O
; O
they O
were O
viable O
and O
fertile O
. O

Neither O
vWf O
nor O
vWf O
propolypeptide O
( O
von B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
Willebrand B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
antigen O
II O
) O
were O
detectable O
in O
plasma O
, O
platelets O
, O
or O
endothelial O
cells O
of O
the O
homozygous O
mutant O
mice O
. O

The O
mutant B_PERSON/B_DISEASE
mice I_PERSON/I_DISEASE
exhibited O
defects B_DISEASE_ADJECTIVE[DISEASE]
in O
hemostasis B_DISEASE
with O
a O
highly O
prolonged B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
bleeding I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
time I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
spontaneous B_DISEASE
bleeding I_DISEASE
events I_DISEASE
in O
approximately O
10 B_MEASURE
% I_MEASURE
of O
neonates B_BIO/B_PERSON
. O

As O
in O
the O
human B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
disease B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
, O
the O
factor B_DISEASE
VIII I_DISEASE
level I_DISEASE
in O
these O
mice B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
reduced O
strongly O
as O
a O
result B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
lack B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
protection B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
provided O
by O
vWF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Defective O
thrombosis B_DISEASE
in O
mutant O
mice O
was O
also O
evident O
in O
an O
in O
vivo O
model O
of O
vascular B_DISEASE/B_LOCATION
injury I_DISEASE/I_LOCATION
. O

In O
this O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
the O
exteriorized B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mesentery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
superfused O
with O
ferric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
accumulation B_DISEASE/B_CELL_FUNCTION[ORGANISM_FUNCTION]
of O
fluorescently O
labeled O
platelets B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
was O
observed O
by O
intravital B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
conclude O
that O
these O
mice O
very O
closely O
mimic O
severe O
human O
von B_DISEASE
Willebrand I_DISEASE
disease I_DISEASE
and O
will O
be O
very O
useful O
for O
investigating O
the O
role O
of O
vWf O
in O
normal O
physiology O
and O
in O
disease O
models O
. O
. O

Oral O
contraceptives O
and O
the O
risk O
of O
hereditary B_DISEASE
ovarian I_DISEASE
cancer I_DISEASE
. O

Hereditary B_LOCATION/B_PERSON
Ovarian I_LOCATION/I_PERSON
Cancer I_LOCATION/I_PERSON
Clinical O
Study O
Group O
. O

Background O
Women O
with O
mutations O
in O
either O
the O
BRCA1 O
or O
the O
BRCA2 O
gene O
have O
a O
high O
lifetime O
risk O
of O
ovarian B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
. O

Oral O
contraceptives O
protect O
against O
ovarian B_DISEASE/B_ORGANISM_FUNCTION
cancer I_DISEASE/I_ORGANISM_FUNCTION
in O
general O
, O
but O
it O
is O
not O
known O
whether O
they O
also O
protect O
against O
hereditary B_DISEASE
forms I_DISEASE
of I_DISEASE
ovarian I_DISEASE
cancer I_DISEASE
. O

methods O
We O
enrolled O
207 O
women O
with O
hereditary B_DISEASE/B_LOCATION
ovarian I_DISEASE/I_LOCATION
cancer I_DISEASE/I_LOCATION
and O
161 O
of O
their O
sisters O
as O
controls O
in O
a O
case O
- O
control O
study O
. O

All O
the O
patients B_PERSON/B_BIO
carried O
a O
pathogenic B_DISEASE/B_GENE
mutation I_DISEASE/I_GENE
in O
either O
BRCA1 B_GENE/B_DISEASE
( O
179 B_MEASURE/B_PERSON
women I_MEASURE/I_PERSON
) O
or O
BRCA2 B_GENE/B_LOCATION
( O
28 B_TIME[MEASURE]/B_PERSON
women I_TIME[MEASURE]/I_PERSON
) O
. O

The O
control B_PERSON/B_ORGANIZATION
women I_PERSON/I_ORGANIZATION
were O
enrolled O
regardless O
of O
whether O
or O
not O
they O
had O
either O
mutation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

lifetime B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
histories I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
oral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
contraceptive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
obtained O
by O
interview B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
or O
by O
written O
questionnaire B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
were O
compared O
between O
patients B_PERSON
and O
control B_PERSON/B_ORGANIZATION
women I_PERSON/I_ORGANIZATION
, O
after O
adjustment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
year B_TIME[MEASURE]
of O
birth B_TIME[MEASURE]/B_PERSON
and O
parity B_PERSON/B_TIME[MEASURE]
. O

Results O
The O
adjusted O
odds O
ratio O
for O
ovarian B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
associated O
with O
any O
past O
use O
of O
oral O
contraceptives O
was O
0 O
. O

5 O
( O
95 B_MEASURE/B_LOCATION
percent I_MEASURE/I_LOCATION
confidence I_MEASURE/I_LOCATION
interval I_MEASURE/I_LOCATION
, O
0 B_MEASURE
. O
3 B_MEASURE
to O
0 B_MEASURE
. O
8 B_MEASURE
) O
. O

The O
risk B_DISEASE/B_MEASURE
decreased O
with O
increasing O
duration B_TIME[MEASURE]
of O
use B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
P B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
trend B_TIME[MEASURE]
, O
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
; O
use O
for O
six B_NUMBER[MEASURE]
or O
more B_NUMBER[MEASURE]/B_ENT
years I_NUMBER[MEASURE]/I_ENT
was O
associated O
with O
a O
60 B_MEASURE
percent I_MEASURE
reduction I_MEASURE
in O
risk B_DISEASE
. O

Oral O
- O
contraceptive O
use O
protected O
against O
ovarian B_DISEASE
cancer I_DISEASE
both O
for O
carriers O
of O
the O
BRCA1 O
mutation O
( O
odds O
ratio O
, O
0 O
. O
5 O
; O
95 O
percent O
confidence O
interval O
, O
0 O
. O
3 O
to O
0 O
. O
9 O
) O
and O
for O
carriers O
of O
the O
BRCA2 O
mutation O
( O
odds O
ratio O
, O
0 O
. O
4 O
; O
95 O
percent O
confidence O
interval O
, O
0 O
. O
2 O
to O
1 O
. O
1 O
) O
. O

conclusions O
Oral O
- O
contraceptive O
use O
may O
reduce O
the O
risk O
of O
ovarian B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
in O
women O
with O
pathogenic O
mutations O
in O
the O
BRCA1 O
or O
BRCA2 O
gene O
. O

A O
Japanese O
family O
with O
adrenoleukodystrophy B_DISEASE/B_GENE
with O
a O
codon O
291 O
deletion O
: O
a O
clinical O
, O
biochemical O
, O
pathological O
, O
and O
genetic O
report O
. O

We O
report O
a O
Japanese O
family O
with O
adrenoleukodystrophy B_DISEASE
( O
ALD B_DISEASE/B_PROTEIN[GENE]
) O
with O
a O
three O
base O
pair O
deletion O
( O
delGAG O
291 O
) O
in O
the O
ALD B_DISEASE/B_GENE
gene O
. O

A O
variety B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
phenotypes B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
were O
observed O
within O
this O
family B_PERSON/B_BIO
. O

While O
the O
proband O
( O
patient O
1 O
) O
was O
classified O
as O
having O
a O
rare O
intermediate O
type O
of O
adult O
cerebral O
and O
cerebello O
- O
brain O
stem O
forms O
, O
his O
younger O
brother O
( O
patient O
2 O
) O
and O
nephew O
( O
patient O
3 O
) O
had O
a O
childhood O
ALD B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
type O
. O

Another O
nephew B_PERSON
( O
patient B_PERSON
4 I_PERSON
) O
of O
patient B_PERSON
1 I_PERSON
was O
classified O
as O
having O
an O
adolescent B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
Tau O
level O
in O
the O
cerebrospinal O
fluid O
( O
CSF O
) O
in O
patient O
1 O
was O
as O
high O
as O
that O
of O
patients O
with O
Alzheimers B_DISEASE
disease I_DISEASE
( O
AD B_DISEASE
) O
. O

His O
brain O
magnetic O
resonance O
image O
( O
MRI O
) O
showed O
abnormalities B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
in I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
the I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
bilateral I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cerebellar I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
hemispheres I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
brain O
stem O
, O
but O
not O
in O
the O
cerebral O
white O
matter O
, O
where O
marked O
reductions O
of O
the O
cerebral O
blood O
flow O
and O
oxygen O
metabolism O
were O
clearly O
demonstrated O
by O
positron O
emission O
tomography O
( O
Pet O
) O
. O

In O
patients O
2 O
and O
3 O
, O
the O
autopsy O
findings O
showed O
massive O
demyelination B_DISEASE
of I_DISEASE
the I_DISEASE
cerebral I_DISEASE
white I_DISEASE
matter I_DISEASE
with O
sparing O
of O
the O
U O
- O
fibers O
, O
compatible O
with O
the O
findings O
of O
childhood O
ALD B_DISEASE/B_LOCATION
. O

oleic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
erucic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
Lorenzos B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
oil I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
were O
administered O
to O
patients B_PERSON
1 I_PERSON
and O
4 B_SEQUENCE[MEASURE]
, O
but O
sufficient B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
effectiveness I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O
not O
obtained O
. O

The O
findings O
in O
this O
family O
suggest O
that O
delGAG291 O
is O
part O
of O
the O
cause O
of O
Japanese O
ALD B_DISEASE/B_PERSON
with O
phenotypic O
variations O
. O

Moreover O
, O
although O
the O
scale O
of O
the O
study O
is O
limited O
, O
there O
is O
a O
possibility O
that O
Pet O
can O
detect O
an O
insidious B_DISEASE/B_GENE
lesion I_DISEASE/I_GENE
which O
is O
undetectable O
by O
computed O
tomogram O
( O
CT O
) O
or O
MRI O
analysis O
, O
and O
that O
the O
higher O
level O
of O
Tau O
reflects O
the O
process O
of O
neuronal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
degeneration I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
ALD B_DISEASE/B_LOCATION
. O

Lorenzos B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
oil I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
should O
be O
given O
in O
the O
early B_TIME[MEASURE]/B_LOCATION
stage I_TIME[MEASURE]/I_LOCATION
. O
. O

nonsense O
mutation O
in O
exon O
4 O
of O
human O
complement O
C9 O
gene O
is O
the O
major O
cause O
of O
Japanese O
complement B_DISEASE/B_PERSON
C9 I_DISEASE/I_PERSON
deficiency I_DISEASE/I_PERSON
. O

Deficiency B_DISEASE/B_PROTEIN[GENE]
of B_DISEASE/I_PROTEIN[GENE]
the B_DISEASE/I_PROTEIN[GENE]
ninth B_DISEASE/I_PROTEIN[GENE]
component B_DISEASE/I_PROTEIN[GENE]
of B_DISEASE/I_PROTEIN[GENE]
human B_DISEASE/I_PROTEIN[GENE]
complement B_DISEASE/I_PROTEIN[GENE]
( O
C9 O
) O
is O
the O
most O
common O
complement B_DISEASE_ADJECTIVE[DISEASE]
deficiency I_DISEASE_ADJECTIVE[DISEASE]
in O
Japan O
but O
is O
rare O
in O
other O
countries O
. O

We O
studied O
the O
molecular O
basis O
of O
C9 B_DISEASE
deficiency I_DISEASE
in O
four O
Japanese O
C9 B_PERSON/B_LOCATION
- I_PERSON/I_LOCATION
deficient I_PERSON/I_LOCATION
patients O
who O
had O
suffered O
from O
meningococcal B_DISEASE
meningitis I_DISEASE
. O

Direct O
sequencing O
of O
amplified O
C9 O
cDNA O
and O
DNA O
revealed O
a O
nonsense O
substitution O
( O
CGA O
- O
- O
> O
TGA O
) O
at O
codon O
95 O
in O
exon O
4 O
in O
the O
four O
C9 B_DISEASE_ADJECTIVE[DISEASE]
- I_DISEASE_ADJECTIVE[DISEASE]
deficient I_DISEASE_ADJECTIVE[DISEASE]
individuals O
. O

An O
allele B_GENE/B_BIO
- O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
polymerase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
chain I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
system I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
designed O
to O
detect O
exclusively O
only O
one B_NUMBER[MEASURE]/B_PERSON
of O
the O
normal B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
mutant B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
alleles B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
indicated O
that O
all O
the O
four B_PERSON/B_BIO
patients I_PERSON/I_BIO
were O
homozygous B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
for O
the O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O
exon B_MEASURE/B_GENE
4 I_MEASURE/I_GENE
and O
that O
the O
parents B_PERSON/B_DISEASE
of O
patient B_PERSON/B_NUMBER[MEASURE]
2 B_PERSON/I_NUMBER[MEASURE]
were O
heterozygous B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
common O
mutation O
at O
codon O
95 O
in O
exon O
4 O
might O
be O
responsible O
for O
most O
Japanese O
C9 B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
deficiency B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O
. O

BRCA1 B_GENE/B_DISEASE
required O
for O
transcription B_GENE
- O
coupled O
repair B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
oxidative B_DISEASE/B_GENE
DNA I_DISEASE/I_GENE
damage I_DISEASE/I_GENE
. O

The O
breast B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
ovarian I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancer I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
susceptibility O
gene O
BRCA1 O
encodes O
a O
zinc O
finger O
protein O
of O
unknown O
function O
. O

Association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
BRCA1 B_GENE/B_BIO
protein I_GENE/I_BIO
with O
the O
DNA B_GENE
repair I_GENE
protein I_GENE
Rad51 I_GENE
and O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
phosphorylation B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cellular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
localization B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
protein B_ENZYME[GENE]/B_BACTERIUM[BIO]
after O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O
DNA B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
damaging O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
a O
role B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
BRCA1 B_GENE/B_DISEASE
in O
DNA B_DISEASE/B_BIO
repair I_DISEASE/I_BIO
. O

Here O
, O
it O
is O
shown O
that O
mouse O
embryonic O
stem O
cells O
deficient B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
BRCA1 I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
are O
defective O
in O
the O
ability O
to O
carry O
out O
transcription O
- O
coupled O
repair O
of O
oxidative O
DNA O
damage O
, O
and O
are O
hypersensitive O
to O
ionizing O
radiation O
and O
hydrogen O
peroxide O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
BRCA1 B_GENE/B_DISEASE
participates O
, O
directly O
or O
indirectly O
, O
in O
transcription B_GENE/B_LOCATION
- O
coupled O
repair B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
oxidative B_DISEASE/B_GENE
DNA B_DISEASE/I_GENE
damage B_DISEASE/I_GENE
. O
. O

Truncation B_DISEASE_ADJECTIVE[DISEASE]
mutations I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
transactivation B_LOCATION/B_BIO
region I_LOCATION/I_BIO
of O
PAX6 B_GENE
result O
in O
dominant B_DISEASE/B_GENE
- O
negative B_DISEASE_ADJECTIVE[DISEASE]
mutants I_DISEASE_ADJECTIVE[DISEASE]
. O

PAX6 B_GENE
is O
a O
transcription B_GENE/B_BIO
factor I_GENE/I_BIO
with O
two B_GENE
DNA I_GENE
- O
binding O
domains B_LOCATION/B_PERSON
( O
paired O
box B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
and O
homeobox B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
a O
proline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
serine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
threonine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PST B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
- O
rich B_MEASURE/B_LOCATION
transactivation B_MEASURE/I_LOCATION
domain B_MEASURE/I_LOCATION
. O

PAX6 B_GENE
regulates O
eye B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
development B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
in O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ranging O
from O
jellyfish B_SPECIES[BIO]
to O
Drosophila B_SPECIES[BIO]
to O
humans B_SPECIES[BIO]
. O

Heterozygous O
mutations O
in O
the O
human O
PAX6 O
gene O
result O
in O
various O
phenotypes O
, O
including O
aniridia B_DISEASE/B_SPECIES[BIO]
, O
Peters B_DISEASE
anomaly I_DISEASE
, O
autosomal B_DISEASE
dominant I_DISEASE
keratitis I_DISEASE
, O
and O
familial B_DISEASE
foveal I_DISEASE
dysplasia I_DISEASE
. O

It O
is O
believed O
that O
the O
mutated O
allele O
of O
PAX6 O
produces O
an O
inactive O
protein O
and O
aniridia B_DISEASE/B_SPECIES[BIO]
is O
caused O
due O
to O
genetic O
haploinsufficiency O
. O

However O
, O
several O
truncation O
mutations O
have O
been O
found O
to O
occur O
in O
the O
C O
- O
terminal O
half O
of O
PAX6 O
in O
patients O
with O
Aniridia B_DISEASE/B_SPECIES[BIO]
resulting O
in O
mutant O
proteins O
that O
retain O
the O
DNA O
- O
binding O
domains O
but O
have O
lost O
most O
of O
the O
transactivation O
domain O
. O

It O
is O
not O
clear B_DISEASE_ADJECTIVE[DISEASE]
whether O
such B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
mutants I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
really O
behave O
as O
loss B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
of O
- O
function B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mutants B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
predicted O
by O
haploinsufficiency B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O

contrary B_PERSON/B_MEASURE
to O
this O
theory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
, O
our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
that O
these O
mutants B_DISEASE/B_GENE
are O
dominant B_DISEASE/B_GENE
- O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
transient B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
transfection B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
assays B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
when O
they O
are O
coexpressed O
with O
wild B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
type B_GENE/B_MEASURE
PAX6 I_GENE/I_MEASURE
. O

We O
found O
that O
the O
dominant B_DISEASE
- O
negative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
result O
from O
the O
enhanced B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
binding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ability I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
these O
mutants B_DISEASE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Kinetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
binding B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dissociation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
revealed O
that O
various B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
truncation I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
mutants I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
have O
3 B_NUMBER[MEASURE]/B_LOCATION
- O
5 B_NUMBER[MEASURE]
- O
fold O
higher B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affinity B_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
various B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
binding O
sites B_LOCATION/B_ENT
when O
compared O
with O
the O
wild B_PERSON/B_BIO
- O
type B_PROTEIN[GENE]/B_MEASURE
PAX6 I_PROTEIN[GENE]/I_MEASURE
. O

These O
results O
provide O
a O
new O
insight O
into O
the O
role O
of O
mutant O
PAX6 O
in O
causing O
aniridia B_DISEASE/B_SPECIES[BIO]
. O
. O

reversal O
of O
severe O
hypertrophic B_DISEASE
cardiomyopathy I_DISEASE
and O
excellent O
neuropsychologic O
outcome O
in O
very B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
long I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
- I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
chain I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
acyl I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
- I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
coenzyme I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
A I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
dehydrogenase I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
deficiency I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

Very B_DISEASE
- I_DISEASE
long I_DISEASE
- I_DISEASE
chain I_DISEASE
acyl I_DISEASE
- I_DISEASE
coenzyme I_DISEASE
A I_DISEASE
dehydrogenase I_DISEASE
( I_DISEASE
VLCAD I_DISEASE
) I_DISEASE
deficiency I_DISEASE
is O
a O
disorder O
of O
fatty O
acid O
beta O
oxidation O
that O
reportedly O
has O
high O
rates O
of O
morbidity O
and O
mortality O
. O

We O
describe O
the O
outcome O
of O
a O
5 O
- O
year O
- O
old O
girl O
with O
VLCAD B_DISEASE
deficiency I_DISEASE
who O
was O
first O
seen O
at O
5 O
months O
of O
age O
with O
severe O
hypertrophic B_DISEASE
cardiomyopathy I_DISEASE
, O
hepatomegaly B_DISEASE
, O
encephalopathy B_DISEASE
, O
and O
hypotonia B_DISEASE
. O

Biochemical O
studies O
indicated O
VLCAD B_DISEASE_ADJECTIVE[DISEASE]
deficiency I_DISEASE_ADJECTIVE[DISEASE]
caused O
by O
a O
stable O
yet O
inactive O
enzyme O
. O

Molecular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
genetic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
her O
VLCAD B_GENE/B_BIO
gene I_GENE/I_BIO
revealed O
a O
T1372C B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
F458L B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
missense B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
and O
a O
1668 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
ACAG B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
1669 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
splice B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
site B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

After O
initial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
intravenous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
glucose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
carnitine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
patient B_PERSON/B_BIO
has O
thrived O
on O
a O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
fat B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
diet I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
supplemented O
with O
medium B_MEASURE/B_COLOR
- O
chain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
triglyceride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
oil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
carnitine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
avoidance B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
fasting B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Her O
ventricular B_DISEASE
hypertrophy I_DISEASE
resolved O
significantly O
over O
1 B_TIME[MEASURE]/B_PERSON
year I_TIME[MEASURE]/I_PERSON
, O
and O
cognitively O
, O
she O
is O
in O
the O
superior B_LOCATION/B_PERSON
range I_LOCATION/I_PERSON
for O
age B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Clinical O
recognition O
of O
VLCAD B_DISEASE
deficiency I_DISEASE
is O
important O
because O
it O
is O
one O
of O
the O
few O
directly O
treatable O
causes O
of O
cardiomyopathy B_DISEASE
in O
children O
. O
. O

Cloning O
of O
a O
novel B_PERSON/B_GENE
member I_PERSON/I_GENE
of O
the O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
density B_MEASURE/B_PERSON
lipoprotein I_MEASURE/I_PERSON
receptor I_MEASURE/I_PERSON
family I_MEASURE/I_PERSON
. O

A O
gene O
encoding O
a O
novel O
transmembrane O
protein O
was O
identified O
by O
DNA O
sequence O
analysis O
within O
the O
insulin B_DISEASE/B_GENE
- I_DISEASE/I_GENE
dependent I_DISEASE/I_GENE
diabetes I_DISEASE/I_GENE
mellitus I_DISEASE/I_GENE
( O
IDDM B_DISEASE/B_GENE
) O
locus O
IDDM4 O
on O
chromosome O
11q13 O
. O

Based O
on O
its O
chromosomal O
position O
, O
this O
gene O
is O
a O
candidate O
for O
conferring O
susceptibility O
to O
diabetes B_DISEASE/B_LOCATION
. O

The O
gene B_GENE
, O
termed O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
density B_GENE/B_MEASURE
lipoprotein B_GENE/I_MEASURE
receptor B_GENE/I_MEASURE
related O
protein B_GENE/B_NUMBER[MEASURE]
5 B_GENE/I_NUMBER[MEASURE]
( O
LRP5 B_GENE
) O
, O
encodes O
a O
protein B_BIO/B_PROTEIN[GENE]
of O
1615 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
amino I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acids I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
that O
contains O
conserved B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
modules B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
which O
are O
characteristic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
density B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lipoprotein I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
LDL B_PROTEIN[GENE]/B_LOCATION
) O
receptor B_GENE/B_BIO
family I_GENE/I_BIO
. O

These O
modules B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
include O
a O
putative B_GENE/B_LOCATION
signal B_GENE/I_LOCATION
peptide B_GENE/I_LOCATION
for O
protein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
export I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
four B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
epidermal I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
EGF B_GENE/B_LOCATION
) O
repeats O
with O
associated O
spacer B_LOCATION/B_BIO
domains I_LOCATION/I_BIO
, O
three B_GENE
LDL I_GENE
- O
receptor B_GENE
( O
LDLR B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
repeats O
, O
a O
single B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
transmembrane I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
spanning O
domain B_LOCATION/B_MEASURE
, O
and O
a O
cytoplasmic B_GENE
domain I_GENE
. O

The O
encoded B_GENE/B_LOCATION
protein I_GENE/I_LOCATION
has O
a O
unique B_LOCATION/B_PERSON
organization I_LOCATION/I_PERSON
of O
EGF B_GENE
and O
LDLR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
repeats I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
; O
therefore O
, O
LRP5 B_GENE/B_MEASURE
likely O
represents O
a O
new B_MEASURE/B_PERSON
category B_MEASURE/I_PERSON
of O
the O
LDLR B_GENE/B_BIO
family I_GENE/I_BIO
. O

Both O
human B_SPECIES[BIO]
and O
mouse B_SPECIES[BIO]/B_GENE
LRP5 I_SPECIES[BIO]/I_GENE
cDNAs I_SPECIES[BIO]/I_GENE
have O
been O
isolated O
and O
the O
encoded O
mature B_PROTEIN[GENE]
proteins I_PROTEIN[GENE]
are O
95 B_MEASURE
% I_MEASURE
identical I_MEASURE
, O
indicating O
a O
high B_MEASURE/B_LOCATION
degree I_MEASURE/I_LOCATION
of O
evolutionary B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
conservation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O
. O

The O
APC B_GENE/B_BACTERIUM[BIO]
variants O
I1307K O
and O
E1317Q O
are O
associated O
with O
colorectal B_DISEASE/B_LOCATION
tumors I_DISEASE/I_LOCATION
, O
but O
not O
always O
with O
a O
family O
history O
. O

Classical O
familial B_DISEASE
adenomatous I_DISEASE
polyposis I_DISEASE
( O
FAP B_DISEASE/B_LOCATION
) O
is O
a O
high O
- O
penetrance O
autosomal B_DISEASE/B_GENE
dominant I_DISEASE/I_GENE
disease I_DISEASE/I_GENE
that O
predisposes O
to O
hundreds O
or O
thousands O
of O
colorectal B_DISEASE/B_PERSON
adenomas I_DISEASE/I_PERSON
and I_DISEASE/I_PERSON
carcinoma I_DISEASE/I_PERSON
and O
that O
results O
from O
truncating O
mutations O
in O
the O
APC B_GENE/B_BACTERIUM[BIO]
gene O
. O

A O
variant O
of O
FAP B_DISEASE/B_GENE
is O
attenuated B_DISEASE_ADJECTIVE[DISEASE]
adenomatous I_DISEASE_ADJECTIVE[DISEASE]
polyposis I_DISEASE_ADJECTIVE[DISEASE]
coli I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
results O
from O
germ O
- O
line O
mutations O
in O
the O
5 O
and O
3 O
regions O
of O
the O
APC B_GENE/B_BACTERIUM[BIO]
gene O
. O

Attenuated B_NUMBER[MEASURE]/B_PERSON
adenomatous I_NUMBER[MEASURE]/I_PERSON
polyposis I_NUMBER[MEASURE]/I_PERSON
coli I_NUMBER[MEASURE]/I_PERSON
patients O
have O
' O
multiple O
' O
colorectal B_DISEASE/B_GENE
adenomas I_DISEASE/I_GENE
( O
typically O
fewer O
than O
100 O
) O
without O
the O
florid O
phenotype O
of O
classical O
FAP B_DISEASE
. O

Another O
group O
of O
patients O
with O
multiple O
adenomas B_DISEASE
has O
no O
mutations O
in O
the O
APC B_GENE/B_BACTERIUM[BIO]
gene O
, O
and O
their O
phenotype O
probably O
results O
from O
variation O
at O
a O
locus O
, O
or O
loci O
, O
elsewhere O
in O
the O
genome O
. O

Recently O
, O
however O
, O
a O
missense O
variant O
of O
APC B_GENE/B_BACTERIUM[BIO]
( O
I1307K O
) O
was O
described O
that O
confers O
an O
increased O
risk O
of O
colorectal B_DISEASE
tumors I_DISEASE
, O
including O
multiple O
adenomas B_DISEASE
, O
in O
Ashkenazim O
. O

We O
have O
studied O
a O
set O
of O
164 O
patients O
with O
multiple O
colorectal B_DISEASE
adenomas I_DISEASE
and I_DISEASE
/ I_DISEASE
or I_DISEASE
carcinoma I_DISEASE
and O
analyzed O
codons O
1263 O
- O
1377 O
( O
exon O
15G O
) O
of O
the O
APC B_GENE/B_BACTERIUM[BIO]
gene O
for O
germ O
- O
line O
variants O
. O

Three B_PERSON
patients I_PERSON
with O
the O
I1307K B_DISEASE/B_GENE
allele I_DISEASE/I_GENE
were O
detected O
, O
each O
of O
Ashkenazi B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
descent I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

Four O
patients O
had O
a O
germ O
- O
line O
E1317Q O
missense O
variant O
of O
APC O
that O
was O
not O
present O
in O
controls O
; O
one O
of O
these O
individuals O
had O
an O
unusually O
large O
number O
of O
metaplastic B_DISEASE/B_GENE
polyps I_DISEASE/I_GENE
of I_DISEASE/I_GENE
the I_DISEASE/I_GENE
colorectum I_DISEASE/I_GENE
. O

There O
is O
increasing O
evidence O
that O
there O
exist O
germ O
- O
line O
variants O
of O
the O
APC B_GENE/B_BACTERIUM[BIO]
gene O
that O
predispose O
to O
the O
development O
of O
multiple O
colorectal B_DISEASE
adenomas I_DISEASE
and I_DISEASE
carcinoma I_DISEASE
, O
but O
without O
the O
florid O
phenotype O
of O
classical O
FAP B_DISEASE
, O
and O
possibly O
with O
importance O
for O
colorectal B_DISEASE/B_GENE
cancer I_DISEASE/I_GENE
risk O
in O
the O
general O
population O
. O
. O

Genomic O
structure O
of O
the O
human O
congenital B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
chloride B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
diarrhea B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
CLD B_DISEASE/B_LOCATION
) O
gene O
. O

Congenital B_DISEASE
chloride I_DISEASE
diarrhea I_DISEASE
( O
CLD B_LOCATION
) O
is O
caused O
by O
mutations O
in O
a O
gene O
which O
encodes O
an O
intestinal O
anion O
transporter O
. O

We O
report O
here O
the O
complete O
genomic O
organization O
of O
the O
human O
CLD B_GENE/B_DISEASE
gene O
which O
spans O
approximately O
39kb O
, O
and O
comprises O
21 O
exons O
. O

All O
exon B_GENE
/ O
intron B_GENE/B_LOCATION
boundaries I_GENE/I_LOCATION
conform O
to O
the O
GT B_LOCATION/B_ORGANIZATION
/ O
AG B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rule I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

An O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
putative B_GENE
promoter I_GENE
region I_GENE
sequence I_GENE
shows O
a O
putative B_MEASURE/B_GENE
TATA I_MEASURE/I_GENE
box I_MEASURE/I_GENE
and O
predicts O
multiple B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
transcription B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
factor B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
binding B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
sites B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

The O
genomic O
structure O
was O
determined O
using O
DNA O
from O
several O
sources O
including O
multiple O
large O
- O
insert O
libaries O
and O
genomic O
DNA O
from O
Finnish O
CLD B_DISEASE/B_LOCATION
patients O
and O
controls O
. O

exon B_GENE/B_PERSON
- O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
primers B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
developed O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
will O
facilitate O
mutation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
screening I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patients B_PERSON/B_BIO
with O
the O
disease B_DISEASE/B_GENE
. O

Genomic O
sequencing O
of O
a O
BAC O
clone O
H O
_ O
RG364P16 O
revealed O
the O
presence O
of O
another O
, O
highly O
homologous O
gene O
3 O
of O
the O
CLD B_DISEASE/B_GENE
gene O
, O
with O
a O
similar O
genomic O
structure O
, O
recently O
identified O
as O
the O
Pendred B_DISEASE_ADJECTIVE[DISEASE]
syndrome I_DISEASE_ADJECTIVE[DISEASE]
gene O
( O
PDS B_DISEASE/B_PROTEIN[GENE]
) O
. O
. O

The O
APCI1307K O
allele O
and O
cancer B_DISEASE/B_LOCATION
risk O
in O
a O
community O
- O
based O
study O
of O
Ashkenazi O
Jews O
. O

mutations O
in O
APC O
are O
classically O
associated O
with O
familial B_DISEASE
adenomatous I_DISEASE
polyposis I_DISEASE
( O
FAP B_DISEASE/B_PROTEIN[GENE]
) O
, O
a O
highly O
penetrant O
autosomal B_DISEASE/B_GENE
dominant I_DISEASE/I_GENE
disorder I_DISEASE/I_GENE
characterized O
by O
multiple O
intestinal O
polyps B_DISEASE
and O
, O
without O
surgical O
intervention O
, O
the O
development O
of O
colorectal B_DISEASE
cancer I_DISEASE
( O
CRC B_DISEASE/B_LOCATION
) O
. O

APC B_GENE/B_BACTERIUM[BIO]
is O
a O
tumour O
- O
suppressor O
gene O
, O
and O
somatic O
loss O
occurs O
in O
tumours B_DISEASE/B_PERSON
. O

The O
germline B_PROTEIN[GENE]/B_LOCATION
T B_PROTEIN[GENE]/I_LOCATION
- O
to O
- O
A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
transversion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
responsible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
the O
APC B_DISEASE_ADJECTIVE[DISEASE]
I1307K I_DISEASE_ADJECTIVE[DISEASE]
allele I_DISEASE_ADJECTIVE[DISEASE]
converts O
the O
wild B_BIO/B_GENE
- O
type B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sequence I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
a O
homopolymer B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
tract B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
A8 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
that O
is O
genetically O
unstable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
prone B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
somatic B_DISEASE
mutation I_DISEASE
. O

The O
I1307K B_DISEASE_ADJECTIVE[DISEASE]
allele I_DISEASE_ADJECTIVE[DISEASE]
was O
found O
in O
6 B_NUMBER[MEASURE]/B_LOCATION
. O

1 O
% O
of O
unselected O
Ashkenazi O
Jews O
and O
higher O
proportions O
of O
Ashkenazim O
with O
family O
or O
personal O
histories O
of O
CRC B_DISEASE/B_LOCATION
( O
ref O
. O
2 O
) O
. O

To O
evaluate O
the O
role O
of O
I1307K O
in O
cancer B_DISEASE/B_LOCATION
, O
we O
genotyped O
5 O
, O
081 O
Ashkenazi O
volunteers O
in O
a O
community O
survey O
. O

Risk O
of O
developing O
colorectal B_DISEASE
, I_DISEASE
breast I_DISEASE
and I_DISEASE
other I_DISEASE
cancers I_DISEASE
were O
compared O
between O
genotyped O
I1307K O
carriers O
and O
non O
- O
carriers O
and O
their O
first O
- O
degree O
relatives O
. O

sperm O
DNA O
analysis O
in O
a O
Friedreich B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
ataxia I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
premutation O
carrier O
suggests O
both O
meiotic O
and O
mitotic O
expansion O
in O
the O
FRDA B_DISEASE/B_GENE
gene O
. O

Friedreich B_DISEASE
ataxia I_DISEASE
is O
usually O
caused O
by O
an O
expansion O
of O
a O
GAA O
trinucleotide O
repeat O
in O
intron O
1 O
of O
the O
FRDA B_DISEASE/B_GENE
gene O
. O

Occasionally O
, O
a O
fully O
expanded O
allele B_GENE/B_LOCATION
has O
been O
found O
to O
arise O
from O
a O
premutation B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
of O
100 B_NUMBER[MEASURE]
or O
less B_MEASURE
triplet I_MEASURE
repeats I_MEASURE
. O

We O
have O
examined O
the O
sperm B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
premutation B_PERSON/B_BIO
carrier I_PERSON/I_BIO
. O

This O
mans B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
leucocyte I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
showed O
one B_NUMBER[MEASURE]/B_GENE
normal I_NUMBER[MEASURE]/I_GENE
allele I_NUMBER[MEASURE]/I_GENE
and O
one B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
allele B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
approximately O
100 B_NUMBER[MEASURE]
repeats I_NUMBER[MEASURE]
. O

His O
sperm B_BIO/B_PERSON
showed O
an O
expanded O
allele B_GENE
in O
a O
tight B_PERSON/B_LOCATION
range B_PERSON/I_LOCATION
centering O
on O
a O
size B_MEASURE/B_LOCATION
of O
approximately O
320 B_NUMBER[MEASURE]
trinucleotide I_NUMBER[MEASURE]
repeats I_NUMBER[MEASURE]
. O

His O
affected B_GENE
son I_GENE
has O
repeat B_TIME[MEASURE]/B_PERSON
sizes I_TIME[MEASURE]/I_PERSON
of O
1040 B_MEASURE
and O
540 B_MEASURE
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
expansion B_DISEASE/B_ORGANISM_FUNCTION
occurs O
in O
two B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stages I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
during O
meiosis B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_CELL_FUNCTION[ORGANISM_FUNCTION]
followed O
by O
a O
second B_SEQUENCE[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
mitotic I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
expansion I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
also O
show O
that O
in O
all O
informative B_PERSON/B_LOCATION
carrier I_PERSON/I_LOCATION
father I_PERSON/I_LOCATION
to O
affected B_PERSON
child I_PERSON
transmissions I_PERSON
, O
with O
the O
notable B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
exception I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
the O
premutation B_PERSON
carrier I_PERSON
, O
the O
expansion B_MEASURE
size I_MEASURE
decreases O
. O
. O

The O
R496H O
mutation O
of O
arylsulfatase O
A O
does O
not O
cause O
metachromatic B_DISEASE
leukodystrophy I_DISEASE
. O

Deficiency B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
of I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
arylsulfatase I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
A I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
ARSA O
) O
enzyme O
activity O
causes O
metachromatic B_DISEASE
leukodystrophy I_DISEASE
( O
MLD B_DISEASE
) O
. O

A O
number O
of O
ARSA O
gene O
mutations O
responsible O
for O
MLD B_DISEASE
have O
been O
identified O
. O

Recently O
, O
the O
R496H O
mutation O
of O
ARSA O
was O
proposed O
to O
be O
a O
cause O
of O
MLD B_DISEASE
( O
Draghia O
et O
al O
. O
, O
1997 O
) O
. O

We O
have O
investigated O
the O
R496H B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
found O
this O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
at O
a O
relatively O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
frequency I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
an O
African B_MEASURE/B_PERSON
American I_MEASURE/I_PERSON
population I_MEASURE/I_PERSON
( O
f B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
09 B_MEASURE
, O
n O
= O
61 B_MEASURE
subjects I_MEASURE
) O
. O

The O
ARSA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
enzyme I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
subjects B_PERSON/B_BIO
with O
and O
without O
the O
R496H B_DISEASE/B_GENE
mutation I_DISEASE/I_GENE
was O
determined O
and O
found O
to O
be O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
therefore O
concluded O
that O
the O
R496H O
mutation O
of O
ARSA O
does O
not O
negatively O
influence O
the O
activity O
of O
ARSA O
and O
is O
not O
a O
cause O
of O
MLD B_DISEASE
. O

Down O
- O
regulation O
of O
transmembrane O
carbonic O
anhydrases O
in O
renal B_DISEASE
cell I_DISEASE
carcinoma I_DISEASE
cell O
lines O
by O
wild O
- O
type O
von B_DISEASE/B_GENE
Hippel B_DISEASE/I_GENE
- B_DISEASE/I_GENE
Lindau B_DISEASE/I_GENE
transgenes O
. O

To O
discover O
genes O
involved O
in O
von B_DISEASE/B_VIRUS[BIO]
Hippel B_DISEASE/I_VIRUS[BIO]
- B_DISEASE/I_VIRUS[BIO]
Lindau B_DISEASE/I_VIRUS[BIO]
( O
VHL B_DISEASE/B_GENE
) O
- O
mediated O
carcinogenesis O
, O
we O
used O
renal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cell I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
carcinoma I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cell O
lines O
stably O
transfected O
with O
wild O
- O
type O
VHL O
- O
expressing O
transgenes O
. O

Large B_MEASURE/B_GENE
- O
scale B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
RNA I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
differential I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
display I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
technology I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
applied O
to O
these O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lines B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identified O
several B_NUMBER[MEASURE]
differentially O
expressed O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
including O
an O
alpha B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
carbonic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
anhydrase I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
termed O
CA12 B_GENE/B_DISEASE
. O

The O
deduced B_PROTEIN[GENE]/B_LOCATION
protein I_PROTEIN[GENE]/I_LOCATION
sequence I_PROTEIN[GENE]/I_LOCATION
was O
classified O
as O
a O
one B_NUMBER[MEASURE]
- O
pass B_GENE/B_MEASURE
transmembrane B_GENE/I_MEASURE
CA B_GENE/I_MEASURE
possessing O
an O
apparently O
intact B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
catalytic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
domain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
the O
extracellular B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
CA I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
module I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Reintroduced O
wild O
- O
type O
VHL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
strongly O
inhibited O
the O
overexpression O
of O
the O
CA12 O
gene O
in O
the O
parental O
renal B_DISEASE
cell I_DISEASE
carcinoma I_DISEASE
cell O
lines O
. O

Similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
obtained O
with O
CA9 B_GENE/B_LOCATION
, O
encoding O
another O
transmembrane B_ENZYME[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
CA I_ENZYME[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
with O
an O
intact B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
catalytic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
domain I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Although O
both O
domains O
of O
the O
VHL B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
protein O
contribute O
to O
regulation O
of O
CA12 O
expression O
, O
the O
elongin O
binding O
domain O
alone O
could O
effectively O
regulate O
CA9 O
expression O
. O

We O
mapped O
CA12 B_GENE/B_LOCATION
and O
CA9 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
loci I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
to O
chromosome B_MEASURE/B_GENE
bands I_MEASURE/I_GENE
15q22 I_MEASURE/I_GENE
and O
17q21 B_MEASURE
. O

2 O
respectively O
, O
regions O
prone O
to O
amplification O
in O
some O
human O
cancers B_DISEASE/B_BIO
. O

Additional O
experiments O
are O
needed O
to O
define O
the O
role O
of O
CA O
IX O
and O
CA O
XII O
enzymes O
in O
the O
regulation O
of O
pH O
in O
the O
extracellular O
microenvironment O
and O
its O
potential O
impact O
on O
cancer B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cell O
growth O
. O

A O
gene O
encoding O
a O
transmembrane O
protein O
is O
mutated O
in O
patients O
with O
diabetes B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
mellitus I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
optic B_DISEASE
atrophy I_DISEASE
( O
Wolfram B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
syndrome I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
) O
. O

Wolfram B_DISEASE/B_GENE
syndrome I_DISEASE/I_GENE
( O
WFS B_DISEASE/B_PROTEIN[GENE]
; O
OMIM O
222300 O
) O
is O
an O
autosomal B_DISEASE/B_GENE
recessive I_DISEASE/I_GENE
neurodegenerative I_DISEASE/I_GENE
disorder I_DISEASE/I_GENE
defined O
by O
young O
- O
onset O
non O
- O
immune O
insulin B_DISEASE
- I_DISEASE
dependent I_DISEASE
diabetes I_DISEASE
mellitus I_DISEASE
and O
progressive O
optic B_DISEASE
atrophy I_DISEASE
. O

linkage B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
markers B_DISEASE/B_GENE
on O
chromosome B_GENE/B_MEASURE
4p I_GENE/I_MEASURE
was O
confirmed O
in O
five B_PERSON/B_TIME[MEASURE]
families I_PERSON/I_TIME[MEASURE]
. O

On O
the O
basis O
of O
meiotic O
recombinants O
and O
disease O
- O
associated O
haplotypes O
, O
the O
WFS B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
gene O
was O
localized O
to O
a O
BAC O
/ O
P1 O
contig O
of O
less O
than O
250 O
kb O
. O

mutations O
in O
a O
novel O
gene O
( O
WFS1 O
) O
encoding O
a O
putative O
transmembrane O
protein O
were O
found O
in O
all O
affected O
individuals O
in O
six O
WFS B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
families O
, O
and O
these O
mutations O
were O
associated O
with O
the O
disease O
phenotype O
. O

WFS1 B_GENE
appears O
to O
function O
in O
survival B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
islet B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
beta I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O
. O

stable O
interaction O
between O
the O
products O
of O
the O
BRCA1 O
and O
BRCA2 O
tumor B_DISEASE
suppressor O
genes O
in O
mitotic O
and O
meiotic O
cells O
. O

BRCA1 O
and O
BRCA2 O
account O
for O
most O
cases O
of O
familial O
, O
early O
onset O
breast B_DISEASE
and I_DISEASE
/ I_DISEASE
or I_DISEASE
ovarian I_DISEASE
cancer I_DISEASE
and O
encode O
products O
that O
each O
interact O
with O
hRAD51 O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
presented O
here O
show O
that O
BRCA1 B_GENE/B_DISEASE
and O
BRCA2 B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
coexist I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
biochemical B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
complex I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
and O
colocalize B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
in O
subnuclear B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
foci B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
somatic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
on O
the O
axial B_LOCATION/B_MEASURE
elements I_LOCATION/I_MEASURE
of O
developing O
synaptonemal B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
complexes I_BODY_PART_OR_ORGAN_COMPONENT/I_BACTERIUM[BIO]
. O

Like O
BRCA1 B_GENE/B_DISEASE
and O
RAD51 B_GENE
, O
BRCA2 B_GENE/B_DISEASE
relocates O
to O
PCNA B_PROTEIN[GENE]/B_MEASURE
+ O
replication B_LOCATION/B_ORGANIZATION
sites I_LOCATION/I_ORGANIZATION
following O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
S B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
phase I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_BIO
to O
hydroxyurea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
or O
UV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
irradiation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Thus O
, O
BRCA1 B_GENE/B_DISEASE
and O
BRCA2 B_GENE
participate O
, O
together O
, O
in O
a O
pathway B_LOCATION
( O
s O
) O
associated O
with O
the O
activation B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O
double B_NUMBER[MEASURE]/B_BIO
- O
strand B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
break B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
repair B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
/ O
or O
homologous B_DISEASE/B_GENE
recombination I_DISEASE/I_GENE
. O

Dysfunction O
of O
this O
pathway O
may O
be O
a O
general O
phenomenon O
in O
the O
majority O
of O
cases O
of O
hereditary B_DISEASE
breast I_DISEASE
and I_DISEASE
/ I_DISEASE
or I_DISEASE
ovarian I_DISEASE
cancer I_DISEASE
. O
. O

A O
novel B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
Arg362Ser B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
sterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
27 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
hydroxylase B_ENZYME[GENE]/B_PERSON
gene I_ENZYME[GENE]/I_PERSON
( O
CYP27 B_GENE
) O
: O
its O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
mRNA B_GENE
splicing I_GENE
and O
enzyme B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
activity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
. O

A O
novel O
C O
to O
A O
mutation O
in O
the O
sterol O
27 O
- O
hydroxylase O
gene O
( O
CYP27 O
) O
was O
identified O
by O
sequencing O
amplified O
CYP27 O
gene O
products O
from O
a O
patient O
with O
cerebrotendinous B_DISEASE
xanthomatosis I_DISEASE
( O
CTX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
. O

The O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
changed O
the O
adrenodoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cofactor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
residue I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
362Arg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
362Ser B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
CGT B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
362Arg I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
AGT B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
362Ser I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
) O
, O
and O
was O
responsible B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
for O
deficiency B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
sterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
27 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
hydroxylase B_ENZYME[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_ENZYME[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
confirmed O
by O
expression B_GENE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
mutant B_GENE
cDNA I_GENE
into O
COS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
1 B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Quantitative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
that O
the O
expression B_MEASURE/B_GENE
of O
CYP27 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
mRNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
patient B_BODY_PART_OR_ORGAN_COMPONENT
represented O
52 B_MEASURE/B_DISEASE
. O

5 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
the O
normal B_MEASURE/B_PERSON
level B_MEASURE/I_PERSON
. O

As O
the O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurred O
at O
the O
penultimate B_LOCATION/B_MEASURE
nucleotide I_LOCATION/I_MEASURE
of O
exon B_GENE
6 I_GENE
( O
- O
2 B_LOCATION/B_MEASURE
position I_LOCATION/I_MEASURE
of O
exon B_GENE/B_DISEASE
6 I_GENE/I_DISEASE
- O
intron B_MEASURE
6 I_MEASURE
splice I_MEASURE
site I_MEASURE
) O
of O
the O
gene B_PERSON/B_GENE
, O
we O
hypothesized O
that O
the O
mutation B_DISEASE_ADJECTIVE[DISEASE]
may O
partially O
affect O
the O
normal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splicing I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
efficiency I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
exon B_GENE/B_BIO
6 I_GENE/I_BIO
and O
cause O
alternative B_DISEASE/B_GENE
splicing I_DISEASE/I_GENE
elsewhere O
, O
which O
resulted O
in O
decreased B_DISEASE/B_GENE
transcript I_DISEASE/I_GENE
in O
the O
patient B_PERSON/B_BIO
. O

transfection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
constructed O
minigenes B_GENE/B_BIO
, O
with O
or O
without O
the O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
, O
into O
COS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
1 B_MEASURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_MEASURE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
confirmed O
that O
the O
mutant B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
minigene I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
was O
responsible B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
for O
a O
mRNA B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
species I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
alternatively O
spliced O
at O
an O
activated O
cryptic B_LOCATION/B_PERSON
5 I_LOCATION/I_PERSON
splice I_LOCATION/I_PERSON
site I_LOCATION/I_PERSON
88 I_LOCATION/I_PERSON
BP I_LOCATION/I_PERSON
upstream O
from O
the O
3 B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
exon B_GENE
6 I_GENE
. O

Our O
data O
suggest O
that O
the O
C O
to O
A O
mutation O
at O
the O
penultimate O
nucleotide O
of O
exon O
6 O
of O
the O
CYP27 O
gene O
not O
only O
causes O
the O
deficiency B_DISEASE/B_GENE
in I_DISEASE/I_GENE
the I_DISEASE/I_GENE
sterol I_DISEASE/I_GENE
27 I_DISEASE/I_GENE
- I_DISEASE/I_GENE
hydroxylase I_DISEASE/I_GENE
activity I_DISEASE/I_GENE
, O
but O
also O
partially O
leads O
to O
alternative O
pre O
- O
mRNA O
splicing O
of O
the O
gene O
. O

To O
our O
knowledge B_PERSON
, O
this O
is O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_SEQUENCE[MEASURE]
regarding O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
mRNA B_GENE
splicing I_GENE
of O
a O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
- O
2 B_LOCATION/B_MEASURE
position I_LOCATION/I_MEASURE
of O
a O
5 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
splice I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
site I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

ATM O
germline O
mutations O
in O
classical O
ataxia B_DISEASE/B_GENE
- I_DISEASE/I_GENE
telangiectasia I_DISEASE/I_GENE
patients O
in O
the O
Dutch O
population O
. O

Germline O
mutations O
in O
the O
ATM O
gene O
are O
responsible O
for O
the O
autosomal B_DISEASE_ADJECTIVE[DISEASE]
recessive I_DISEASE_ADJECTIVE[DISEASE]
disorder I_DISEASE_ADJECTIVE[DISEASE]
ataxia I_DISEASE_ADJECTIVE[DISEASE]
- I_DISEASE_ADJECTIVE[DISEASE]
telangiectasia I_DISEASE_ADJECTIVE[DISEASE]
( O
A B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

In O
our O
study O
, O
we O
have O
determined O
the O
ATM O
mutation O
spectrum O
in O
19 O
classical O
A B_DISEASE/B_LOCATION
- B_DISEASE/I_LOCATION
T B_DISEASE/I_LOCATION
patients O
, O
including O
some O
immigrant O
populations O
, O
as O
well O
as O
12 O
of O
Dutch O
ethnic O
origin O
. O

Both O
the O
protein B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
truncation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
test I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
PTT B_LOCATION/B_ORGANIZATION
) O
and O
the O
restriction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
endonuclease I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fingerprinting I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
REF B_LOCATION/B_ORGANIZATION
) O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
were O
used O
and O
compared O
for O
their O
detection B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efficiency B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
identifying O
76 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
and O
60 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
the O
mutations B_GENE/B_DISEASE
, O
respectively O
. O

Most B_PERSON/B_NUMBER[MEASURE]
patients I_PERSON/I_NUMBER[MEASURE]
were O
found O
to O
be O
compound B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
heterozygote I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

seventeen B_NUMBER[MEASURE]
mutations I_NUMBER[MEASURE]
were O
distinct B_DISEASE_ADJECTIVE[DISEASE]
, O
of O
which O
10 B_NUMBER[MEASURE]
were O
not O
reported O
previously O
. O

Mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_NUMBER[MEASURE]
are O
small B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
deletions I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
or O
point B_DISEASE_ADJECTIVE[DISEASE]
mutations I_DISEASE_ADJECTIVE[DISEASE]
frequently O
affecting O
splice B_GENE/B_BIO
sites I_GENE/I_BIO
. O

Moreover O
, O
a O
16 B_NUMBER[MEASURE]/B_LOCATION
. O

7 O
- O
kb B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
genomic I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
deletion I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
3 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
gene B_GENE/B_LOCATION
, O
most O
likely O
a O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
recombination B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
between O
two B_GENE/B_PERSON
Line I_GENE/I_PERSON
elements I_GENE/I_PERSON
, O
was O
identified O
. O

The O
most O
frequently O
found O
mutation O
, O
identified O
in O
three O
unrelated O
Turkish O
A B_PERSON/B_LOCATION
- I_PERSON/I_LOCATION
T I_PERSON/I_LOCATION
individuals O
, O
was O
previously O
described O
to O
be O
a O
Turkish O
A B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
T I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
founder O
mutation O
. O

The O
presence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
a O
founder B_GENE/B_DISEASE
mutation I_GENE/I_DISEASE
among O
relatively O
small B_PERSON/B_MEASURE
ethnic I_PERSON/I_MEASURE
population I_PERSON/I_MEASURE
groups I_PERSON/I_MEASURE
in O
Western B_LOCATION
Europe I_LOCATION
could O
indicate O
a O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
carrier I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
frequency I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
such B_LOCATION/B_PERSON
communities I_LOCATION/I_PERSON
. O

In O
patients B_PERSON/B_LOCATION
of O
Dutch B_DISEASE/B_PERSON
ethnic I_DISEASE/I_PERSON
origin I_DISEASE/I_PERSON
, O
however O
, O
no O
significant B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
founder I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
effect I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
could O
be O
identified O
. O

The O
observed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
genetic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
heterogeneity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
including O
the O
relative B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
high B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
percentage B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
splice B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
site B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
mutations B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
had O
no O
reflection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
phenotype B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

All O
patients O
manifested O
classical O
A B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
T I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
increased O
cellular O
radioresistant O
DNA O
synthesis O
. O

determination O
of O
the O
genomic O
structure O
of O
the O
COL4A4 O
gene O
and O
of O
novel O
mutations O
causing O
autosomal B_DISEASE/B_GENE
recessive I_DISEASE/I_GENE
Alport I_DISEASE/I_GENE
syndrome I_DISEASE/I_GENE
. O

Autosomal B_DISEASE
recessive I_DISEASE
Alport I_DISEASE
syndrome I_DISEASE
is O
a O
progressive O
hematuric B_DISEASE
glomerulonephritis I_DISEASE
characterized O
by O
glomerular B_DISEASE
basement I_DISEASE
membrane I_DISEASE
abnormalities I_DISEASE
and O
associated O
with O
mutations O
in O
either O
the O
COL4A3 O
or O
the O
COL4A4 O
gene O
, O
which O
encode O
the O
alpha3 O
and O
alpha4 O
type O
IV O
collagen O
chains O
, O
respectively O
. O

To O
date B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
mutation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
screening I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
two B_LOCATION/B_GENE
genes I_LOCATION/I_GENE
has O
been O
hampered O
by O
the O
lack B_DISEASE_ADJECTIVE[DISEASE]
of O
genomic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
structure I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
information I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

We O
report O
here O
the O
complete O
characterization O
of O
the O
48 O
exons O
of O
the O
COL4A4 O
gene O
, O
a O
comprehensive O
gene O
screen O
, O
and O
the O
subsequent O
detection O
of O
10 O
novel O
mutations O
in O
eight O
patients O
diagnosed O
with O
autosomal B_DISEASE
recessive I_DISEASE
Alport I_DISEASE
syndrome I_DISEASE
. O

Furthermore O
, O
we O
identified O
a O
glycine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
alanine O
substitution B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O
the O
collagenous B_GENE/B_DISEASE
domain I_GENE/I_DISEASE
that O
is O
apparently O
silent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O
the O
heterozygous B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
carriers I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
in O
11 B_MEASURE/B_BIO
. O

5 B_TIME[MEASURE]/B_PERSON
% I_TIME[MEASURE]/I_PERSON
of O
all O
control B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
individuals I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
in O
one B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
individual I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homozygous I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
this O
glycine B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
substitution B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

There O
has O
been O
no O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
finding I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
a O
glycine B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
substitution B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
that O
is O
not O
associated O
with O
any O
obvious B_DISEASE/B_GENE
phenotype I_DISEASE/I_GENE
in O
homozygous B_PERSON/B_BIO
individuals B_PERSON/I_BIO
. O

Founder O
BRCA1 O
and O
BRCA2 O
mutations O
in O
French O
Canadian O
breast B_DISEASE/B_PERSON
and I_DISEASE/I_PERSON
ovarian I_DISEASE/I_PERSON
cancer I_DISEASE/I_PERSON
families O
. O

We O
have O
identified O
four O
mutations O
in O
each O
of O
the O
breast B_DISEASE/B_GENE
cancer I_DISEASE/I_GENE
- O
susceptibility O
genes O
, O
BRCA1 O
and O
BRCA2 O
, O
in O
French O
Canadian O
breast B_DISEASE/B_PERSON
cancer I_DISEASE/I_PERSON
and O
breast B_DISEASE/B_PERSON
/ I_DISEASE/I_PERSON
ovarian I_DISEASE/I_PERSON
cancer I_DISEASE/I_PERSON
families O
from O
Quebec O
. O

To O
identify O
founder O
effects O
, O
we O
examined O
independently O
ascertained O
French O
Canadian O
cancer B_DISEASE/B_LOCATION
families O
for O
the O
distribution O
of O
these O
eight O
mutations O
. O

Mutations B_DISEASE/B_PERSON
were O
found O
in O
41 B_NUMBER[MEASURE]
of O
97 B_PERSON/B_ENT
families I_PERSON/I_ENT
. O

Six B_NUMBER[MEASURE]
of O
eight B_NUMBER[MEASURE]/B_PERSON
mutations B_NUMBER[MEASURE]/I_PERSON
were O
observed O
at O
least O
twice O
. O

The O
BRCA1 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
C4446T B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
was O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]
mutation I_DISEASE_ADJECTIVE[DISEASE]
found O
, O
followed O
by O
the O
BRCA2 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
8765delAG I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
mutation I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Together O
, O
these O
mutations B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
were O
found O
in O
28 B_NUMBER[MEASURE]
of O
41 B_MEASURE/B_PERSON
families I_MEASURE/I_PERSON
identified O
to O
have O
a O
mutation B_DISEASE/B_GENE
. O

The O
odds B_TIME[MEASURE]/B_PERSON
of O
detection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
any O
of O
the O
four B_DISEASE/B_GENE
BRCA1 I_DISEASE/I_GENE
mutations I_DISEASE/I_GENE
was O
18 B_TIME[MEASURE]
. O

7x O
greater O
if O
one O
or O
more O
cases O
of O
ovarian B_DISEASE
cancer I_DISEASE
were O
also O
present O
in O
the O
family O
. O

The O
odds B_PERSON/B_MEASURE
of O
detection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
any O
of O
the O
four B_DISEASE/B_GENE
BRCA2 I_DISEASE/I_GENE
mutations I_DISEASE/I_GENE
was O
5 B_TIME[MEASURE]
. O

3x O
greater O
if O
there O
were O
at O
least O
five O
cases O
of O
breast B_DISEASE/B_GENE
cancer I_DISEASE/I_GENE
in O
the O
family O
. O

Interestingly O
, O
the O
presence O
of O
a O
breast B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cancer I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
case O
< O
36 O
years O
of O
age O
was O
strongly O
predictive O
of O
the O
presence O
of O
any O
of O
the O
eight O
mutations O
screened O
. O

carriers B_PERSON
of O
the O
same B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_PERSON
mutation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_PERSON
, O
from O
different B_LOCATION/B_PERSON
families I_LOCATION/I_PERSON
, O
shared O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
haplotypes I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
, O
indicating O
that O
the O
mutant B_PERSON/B_GENE
alleles I_PERSON/I_GENE
were O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
be O
identical B_DISEASE_ADJECTIVE[DISEASE]
by O
descent B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
a O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O
the O
founder B_PERSON/B_BIO
population I_PERSON/I_BIO
. O

The O
identification O
of O
common O
BRCA1 O
and O
BRCA2 O
mutations O
will O
facilitate O
carrier O
detection O
in O
French O
Canadian O
breast B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
breast B_DISEASE/B_GENE
/ I_DISEASE/I_GENE
ovarian I_DISEASE/I_GENE
cancer I_DISEASE/I_GENE
families O
. O

Are O
Dp71 O
and O
Dp140 O
brain O
dystrophin O
isoforms O
related O
to O
cognitive B_DISEASE_ADJECTIVE[DISEASE]
impairment I_DISEASE_ADJECTIVE[DISEASE]
in O
Duchenne B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
muscular I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
dystrophy I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON

Molecular O
study O
and O
neuropsychological O
analysis O
were O
performed O
concurrently O
on O
49 O
patients O
with O
Duchenne B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
muscular I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
dystrophy I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
DMD B_DISEASE
) O
in O
order O
to O
find O
a O
molecular O
explanation O
for O
the O
cognitive B_DISEASE_ADJECTIVE[DISEASE]
impairment I_DISEASE_ADJECTIVE[DISEASE]
observed O
in O
most O
DMD B_DISEASE/B_MEASURE
patients O
. O

Complete O
analysis O
of O
the O
dystrophin O
gene O
was O
performed O
to O
define O
the O
localization O
of O
deletions O
and O
duplications O
in O
relation O
to O
the O
different O
DMD B_DISEASE/B_GENE
promoters O
. O

Qualitative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
the O
Dp71 B_GENE/B_BIO
transcript I_GENE/I_BIO
and O
testing B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
the O
specific B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
first I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
exon I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
of O
Dp140 B_GENE
were O
also O
carried O
out O
. O

neuropsychological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
assessed O
verbal B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O
visuospatial B_EDU[ORGANIZATION]/B_DISEASE_ADJECTIVE[DISEASE]
intelligence I_EDU[ORGANIZATION]/I_DISEASE_ADJECTIVE[DISEASE]
, O
verbal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
memory I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
and O
reading B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
skills I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

comparison O
of O
molecular O
and O
psychometric O
findings O
demonstrated O
that O
deletions O
and O
duplications O
that O
were O
localized O
in O
the O
distal O
part O
of O
the O
gene O
seemed O
to O
be O
preferentially O
associated O
with O
cognitive B_DISEASE
impairment I_DISEASE
. O

Two O
altered O
Dp71 O
transcripts O
and O
two O
deleted O
Dp140 O
DNA O
sequences O
were O
found O
in O
four O
patients O
with O
severe O
cerebral B_DISEASE
dysfunction I_DISEASE
. O

These O
findings O
suggest O
that O
some O
sequences O
located O
in O
the O
distal O
part O
of O
the O
gene O
and O
, O
in O
particular O
, O
some O
DMD B_DISEASE/B_GENE
isoforms O
expressed O
in O
the O
brain O
may O
be O
related O
to O
the O
cognitive B_DISEASE/B_GENE
impairment I_DISEASE/I_GENE
associated O
with O
DMD B_DISEASE
. O
. O

I1307K O
APC O
and O
hMLH1 O
mutations O
in O
a O
non O
- O
Jewish O
family O
with O
hereditary B_DISEASE
non I_DISEASE
- I_DISEASE
polyposis I_DISEASE
colorectal I_DISEASE
cancer I_DISEASE
. O

We O
describe O
a O
French O
Canadian O
hereditary B_DISEASE
non I_DISEASE
- I_DISEASE
polyposis I_DISEASE
colorectal I_DISEASE
cancer I_DISEASE
( O
HNPCC B_DISEASE/B_GENE
) O
kindred O
which O
carries O
a O
novel O
truncating O
mutation O
in O
hMLH1 O
. O

Interestingly O
, O
the O
I1307K O
APC O
polymorphism O
, O
associated O
with O
an O
increased O
risk O
of O
colorectal B_DISEASE
cancer I_DISEASE
, O
is O
also O
present O
in O
this O
family O
. O

The O
I1307K B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
polymorphism B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
has O
previously O
only O
been O
identified O
in O
individuals B_PERSON/B_BIO
of O
self B_PERSON/B_MEASURE
- O
reported O
Ashkenazi B_DISEASE/B_LOCATION
Jewish I_DISEASE/I_LOCATION
origins I_DISEASE/I_LOCATION
. O

In O
addition O
, O
in O
this O
family O
, O
there O
appears O
to O
be O
no O
relationship O
between O
the O
I1307K O
polymorphism O
and O
the O
presence O
or O
absence O
of O
cancer B_DISEASE
. O
. O

identification O
of O
a O
novel O
mutation O
of O
the O
CPO O
gene O
in O
a O
Japanese O
hereditary B_DISEASE/B_BIO
coproporphyria I_DISEASE/I_BIO
family O
. O

Hereditary B_DISEASE
coproporphyria I_DISEASE
( O
HCP B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
is O
an O
autosomal B_DISEASE/B_GENE
dominant I_DISEASE/I_GENE
disease I_DISEASE/I_GENE
characterized O
by O
a O
deficiency B_DISEASE
of I_DISEASE
coproporphyrinogen I_DISEASE
oxidase I_DISEASE
( O
CPO O
) O
caused O
by O
a O
mutation O
in O
the O
CPO O
gene O
. O

Only O
11 O
mutations O
of O
the O
gene O
have O
been O
reported O
in O
HCP B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
patients O
. O

We O
report O
another O
mutation B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
in O
a O
Japanese B_PERSON/B_ORGANIZATION
family I_PERSON/I_ORGANIZATION
. O

polymerase B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chain I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
single B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
strand B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conformational B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphism B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
direct B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analyses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
demonstrated O
a O
C B_PROTEIN[GENE]/B_LOCATION
to O
T B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
substitution B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
exon B_GENE/B_MEASURE
1 I_GENE/I_MEASURE
of O
the O
CPO B_GENE/B_BIO
gene I_GENE/I_BIO
at O
nucleotide B_TIME[MEASURE]/B_PROTEIN[GENE]
position I_TIME[MEASURE]/I_PROTEIN[GENE]
85 I_TIME[MEASURE]/I_PROTEIN[GENE]
, O
which O
lies O
in O
the O
putative B_LOCATION/B_MEASURE
presequence I_LOCATION/I_MEASURE
for O
targeting O
to O
mitochondria B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
. O

This O
mutation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
changes O
the O
codon B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
glutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
a O
termination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
codon I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
position I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
29 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

MaeI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
restriction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
two B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
other I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
carriers I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
in O
the O
family B_PERSON/B_BIO
. O

The O
C B_PROTEIN[GENE]
- O
T B_LOCATION/B_GENE
mutation I_LOCATION/I_GENE
is O
located O
within O
a O
recently O
proposed O
putative B_GENE/B_LOCATION
alternative I_GENE/I_LOCATION
translation I_GENE/I_LOCATION
initiation I_GENE/I_LOCATION
codon I_GENE/I_LOCATION
( O
TIC B_LOCATION/B_ORGANIZATION
- O
1 B_NUMBER[MEASURE]/B_LOCATION
) O
, O
supporting O
that O
TIC B_LOCATION/B_ORGANIZATION
- O
1 B_NUMBER[MEASURE]
is O
the O
real B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
tic I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
rather O
than O
TIC B_LOCATION
- O
2 B_NUMBER[MEASURE]/B_LOCATION
. O
. O

Human B_DISEASE/B_PERSON
complement I_DISEASE/I_PERSON
factor I_DISEASE/I_PERSON
H I_DISEASE/I_PERSON
deficiency I_DISEASE/I_PERSON
associated O
with O
hemolytic B_DISEASE/B_GENE
uremic I_DISEASE/I_GENE
syndrome I_DISEASE/I_GENE
. O

This O
study O
reports O
on O
six O
cases O
of O
deficiency B_DISEASE
in I_DISEASE
the I_DISEASE
human I_DISEASE
complement I_DISEASE
regulatory I_DISEASE
protein I_DISEASE
Factor I_DISEASE
H I_DISEASE
( O
FH O
) O
in O
the O
context O
of O
an O
acute B_DISEASE
renal I_DISEASE
disease I_DISEASE
. O

Five O
of O
the O
cases O
were O
observed O
in O
children O
presenting O
with O
idiopathic O
hemolytic B_DISEASE
uremic I_DISEASE
syndrome I_DISEASE
( O
HUS B_DISEASE/B_LOCATION
) O
. O

Two B_NUMBER[MEASURE]/B_PERSON
of O
the O
children B_PERSON/B_BIO
exhibited O
a O
homozygous B_DISEASE_ADJECTIVE[DISEASE]
deficiency I_DISEASE_ADJECTIVE[DISEASE]
characterized O
by O
the O
absence B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
150 B_MEASURE
- O
kD B_MEASURE/B_LOCATION
form I_MEASURE/I_LOCATION
of O
Factor B_PROTEIN[GENE]/B_DISEASE
H I_PROTEIN[GENE]/I_DISEASE
and O
the O
presence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
upon O
immunoblotting O
, O
of O
the O
42 B_MEASURE
- O
kD B_PROTEIN[GENE]/B_MEASURE
Factor I_PROTEIN[GENE]/I_MEASURE
H I_PROTEIN[GENE]/I_MEASURE
- O
like B_DISEASE_ADJECTIVE[DISEASE]
protein I_DISEASE_ADJECTIVE[DISEASE]
1 I_DISEASE_ADJECTIVE[DISEASE]
( O
FHL B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
1 B_NUMBER[MEASURE]
) O
and O
other B_DISEASE/B_GENE
FH B_DISEASE/I_GENE
- O
related O
protein B_GENE/B_BACTERIUM[BIO]
( O
FHR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
bands B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Southern B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blot B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
PCR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
DNA B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
of O
one B_PERSON/B_BIO
patient I_PERSON/I_BIO
with O
homozygous B_DISEASE
deficiency I_DISEASE
ruled O
out O
the O
presence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
a O
large B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
deletion I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
of O
the O
FH B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
as O
the O
underlying O
defect B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
deficiency B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
. O

The O
other B_PERSON/B_ENT
four I_PERSON/I_ENT
children I_PERSON/I_ENT
presented O
with O
heterozygous B_DISEASE
deficiency I_DISEASE
and O
exhibited O
a O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
immunoblotting I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
pattern I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
proteins B_BIO/B_PERSON
of O
the O
FH B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
family B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Factor B_DISEASE/B_PROTEIN[GENE]
H B_DISEASE/I_PROTEIN[GENE]
deficiency B_DISEASE/I_PROTEIN[GENE]
is O
the O
only O
complement B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
deficiency I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
associated O
with O
HUS B_DISEASE
. O

These O
observations O
suggest O
a O
role O
for O
FH O
and O
/ O
or O
FH O
receptors O
in O
the O
pathogenesis O
of O
idiopathic O
HUS B_DISEASE
. O
. O

Further O
evidence O
for O
a O
major O
ancient O
mutation O
underlying O
myotonic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dystrophy B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
linkage O
disequilibrium O
studies O
in O
the O
Japanese O
population O
. O

The O
myotonic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
dystrophy I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
DM B_LOCATION
) O
mutation O
is O
an O
unstable O
( O
CTG O
) O
n O
repeat O
, O
present O
at O
a O
copy O
number O
of O
5 O
- O
37 O
repeats O
on O
normal O
chromosomes O
but O
amplified O
to O
50 O
- O
3000 O
copies O
on O
DM B_DISEASE/B_MEASURE
chromosomes O
. O

Previous O
findings O
in O
Caucasian O
populations O
of O
a O
DM B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
founder O
chromosome O
raise O
a O
question O
about O
the O
molecular O
events O
involved O
in O
the O
expansion O
mutation O
. O

To O
investigate O
whether O
a O
founder O
chromosome O
for O
the O
DM B_DISEASE/B_GENE
mutation O
exists O
in O
the O
Japanese O
population O
, O
we O
genotyped O
families O
using O
polymorphic O
markers O
near O
the O
( O
CTG O
) O
n O
repeat O
region O
and O
constructed O
haplotypes O
. O

Six O
different O
haplotypes O
were O
found O
and O
DM B_PERSON
alleles O
were O
always O
haplotype O
A O
. O

To O
find O
an O
origin O
of O
the O
( O
CTG O
) O
n O
repeat O
mutation O
and O
to O
investigate O
the O
mechanism O
of O
the O
expansion O
mutation O
in O
the O
Japanese O
population O
we O
have O
studied O
90 O
Japanese O
DM B_DISEASE/B_PERSON
families O
comprising O
190 O
affected O
and O
130 O
unaffected O
members O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
suggest O
that O
a O
few B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
common B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
ancestral B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutations B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
both O
Caucasian B_PERSON/B_LOCATION
and O
Japanese B_PERSON/B_LOCATION
populations I_PERSON/I_LOCATION
have O
originated O
by O
expansion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
an O
ancestral B_PROTEIN[GENE]/B_LOCATION
n I_PROTEIN[GENE]/I_LOCATION
= O
5 B_MEASURE
repeat I_MEASURE
to O
n B_OTHER/B_PROTEIN[GENE]
= O
19 B_MEASURE
- O
37 B_MEASURE
copies I_MEASURE
. O

These O
data O
support O
multistep O
models O
of O
triplet O
repeat O
expansion O
that O
have O
been O
proposed O
for O
both O
DM B_DISEASE/B_GENE
and O
Friedreichs B_DISEASE/B_LOCATION
ataxia B_DISEASE/I_LOCATION
. O
. O

The O
molecular O
basis O
of O
C6 B_DISEASE
deficiency I_DISEASE
in O
the O
western O
Cape O
, O
South O
Africa O
. O

Deficiency B_DISEASE
of I_DISEASE
the I_DISEASE
sixth I_DISEASE
component I_DISEASE
of I_DISEASE
human I_DISEASE
complement I_DISEASE
( O
C6 O
) O
has O
been O
reported O
in O
a O
number O
of O
families O
from O
the O
western O
Cape O
, O
South O
Africa O
. O

Meningococcal B_DISEASE/B_PROTEIN[GENE]
disease B_DISEASE/I_PROTEIN[GENE]
is O
endemic O
in O
the O
Cape O
and O
almost O
all O
pedigrees O
of O
total O
C6 B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
deficiency B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
( O
C6Q0 O
) O
have O
been O
ascertained O
because O
of O
recurrent O
disease O
. O

We O
have O
sequenced O
the O
expressed O
exons B_GENE/B_LOCATION
of O
the O
C6 B_GENE/B_BIO
gene I_GENE/I_BIO
from O
selected O
cases B_PERSON/B_BIO
and O
have O
found O
three B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecular I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
defects I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
leading O
to O
total B_DISEASE/B_GENE
deficiency I_DISEASE/I_GENE
879delG I_DISEASE/I_GENE
, O
which O
is O
the O
common B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
defect I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
Cape B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hitherto B_LOCATION/B_ENT
unreported I_LOCATION/I_ENT
, O
and O
1195delC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
1936delG B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
have O
been O
previously O
reported O
in O
African B_PERSON/B_LOCATION
- O
Americans B_PERSON/B_SPORT[ENT]
. O

We O
also O
show O
that O
the O
879delG B_MEASURE/B_GENE
and O
1195delC B_DISEASE/B_PROTEIN[GENE]
defects B_DISEASE/I_PROTEIN[GENE]
are O
associated O
with O
characteristic B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
C6 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
/ O
C7 B_PROTEIN[GENE]/B_DISEASE
region I_PROTEIN[GENE]/I_DISEASE
DNA I_PROTEIN[GENE]/I_DISEASE
marker I_PROTEIN[GENE]/I_DISEASE
haplotypes I_PROTEIN[GENE]/I_DISEASE
, O
although O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
variations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
were O
observed O
. O

The O
1936delG B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
defect I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
was O
observed O
only O
once O
in O
the O
Cape B_LOCATION/B_PERSON
, O
but O
its O
associated B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
haplotype B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
could O
be O
deduced O
. O

The O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
from O
the O
haplotypes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
indicate O
that O
these O
three B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecular I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
defects I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
account O
for O
the O
defects B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
in O
all O
the O
38 B_PERSON/B_BIO
unrelated I_PERSON/I_BIO
C6Q0 I_PERSON/I_BIO
individuals I_PERSON/I_BIO
we O
have O
studied O
from O
the O
Cape B_LOCATION/B_TIME[MEASURE]
. O

We O
have O
also O
observed O
the O
879delG O
defect O
in O
two O
Dutch O
C6 B_LOCATION/B_PERSON
- B_LOCATION/I_PERSON
deficient B_LOCATION/I_PERSON
kindreds O
, O
but O
the O
879delG O
defect O
in O
the O
Cape O
probably O
did O
not O
come O
from O
The O
Netherlands O
. O
. O

Complement B_MEASURE
C7 I_MEASURE
deficiency I_MEASURE
: O
seven O
further O
molecular O
defects O
and O
their O
associated O
marker O
haplotypes O
. O

Seven O
further O
molecular O
bases O
of O
C7 B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deficiency B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
described O
. O

All O
these O
new B_DISEASE_ADJECTIVE[DISEASE]
molecular I_DISEASE_ADJECTIVE[DISEASE]
defects I_DISEASE_ADJECTIVE[DISEASE]
involve O
single B_NUMBER[MEASURE]/B_LOCATION
- O
nucleotide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
events B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
deletions B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
substitutions B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
, O
some O
of O
which O
alter O
splice B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
sites I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
others B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
codons I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
. O

They O
are O
distributed O
along O
the O
C7 B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
gene B_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
, O
but O
predominantly O
towards O
the O
3 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

All O
were O
found O
in O
compound B_LOCATION
heterozygous I_LOCATION
individuals I_LOCATION
. O

The O
C6 O
/ O
C7 O
marker O
haplotypes O
associated O
with O
most O
C7 B_DISEASE/B_GENE
defects I_DISEASE/I_GENE
are O
tabulated O
. O
. O

A O
genome O
- O
wide O
search O
for O
chromosomal O
loci O
linked O
to O
mental O
health O
wellness O
in O
relatives O
at O
high O
risk O
for O
bipolar B_DISEASE
affective I_DISEASE
disorder I_DISEASE
among O
the O
Old O
Order O
Amish O
. O

Bipolar B_DISEASE
affective I_DISEASE
disorder I_DISEASE
( O
BPAD B_LOCATION/B_ORGANIZATION
; O
manic B_DISEASE/B_PROTEIN[GENE]
- B_DISEASE/I_PROTEIN[GENE]
depressive B_DISEASE/I_PROTEIN[GENE]
illness B_DISEASE/I_PROTEIN[GENE]
) O
is O
characterized O
by O
episodes O
of O
mania B_DISEASE
and O
/ O
or O
hypomania B_DISEASE
interspersed O
with O
periods O
of O
depression B_DISEASE
. O

compelling O
evidence O
supports O
a O
significant O
genetic O
component O
in O
the O
susceptibility O
to O
develop O
BPAD B_DISEASE/B_GENE
. O

To O
date O
, O
however O
, O
linkage O
studies O
have O
attempted O
only O
to O
identify O
chromosomal O
loci O
that O
cause O
or O
increase O
the O
risk O
of O
developing O
BPAD B_DISEASE
. O

To O
determine O
whether O
there O
could O
be O
protective O
alleles O
that O
prevent O
or O
reduce O
the O
risk O
of O
developing O
BPAD B_DISEASE
, O
similar O
to O
what O
is O
observed O
in O
other O
genetic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
disorders I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
we O
used O
mental O
health O
wellness O
( O
absence O
of O
any O
psychiatric B_DISEASE_ADJECTIVE[DISEASE]
disorder I_DISEASE_ADJECTIVE[DISEASE]
) O
as O
the O
phenotype O
in O
our O
genome O
- O
wide O
linkage O
scan O
of O
several O
large O
multigeneration O
Old O
Order O
Amish O
pedigrees O
exhibiting O
an O
extremely O
high O
incidence O
of O
BPAD B_DISEASE
. O

We O
have O
found O
strong B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
a O
locus B_LOCATION/B_PERSON
on O
chromosome B_GENE
4p I_GENE
at O
D4S2949 B_PROTEIN[GENE]
( O
maximum B_MEASURE/B_LOCATION
GENEHUNTER B_MEASURE/I_LOCATION
- O
Plus B_MEASURE/B_LOCATION
nonparametric I_MEASURE/I_LOCATION
linkage I_MEASURE/I_LOCATION
score I_MEASURE/I_LOCATION
= O
4 B_MEASURE
. O
05 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
= O
5 B_MEASURE
. O
22 B_MEASURE
x O
10 B_NUMBER[MEASURE]
( O
- O
4 B_NUMBER[MEASURE]
) O
; O
SIBPAL B_LOCATION/B_MEASURE
Pempirical I_LOCATION/I_MEASURE
value I_LOCATION/I_MEASURE
< O
3 B_MEASURE
x O
10 B_NUMBER[MEASURE]
( O
- O
5 B_NUMBER[MEASURE]
) O
) O
and O
suggestive B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence I_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
a O
locus B_GENE/B_LOCATION
on O
chromosome B_GENE
4q I_GENE
at O
D4S397 B_GENE
( O
maximum B_GENE/B_DISEASE
GENEHUNTER I_GENE/I_DISEASE
- O
Plus B_MEASURE/B_LOCATION
nonparametric I_MEASURE/I_LOCATION
linkage I_MEASURE/I_LOCATION
score I_MEASURE/I_LOCATION
= O
3 B_MEASURE
. O
29 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
= O
2 B_MEASURE
. O
57 B_MEASURE
x O
10 B_NUMBER[MEASURE]
( O
- O
3 B_NUMBER[MEASURE]
) O
; O
SIBPAL B_LOCATION/B_MEASURE
Pempirical I_LOCATION/I_MEASURE
value I_LOCATION/I_MEASURE
< O
1 B_NUMBER[MEASURE]
x O
10 B_NUMBER[MEASURE]
( O
- O
3 B_NUMBER[MEASURE]
) O
) O
that O
are O
linked O
to O
mental B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
health B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
wellness B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

These O
findings O
are O
consistent O
with O
the O
hypothesis O
that O
certain O
alleles O
could O
prevent O
or O
modify O
the O
clinical O
manifestations O
of O
BPAD B_DISEASE
and O
perhaps O
other O
related O
affective B_DISEASE/B_GENE
disorders I_DISEASE/I_GENE
. O

segregation O
distortion O
in O
myotonic B_DISEASE/B_PERSON
dystrophy I_DISEASE/I_PERSON
. O

Myotonic B_DISEASE
dystrophy I_DISEASE
( O
DM B_LOCATION/B_ORGANIZATION
) O
is O
an O
autosomal B_DISEASE/B_GENE
dominant I_DISEASE/I_GENE
disease I_DISEASE/I_GENE
which O
, O
in O
the O
typical O
pedigree O
, O
shows O
a O
three O
generation O
anticipation O
Cascade O
. O

This O
results O
in O
infertility B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
congenital B_DISEASE/B_ORGANISM_FUNCTION
myotonic I_DISEASE/I_ORGANISM_FUNCTION
dystrophy I_DISEASE/I_ORGANISM_FUNCTION
( O
CDM B_DISEASE/B_LOCATION
) O
with O
the O
disappearance O
of O
DM B_DISEASE/B_PERSON
in O
that O
pedigree O
. O

The O
concept O
of O
segregation O
distortion O
, O
where O
there O
is O
preferential O
transmission O
of O
the O
larger O
allele O
at O
the O
DM B_DISEASE/B_GENE
locus O
, O
has O
been O
put O
forward O
to O
explain O
partially O
the O
maintenance O
of O
DM B_DISEASE/B_PROTEIN[GENE]
in O
the O
population O
. O

In O
a O
survey O
of O
DM B_PERSON/B_BIO
in O
Northern O
Ireland O
, O
59 O
pedigrees O
were O
ascertained O
. O

Sibships O
where O
the O
status O
of O
all O
the O
members O
had O
been O
identified O
were O
examined O
to O
determine O
the O
transmission O
of O
the O
DM B_DISEASE/B_PERSON
expansion O
from O
affected O
parents O
to O
their O
offspring O
. O

Where O
the O
transmitting O
parent B_PERSON/B_LOCATION
was O
male B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
, O
58 B_TIME[MEASURE]/B_LOCATION
. O

3 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
the O
offspring B_PERSON/B_LOCATION
were O
affected O
, O
and O
in O
the O
case B_PERSON/B_LOCATION
of O
a O
female B_PERSON/B_DISEASE
transmitting O
parent B_PERSON/B_DISEASE
, O
68 B_NUMBER[MEASURE]/B_LOCATION
. O

7 B_PERSON/B_NUMBER[MEASURE]
% B_PERSON/I_NUMBER[MEASURE]
were O
affected O
. O

Studies O
on O
meiotic O
drive O
in O
DM B_SPECIES[BIO]/B_DISEASE
have O
shown O
increased O
transmission O
of O
the O
larger O
allele O
at O
the O
DM B_GENE/B_DISEASE
locus O
in O
non O
- O
DM O
heterozygotes O
for O
CTGn O
. O

This O
study O
provides O
further O
evidence O
that O
the O
DM B_MEASURE/B_LOCATION
expansion O
tends O
to O
be O
transmitted O
preferentially O
. O

diagnosis O
of O
hemochromatosis B_DISEASE
. O

If O
untreated O
, O
hemochromatosis B_DISEASE/B_GENE
can O
cause O
serious O
illness O
and O
early B_DISEASE
death I_DISEASE
, O
but O
the O
disease O
is O
still O
substantially O
under O
- O
diagnosed O
. O

The O
cornerstone B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
screening B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
measurement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
serum B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
transferrin B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
saturation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
the O
serum B_MEASURE/B_GENE
ferritin B_MEASURE/I_GENE
level B_MEASURE/I_GENE
. O

Once O
the O
diagnosis O
is O
suspected O
, O
physicians O
must O
use O
serum O
ferritin O
levels O
and O
hepatic O
iron O
stores O
on O
liver O
biopsy O
specimens O
to O
assess O
patients O
for O
the O
presence O
of O
iron B_DISEASE
overload I_DISEASE
. O

liver O
biopsy O
is O
also O
used O
to O
establish O
the O
presence O
or O
absence O
of O
cirrhosis B_DISEASE
, O
which O
can O
affect O
prognosis O
and O
management O
. O

A O
DNA O
- O
based O
test O
for O
the O
HFE O
gene O
is O
commercially O
available O
, O
but O
its O
place O
in O
the O
diagnosis O
of O
hemochromatosis B_DISEASE/B_LOCATION
is O
still O
being O
evaluated O
. O

Currently O
, O
the O
most O
useful O
role O
for O
this O
test O
is O
in O
the O
detection O
of O
hemochromatosis B_DISEASE
in O
the O
family O
members O
of O
patients O
with O
a O
proven O
case O
of O
the O
disease O
. O

It O
is O
crucial O
to O
diagnose O
hemochromatosis B_DISEASE
before O
hepatic B_DISEASE
cirrhosis I_DISEASE
develops O
because O
phlebotomy O
therapy O
can O
avert O
serious O
chronic O
disease O
and O
can O
even O
lead O
to O
normal O
life O
expectancy O
. O
. O

prevalence O
of O
the O
I1307K O
APC B_GENE/B_BACTERIUM[BIO]
gene O
variant O
in O
Israeli O
Jews O
of O
differing O
ethnic O
origin O
and O
risk O
for O
colorectal B_DISEASE
cancer I_DISEASE
. O

Background O
& O
aims O
Israeli O
Jews O
of O
European O
birth O
, O
i O
. O
e O
. O
, O
Ashkenazim O
, O
have O
the O
highest O
colorectal B_DISEASE
cancer I_DISEASE
incidence O
of O
any O
Israeli O
ethnic O
group O
. O

The O
I1307K O
APC B_GENE/B_BACTERIUM[BIO]
gene O
variant O
was O
found O
in O
6 O
. O

1 O
% O
of O
American O
Jews O
, O
28 O
% O
of O
their O
familial O
colorectal B_DISEASE
cancer I_DISEASE
cases O
, O
but O
not O
in O
non O
- O
Jews O
. O

We O
assessed O
the O
I1307K O
prevalence O
in O
Israeli O
Jews O
of O
differing O
ethnic O
origin O
and O
risk O
for O
colorectal B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
. O

methods O
DNA O
samples O
from O
500 O
unrelated O
Jews O
of O
European O
or O
non O
- O
European O
origin O
, O
with O
or O
without O
a O
personal O
and O
/ O
or O
family O
history O
of O
neoplasia B_PERSON/B_LOCATION
, O
were O
examined O
for O
the O
I1307K O
variant O
by O
the O
allele O
- O
specific O
oligonucleotide O
( O
ASO O
) O
method O
. O

Results O
In O
persons O
at O
average O
risk O
for O
colorectal B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
, O
I1307K O
was O
found O
in O
5 O
. O

0 B_MEASURE/B_PERSON
% B_MEASURE/I_PERSON
of O
120 B_PERSON/B_LOCATION
European I_PERSON/I_LOCATION
and O
1 B_NUMBER[MEASURE]/B_PERSON
. O

6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
188 B_LOCATION/B_DISEASE
non I_LOCATION/I_DISEASE
- O
European B_PERSON/B_ORGANIZATION
Jews I_PERSON/I_ORGANIZATION
( O
P B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
08 B_MEASURE
) O
. O

It O
occurred O
in O
15 B_NUMBER[MEASURE]/B_LOCATION
. O

4 O
% O
of O
52 O
Ashkenazi O
Israelis O
with O
familial O
cancer B_DISEASE/B_GENE
( O
P O
= O
0 O
. O
02 O
) O
and O
was O
not O
detected O
in O
51 O
non O
- O
European O
Jews O
at O
increased O
cancer B_DISEASE/B_GENE
risk O
. O

Colorectal B_DISEASE/B_PERSON
neoplasia I_DISEASE/I_PERSON
occurred O
personally O
or O
in O
the O
families O
of O
13 O
of O
20 O
Ashkenazi O
I1307K O
carriers O
, O
8 O
of O
whom O
also O
had O
a O
personal O
or O
family O
history O
of O
noncolonic O
neoplasia B_DISEASE
. O

conclusions O
The O
I1307K O
APC O
variant O
may O
represent O
a O
susceptibility O
gene O
for O
colorectal B_DISEASE
, I_DISEASE
or I_DISEASE
other I_DISEASE
, I_DISEASE
cancers I_DISEASE
in O
Ashkenazi O
Jews O
, O
and O
partially O
explains O
the O
higher O
incidence O
of O
colorectal B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
in O
European O
Israelis O
. O

systematic O
analysis O
of O
coproporphyrinogen O
oxidase O
gene O
defects O
in O
hereditary B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
coproporphyria I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
and O
mutation O
update O
. O

Hereditary B_DISEASE
coproporphyria I_DISEASE
( O
HC B_LOCATION/B_DISEASE
) O
is O
an O
acute O
hepatic B_DISEASE
porphyria I_DISEASE
with O
autosomal O
dominant O
inheritance O
caused O
by O
deficient B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
coproporphyrinogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
III I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
oxidase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
CPO O
) O
. O

Clinical O
manifestations O
of O
the O
disease O
are O
characterized O
by O
acute O
attacks O
of O
neurological B_DISEASE
dysfunction I_DISEASE
often O
precipitated O
by O
drugs O
, O
fasting O
, O
cyclical O
hormonal O
changes O
, O
or O
infectious B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
diseases I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Skin B_DISEASE_ADJECTIVE[DISEASE]
photosensitivity I_DISEASE_ADJECTIVE[DISEASE]
may O
also O
be O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
seven O
exons O
, O
the O
exon O
/ O
intron O
boundaries O
and O
part O
of O
3 O
noncoding O
sequence O
of O
the O
CPO O
gene O
were O
systematically O
analyzed O
by O
an O
exon O
- O
by O
- O
exon O
denaturing O
gradient O
gel O
electrophoresis O
( O
DGGE O
) O
strategy O
followed O
by O
direct O
sequencing O
in O
seven O
unrelated O
heterozygous O
HC B_DISEASE/B_GENE
patients O
from O
France O
, O
Holland O
, O
and O
Czech O
Republic O
. O

Seven B_NUMBER[MEASURE]/B_PERSON
novel I_NUMBER[MEASURE]/I_PERSON
mutations I_NUMBER[MEASURE]/I_PERSON
and O
two B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
new B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
polymorphisms B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O
detected O
. O

Among O
these O
mutations B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
two I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
missense B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
G197W B_GENE
, O
W427R B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
two B_NUMBER[MEASURE]/B_PERSON
are O
nonsense B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
Q306X B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Q385X B_PROTEIN[GENE]/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
) O
, O
two B_NUMBER[MEASURE]
are O
small B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
deletions B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
662de14bp B_GENE/B_DISEASE
; O
1168del3bp B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
removing O
a O
glycine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
position B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
390 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
and O
one B_NUMBER[MEASURE]/B_PERSON
is O
a O
splicing B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
mutation I_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/I_GENE
( O
IVS1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
15c B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
- O
> B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
g I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
) O
which O
creates O
a O
new B_DISEASE/B_GENE
acceptor I_DISEASE/I_GENE
splice I_DISEASE/I_GENE
site I_DISEASE/I_GENE
. O

The O
pathological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
point B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutations B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
G197W B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
W427R B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
in O
- O
frame B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
deletion B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
390delGly B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O
assessed O
by O
their O
respective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
expression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
prokaryotic B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
site B_LOCATION/B_BIO
- O
directed O
mutagenesis B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
mutations B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resulted O
in O
the O
absence B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
a O
dramatic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decrease I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
CPO B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
two B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
polymorphisms B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
were O
localized O
in O
noncoding B_LOCATION/B_BIO
part I_LOCATION/I_BIO
of O
the O
gene B_GENE
1 I_GENE
) O
a O
C B_OTHER/B_LOCATION
/ O
G B_PROTEIN[GENE]/B_LOCATION
polymorphism B_PROTEIN[GENE]/I_LOCATION
in O
the O
promotor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
region I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
142 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
BP I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
upstream O
from O
the O
transcriptional B_GENE
initiation I_GENE
site I_GENE
( O
- O
142C B_LOCATION/B_PERSON
/ O
G B_OTHER/B_PROTEIN[GENE]
) O
, O
and O
2 B_SEQUENCE[MEASURE]
) O
a O
6 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
bp I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
deletion I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
polymorphism I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
3 B_SEQUENCE[MEASURE]/B_LOCATION
noncoding O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
CPO B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
574 B_LOCATION
BP I_LOCATION
downstream I_LOCATION
of O
the O
last B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
base B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
normal B_GENE
termination I_GENE
codon I_GENE
( O
+ B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
574 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
delATTCTT I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Five O
intragenic O
dimorphisms O
are O
now O
well O
characterized O
and O
the O
high O
degree O
of O
allelic O
heterogeneity O
in O
HC B_DISEASE/B_LOCATION
is O
demonstrated O
with O
seven O
new O
different O
mutations O
making O
a O
total O
of O
nineteen O
CPO O
gene B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defects I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reported O
so O
far O
. O
. O

coincidence O
of O
two O
novel O
arylsulfatase O
A O
alleles O
and O
mutation O
459 O
+ O
1G O
> O
A O
within O
a O
family O
with O
metachromatic B_DISEASE/B_GENE
leukodystrophy I_DISEASE/I_GENE
: O
molecular O
basis O
of O
phenotypic O
heterogeneity O
. O

In O
a O
family O
with O
three O
siblings O
, O
one O
developed O
classical O
late O
infantile O
metachromatic B_DISEASE
leukodystrophy I_DISEASE
( O
MLD B_DISEASE/B_LOCATION
) O
, O
fatal O
at O
age O
5 O
years O
, O
with O
deficient O
arylsulfatase O
A O
( O
ARSA O
) O
activity O
and O
increased O
galactosylsulfatide O
( O
GS O
) O
excretion O
. O

The O
two O
other O
siblings O
, O
apparently O
healthy O
at O
12 O
( O
1 O
/ O
2 O
) O
and O
15 O
years O
, O
respectively O
, O
and O
their O
father O
, O
apparently O
healthy O
as O
well O
, O
presented O
ARSA O
and O
GS O
values O
within O
the O
range O
of O
MLD B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
patients O
. O

Mutation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
screening I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
sequence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
disclosed O
the O
involvement B_DISEASE/B_PERSON
of O
three B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
different B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
ARSA B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutations B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
being O
the O
molecular B_LOCATION/B_PERSON
basis I_LOCATION/I_PERSON
of O
intrafamilial B_DISEASE
phenotypic I_DISEASE
heterogeneity I_DISEASE
. O

The O
late B_PERSON
infantile I_PERSON
patient I_PERSON
inherited O
from O
his O
mother B_PERSON
the O
frequent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
0 I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
- O
type B_GENE/B_DISEASE
mutation I_GENE/I_DISEASE
459 I_GENE/I_DISEASE
+ I_GENE/I_DISEASE
1G I_GENE/I_DISEASE
> I_GENE/I_DISEASE
A I_GENE/I_DISEASE
, O
and O
from O
his O
father B_PERSON
a O
novel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
single B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basepair I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microdeletion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
guanine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O
nucleotide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
7 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
exon B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
1 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
7delG B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

The O
two B_NUMBER[MEASURE]
clinically O
unaffected B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
siblings I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
carried O
the O
maternal B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
459 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
+ O
1G B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> O
A B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
, O
on O
their O
paternal B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
allele I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O
a O
novel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytosine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
thymidine O
transition B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
at O
nucleotide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2435 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
exon B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
8 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
resulting O
in O
substitution B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
alanine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
464 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
valine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
A464V B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

The O
fathers B_PERSON/B_ENT
genotype O
thus O
was O
7delG B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O
A464V B_MEASURE/B_DISEASE
. O

mutation O
A464V O
was O
not O
found O
in O
18 O
unrelated O
MLD B_DISEASE/B_LOCATION
patients O
and O
50 O
controls O
. O

A464V O
, O
although O
clearly O
modifying O
ARSA O
and O
GS O
levels O
, O
apparently O
bears O
little O
significance O
for O
clinical O
manifestation O
of O
MLD B_DISEASE/B_LOCATION
, O
mimicking O
the O
frequent O
ARSA O
pseudodeficiency O
allele O
. O

Our O
results O
demonstrate O
that O
in O
certain O
genetic O
conditions O
MLD B_DISEASE/B_MEASURE
- O
like O
ARSA O
and O
GS O
values O
need O
not O
be O
paralleled O
by O
clinical O
disease O
, O
a O
finding O
with O
serious O
diagnostic O
and O
prognostic O
implications O
. O

Moreover O
, O
further B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
ARSA B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
alleles B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
functionally O
similar B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
A464V B_PERSON/B_DISEASE
might O
exist O
which O
, O
together O
with O
0 B_MEASURE/B_LOCATION
- O
type B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
mutations I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
may O
cause O
pathological B_DISEASE/B_PROTEIN[GENE]
ARSA B_DISEASE/I_PROTEIN[GENE]
and O
GS B_DISEASE_ADJECTIVE[DISEASE]
levels I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
not O
clinical B_DISEASE_ADJECTIVE[DISEASE]
outbreak I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
disease B_DISEASE/B_BIO
. O
. O

Human O
MLH1 O
deficiency O
predisposes O
to O
hematological B_DISEASE
malignancy I_DISEASE
and O
neurofibromatosis B_DISEASE
type I_DISEASE
1 I_DISEASE
. O

Heterozygous O
germ O
- O
line O
mutations O
in O
the O
DNA O
mismatch O
repair O
genes O
lead O
to O
hereditary B_DISEASE
nonpolyposis I_DISEASE
colorectal I_DISEASE
cancer I_DISEASE
. O

The O
disease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
susceptibility B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
individuals B_PERSON/B_BIO
who O
constitutionally O
lack O
both O
wild B_PERSON/B_BIO
- O
type B_BIO/B_GENE
alleles I_BIO/I_GENE
is O
unknown B_DISEASE_ADJECTIVE[DISEASE]
. O

We O
have O
identified O
three O
offspring O
in O
a O
hereditary B_DISEASE/B_LOCATION
nonpolyposis B_DISEASE/I_LOCATION
colorectal B_DISEASE/I_LOCATION
cancer B_DISEASE/I_LOCATION
family O
who O
developed O
hematological B_DISEASE
malignancy I_DISEASE
at O
a O
very O
early O
age O
, O
and O
at O
least O
two O
of O
them O
displayed O
signs O
of O
neurofibromatosis B_DISEASE/B_GENE
type I_DISEASE/I_GENE
1 I_DISEASE/I_GENE
( O
NF1 B_DISEASE/B_GENE
) O
. O

DNA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sequence I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
allele B_GENE
- O
specific B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
amplification I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
two B_PERSON/B_GENE
siblings B_PERSON/I_GENE
revealed O
a O
homozygous B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
MLH1 B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
mutation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
C676T B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
- O
- O
> B_MEASURE/B_PROTEIN[GENE]
Arg226Stop I_MEASURE/I_PROTEIN[GENE]
) O
. O

Thus O
, O
a O
homozygous O
germ O
- O
line O
MLH1 O
mutation O
and O
consequent O
mismatch O
repair O
deficiency O
results O
in O
a O
mutator O
phenotype O
characterized O
by O
leukemia B_DISEASE
and O
/ O
or O
lymphoma B_DISEASE
associated O
with O
neurofibromatosis B_DISEASE/B_PROTEIN[GENE]
type B_DISEASE/I_PROTEIN[GENE]
1 B_DISEASE/I_PROTEIN[GENE]
. O
. O

Missense O
mutations O
in O
the O
most O
ancient O
residues O
of O
the O
PAX6 O
paired O
domain O
underlie O
a O
spectrum O
of O
human O
congenital B_DISEASE/B_GENE
eye I_DISEASE/I_GENE
malformations I_DISEASE/I_GENE
. O

mutations O
of O
the O
human O
PAX6 O
gene O
underlie O
aniridia B_DISEASE/B_LOCATION
( O
congenital B_LOCATION
absence I_LOCATION
of I_LOCATION
the I_LOCATION
iris I_LOCATION
) O
, O
a O
rare O
dominant O
malformation B_DISEASE/B_GENE
of I_DISEASE/I_GENE
the I_DISEASE/I_GENE
eye I_DISEASE/I_GENE
. O

The O
spectrum O
of O
PAX6 O
mutations O
in O
aniridia B_DISEASE/B_PERSON
patients O
is O
highly O
biased O
, O
with O
92 O
% O
of O
all O
reported O
mutations O
leading O
to O
premature O
truncation O
of O
the O
protein O
( O
nonsense O
, O
splicing O
, O
insertions O
and O
deletions O
) O
and O
just O
2 O
% O
leading O
to O
substitution O
of O
one O
amino O
acid O
by O
another O
( O
missense O
) O
. O

The O
extraordinary O
conservation O
of O
the O
PAX6 O
protein O
at O
the O
amino O
acid O
level O
amongst O
vertebrates O
predicts O
that O
pathological O
missense O
mutations O
should O
in O
fact O
be O
common O
even O
though O
they O
are O
hardly O
ever O
seen O
in O
aniridia B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
patients O
. O

This O
indicates O
that O
there O
is O
a O
heavy O
ascertainment O
bias O
in O
the O
selection O
of O
patients O
for O
PAX6 O
mutation O
analysis O
and O
that O
the O
missing O
PAX6 O
missense O
mutations O
frequently O
may O
underlie O
phenotypes O
distinct O
from O
textbook O
aniridia B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O

Here O
we O
present O
four O
novel O
PAX6 O
missense O
mutations O
, O
two O
in O
association O
with O
atypical O
phenotypes O
ectopia B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
pupillae I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
displaced B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pupils I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
congenital B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
nystagmus I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
searching B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gaze I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
and O
two O
in O
association O
with O
more O
recognizable O
aniridia B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
phenotypes O
. O

Strikingly O
, O
all O
four B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
mutations I_DISEASE_ADJECTIVE[DISEASE]/I_NUMBER[MEASURE]
are O
located O
within O
the O
PAX6 B_GENE/B_SEQUENCE[MEASURE]
paired O
domain B_LOCATION/B_GENE
and O
affect O
amino B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
acids B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
which O
are O
highly O
conserved O
in O
all O
known O
paired O
domain B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Our O
results O
support O
the O
hypothesis O
that O
the O
under O
- O
representation O
of O
missense O
mutations O
is O
caused O
by O
ascertainment O
bias O
and O
suggest O
that O
a O
substantial O
burden O
of O
PAX6 B_DISEASE/B_MEASURE
- I_DISEASE/I_MEASURE
related I_DISEASE/I_MEASURE
disease I_DISEASE/I_MEASURE
remains O
to O
be O
uncovered O
. O
. O

The O
chromosomal O
order O
of O
genes O
controlling O
the O
major O
histocompatibility O
complex O
, O
properdin O
factor O
B O
, O
and O
deficiency B_GENE/B_DISEASE
of I_GENE/I_DISEASE
the I_GENE/I_DISEASE
second I_GENE/I_DISEASE
component I_GENE/I_DISEASE
of I_GENE/I_DISEASE
complement I_GENE/I_DISEASE
. O

The O
relationship O
of O
the O
genes O
coding O
for O
HLA O
to O
those O
coding O
for O
properdin O
Factor O
B O
allotypes O
and O
for O
deficiency B_GENE/B_DISEASE
of I_GENE/I_DISEASE
the I_GENE/I_DISEASE
second I_GENE/I_DISEASE
component I_GENE/I_DISEASE
of I_GENE/I_DISEASE
complement I_GENE/I_DISEASE
( O
C2 O
) O
was O
studied O
in O
families O
of O
patients O
with O
connective O
tissue O
disorders O
. O

patients O
were O
selected O
because O
they O
were O
heterozygous O
or O
homozygous O
for O
C2 B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
deficiency B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
. O

12 O
families O
with O
15 O
matings O
informative O
for O
C2 B_DISEASE
deficiency I_DISEASE
were O
found O
. O

Of O
57 O
informative O
meioses O
, O
two O
crossovers O
were O
noted O
between O
the O
C2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
deficiency I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
gene O
and O
the O
HLA O
- O
B O
gene O
, O
with O
a O
recombinant O
fraction O
of O
0 O
. O

035 B_NUMBER[MEASURE]
. O

A O
lod O
score O
of O
13 O
was O
calculated O
for O
linkage O
between O
C2 B_DISEASE/B_GENE
deficiency I_DISEASE/I_GENE
and O
HLA O
- O
B O
at O
a O
maximum O
likelihood O
value O
of O
the O
recombinant O
fraction O
of O
0 O
. O

04 B_NUMBER[MEASURE]
. O

18 B_PERSON/B_LOCATION
families I_PERSON/I_LOCATION
with O
21 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
informative I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
matings I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
both O
properdin B_LOCATION/B_PERSON
Factor I_LOCATION/I_PERSON
B I_LOCATION/I_PERSON
allotype I_LOCATION/I_PERSON
and O
HLA B_GENE/B_LOCATION
- O
B B_PROTEIN[GENE]/B_DISEASE
were O
found O
. O

Of O
72 B_NUMBER[MEASURE]/B_PERSON
informative B_NUMBER[MEASURE]/I_PERSON
meioses B_NUMBER[MEASURE]/I_PERSON
, O
three B_MEASURE
recombinants I_MEASURE
were O
found O
, O
giving O
a O
recombinant B_MEASURE/B_ENT
fraction I_MEASURE/I_ENT
of O
0 B_NUMBER[MEASURE]/B_BIO
. O

042 B_NUMBER[MEASURE]
. O

A O
lod B_MEASURE
score I_MEASURE
of O
16 B_MEASURE
between O
HLA B_PROTEIN[GENE]/B_MEASURE
- O
B B_PROTEIN[GENE]/B_DISEASE
and O
Factor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
allotypes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
calculated O
at O
a O
maximum B_MEASURE
likelihood I_MEASURE
value I_MEASURE
of O
the O
recombinant B_MEASURE/B_LOCATION
fraction I_MEASURE/I_LOCATION
of O
0 B_MEASURE/B_BIO
. O

04 B_NUMBER[MEASURE]
. O

A O
crossover B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
shown O
to O
have O
occurred O
between O
genes B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
Factor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
B I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
HLA B_GENE/B_MEASURE
- O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
which O
HLA B_PROTEIN[GENE]/B_LOCATION
- O
D B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
segregared O
with O
HLA B_GENE/B_MEASURE
- O
A B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
B B_PROTEIN[GENE]/B_DISEASE
. O

These O
studies O
suggest O
that O
the O
genes O
for O
Factor O
B O
and O
C2 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deficiency I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
located O
outside O
those O
for O
HLA O
, O
that O
the O
order O
of O
genese O
is O
HLA O
- O
A O
, O
- O
B O
, O
- O
D O
, O
Factor O
B O
allotype O
, O
C2 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deficiency I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
that O
the O
genes O
coding O
for O
C2 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
deficiency I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
Factor O
B O
allotypes O
are O
approximately O
3 O
- O
- O
5 O
centimorgans O
from O
the O
HLA O
- O
A O
and O
HLA O
- O
B O
loci O
, O
and O
that O
the O
apparent O
lack O
of O
recombinants O
between O
the O
Factor O
B O
gene O
and O
C2 B_PROTEIN[GENE]/B_LOCATION
deficiency I_PROTEIN[GENE]/I_LOCATION
gene O
suggests O
that O
these O
two O
genes O
lie O
in O
close O
proximity O
to O
one O
another O
. O

Distribution O
of O
emerin O
and O
lamins O
in O
the O
heart O
and O
implications O
for O
Emery B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Dreifuss B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
muscular B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dystrophy B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Emerin O
is O
a O
nuclear O
membrane O
protein O
which O
is O
missing O
or O
defective O
in O
Emery B_DISEASE
- I_DISEASE
Dreifuss I_DISEASE
muscular I_DISEASE
dystrophy I_DISEASE
( O
EDMD B_DISEASE/B_GENE
) O
. O

It O
is O
one B_PERSON/B_MEASURE
member I_PERSON/I_MEASURE
of O
a O
family B_PERSON/B_LOCATION
of O
lamina B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O
associated O
proteins B_BIO/B_GENE
which O
includes O
LAP1 B_GENE/B_DISEASE
, O
LAP2 B_GENE/B_DISEASE
and O
lamin B_GENE/B_LOCATION
B I_GENE/I_LOCATION
receptor I_GENE/I_LOCATION
( O
LBR B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

A O
panel B_PERSON/B_LOCATION
of O
16 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monoclonal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
mAbs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
has O
been O
mapped O
to O
six B_LOCATION/B_BIO
specific I_LOCATION/I_BIO
sites I_LOCATION/I_BIO
throughout O
the O
emerin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
molecule I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
using O
phage B_BACTERIUM[BIO]/B_GENE
- O
displayed O
peptide B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
libraries B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
and O
has O
been O
used O
to O
localize O
emerin B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
human B_SPECIES[BIO]
and O
rabbit B_SPECIES[BIO]
heart I_SPECIES[BIO]
. O

Several B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mAbs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
against O
different B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
emerin I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
epitopes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
did O
not O
recognize O
intercalated B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
discs B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
though O
they O
recognized O
cardiomyocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_MEASURE
nuclei I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_MEASURE
strongly O
, O
both O
at O
the O
rim B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O
in O
intranuclear B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
spots I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
or O
channels B_LOCATION
. O

A O
polyclonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
rabbit I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antiserum I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
against O
emerin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
recognize O
both O
nuclear B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
membrane I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
and O
intercalated B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
discs B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
but O
, O
after O
affinity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
purification I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
against O
a O
pure B_DISEASE
- O
emerin B_PROTEIN[GENE]/B_BACTERIUM[BIO]
band I_PROTEIN[GENE]/I_BACTERIUM[BIO]
on O
a O
western B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
it O
stained O
only O
the O
nuclear B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
membrane I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
. O

These O
results O
would O
not O
be O
expected O
if O
immunostaining O
at O
intercalated O
discs O
were O
due O
to O
a O
product O
of O
the O
emerin O
gene O
and O
, O
therefore O
, O
cast O
some O
doubt O
upon O
the O
hypothesis O
that O
cardiac B_DISEASE_ADJECTIVE[DISEASE]
defects I_DISEASE_ADJECTIVE[DISEASE]
in O
EDMD B_DISEASE/B_SPECIES[BIO]
are O
caused O
by O
absence O
of O
emerin O
from O
intercalated O
discs O
. O

Although O
emerin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
abundant B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
membranes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
of O
cardiomyocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
nuclei I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
it O
was O
absent B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
many B_DISEASE
non I_DISEASE
- O
myocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
in O
the O
heart B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

This O
distribution O
of O
emerin O
was O
similar O
to O
that O
of O
lamin O
A O
, O
a O
candidate O
gene O
for O
an O
autosomal O
form O
of O
EDMD B_DISEASE/B_GENE
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
lamin B_GENE
B1 I_GENE
was O
absent B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
cardiomyocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
nuclei I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
showing O
that O
lamin B_GENE
B1 I_GENE
is O
not O
essential B_TIME[MEASURE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
localization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
emerin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
nuclear B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
lamina I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
. O

lamin B_GENE
B1 I_GENE
is O
also O
almost O
completely O
absent B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
from O
skeletal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
muscle I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
nuclei I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
EDMD B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
additional O
absence O
of O
lamin O
B1 O
from O
heart O
and O
skeletal O
muscle O
nuclei O
which O
already O
lack O
emerin O
may O
offer O
an O
alternative O
explanation O
of O
why O
these O
tissues O
are O
particularly O
affected O
. O
. O

genetic O
mapping O
of O
the O
copper B_DISEASE/B_GENE
toxicosis B_DISEASE/I_GENE
locus O
in O
Bedlington O
terriers O
to O
dog O
chromosome O
10 O
, O
in O
a O
region O
syntenic O
to O
human O
chromosome O
region O
2p13 O
- O
p16 O
. O

abnormal O
hepatic B_DISEASE/B_ORGANISM_FUNCTION
copper I_DISEASE/I_ORGANISM_FUNCTION
accumulation I_DISEASE/I_ORGANISM_FUNCTION
is O
recognized O
as O
an O
inherited B_DISEASE
disorder I_DISEASE
in O
man O
, O
mouse O
, O
rat O
and O
dog O
. O

The O
major O
cause O
of O
hepatic B_DISEASE/B_GENE
copper I_DISEASE/I_GENE
accumulation I_DISEASE/I_GENE
in O
man O
is O
a O
dysfunctional O
ATP7B O
gene O
, O
causing O
Wilson B_DISEASE
disease I_DISEASE
( O
WD B_PROTEIN[GENE]/B_DISEASE
) O
. O

Mutations B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]/B_GENE
in O
the O
ATP7B B_GENE/B_LOCATION
genes I_GENE/I_LOCATION
have O
also O
been O
demonstrated O
in O
mouse B_SPECIES[BIO]/B_DISEASE
and O
rat B_SPECIES[BIO]/B_GENE
. O

The O
ATP7B O
gene O
has O
been O
excluded O
in O
the O
much O
rarer O
human O
copper B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
overload I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
disease O
non B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
Indian B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
childhood B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
cirrhosis B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
indicating O
genetic O
heterogeneity O
. O

By O
investigating O
the O
common O
autosomal O
recessive O
copper B_DISEASE/B_GENE
toxicosis I_DISEASE/I_GENE
( O
CT B_LOCATION/B_ORGANIZATION
) O
in O
Bedlington O
terriers O
, O
we O
have O
identified O
a O
new O
locus O
involved O
in O
progressive O
liver B_DISEASE
disease I_DISEASE
. O

We O
examined O
whether O
the O
WD B_DISEASE/B_PERSON
gene O
ATP7B O
was O
also O
causative O
for O
CT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O
investigating O
the O
chromosomal O
co O
- O
localization O
of O
ATP7B O
and O
C04107 O
, O
using O
fluorescence O
in O
situ O
hybridization O
( O
Fish O
) O
. O

C04107 O
is O
an O
anonymous O
microsatellite O
marker O
closely O
linked O
to O
CT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

However O
, O
BAC O
clones O
containing O
ATP7B O
and O
C04107 O
mapped O
to O
the O
canine O
chromosome O
regions O
CFA22q11 O
and O
CFA10q26 O
, O
respectively O
, O
demonstrating O
that O
WD B_LOCATION/B_PERSON
cannot O
be O
homologous O
to O
CT B_LOCATION/B_ORGANIZATION
. O

The O
copper O
transport O
genes O
CTR1 O
and O
CTR2 O
were O
also O
excluded O
as O
candidate O
genes O
for O
CT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
since O
they O
both O
mapped O
to O
canine O
chromosome O
region O
CFA11q22 O
. O

2 O
- O
22 B_MEASURE
. O

5 B_NUMBER[MEASURE]
. O

A O
transcribed B_GENE/B_MEASURE
sequence I_GENE/I_MEASURE
identified O
from O
the O
C04107 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
containing O
BAC B_GENE/B_DISEASE
was O
found O
to O
be O
homologous B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
a O
gene B_GENE/B_LOCATION
expressed O
from O
human B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
chromosome I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
2p13 I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
p16 B_MEASURE
, O
a O
region B_LOCATION/B_PERSON
devoid B_LOCATION/I_PERSON
of O
any O
positional B_GENE
candidate I_GENE
genes I_GENE
. O

Molecular O
analysis O
of O
the O
APC B_GENE/B_BACTERIUM[BIO]
gene O
in O
205 O
families O
: O
extended O
genotype O
- O
phenotype O
correlations O
in O
FAP B_DISEASE/B_PERSON
and O
evidence O
for O
the O
role O
of O
APC B_MEASURE/B_BACTERIUM[BIO]
amino O
acid O
changes O
in O
colorectal B_DISEASE/B_GENE
cancer I_DISEASE/I_GENE
predisposition O
. O

Background O
/ O
aims O
The O
development O
of O
colorectal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
a O
variable O
range O
of O
extracolonic O
manifestations O
in O
familial B_DISEASE
adenomatous I_DISEASE
polyposis I_DISEASE
( O
FAP B_PROTEIN[GENE]/B_DISEASE
) O
is O
the O
result O
of O
the O
dominant O
inheritance O
of O
adenomatous B_DISEASE/B_GENE
polyposis B_DISEASE/I_GENE
coli B_DISEASE/I_GENE
( O
APC B_GENE/B_BACTERIUM[BIO]
) O
gene O
mutations O
. O

In O
this O
study O
, O
direct O
mutation O
analysis O
of O
the O
APC B_GENE/B_BACTERIUM[BIO]
gene O
was O
performed O
to O
determine O
genotype O
- O
phenotype O
correlations O
for O
nine O
extracolonic O
manifestations O
and O
to O
investigate O
the O
incidence O
of O
APC B_GENE/B_PERSON
mutations O
in O
non O
- O
FAP O
colorectal B_DISEASE/B_PERSON
cancer I_DISEASE/I_PERSON
. O

methods O
The O
APC B_GENE/B_BACTERIUM[BIO]
gene O
was O
analysed O
in O
190 O
unrelated O
FAP B_DISEASE/B_PERSON
and O
15 O
non O
- O
FAP O
colorectal B_DISEASE/B_PERSON
cancer I_DISEASE/I_PERSON
patients O
using O
denaturing O
gradient O
gel O
electrophoresis O
, O
the O
protein O
truncation O
test O
, O
and O
direct O
sequencing O
. O

Results O
Chain O
terminating O
signals O
were O
only O
identified O
in O
patients O
belonging O
to O
the O
FAP B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O
( O
105 O
patients O
) O
. O

amino O
acid O
changes O
were O
identified O
in O
four O
patients O
, O
three O
of O
whom O
belonged O
to O
the O
non O
- O
FAP O
group O
of O
colorectal B_DISEASE/B_NUMBER[MEASURE]
cancer B_DISEASE/I_NUMBER[MEASURE]
patients O
. O

Genotype O
- O
phenotype O
correlations O
identified O
significant O
differences O
in O
the O
nature O
of O
certain O
extracolonic O
manifestations O
in O
FAP B_DISEASE/B_NUMBER[MEASURE]
patients O
belonging O
to O
three O
mutation O
subgroups O
. O

conclusions B_MEASURE/B_PERSON
Extended I_MEASURE
genotype I_MEASURE
- O
phenotype B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
made O
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
may O
have O
the O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
determine O
the O
most O
appropriate B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surveillance I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
prophylactic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
regimens I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
those O
patients B_PERSON
with O
mutations B_DISEASE/B_GENE
associated O
with O
life B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
threatening O
conditions B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

This O
study O
also O
provided O
evidence O
for O
the O
pathological O
nature O
of O
amino O
acid O
changes O
in O
APC O
associated O
with O
both O
FAP B_DISEASE/B_GENE
and O
non O
- O
FAP O
colorectal B_DISEASE
cancer I_DISEASE
patients O
. O
. O

Inherited B_DISEASE
colorectal I_DISEASE
polyposis I_DISEASE
and O
cancer B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
risk O
of O
the O
APC O
I1307K O
polymorphism O
. O

Germ O
- O
line O
and O
somatic O
truncating O
mutations O
of O
the O
APC B_GENE/B_BACTERIUM[BIO]
gene O
are O
thought O
to O
initiate O
colorectal B_DISEASE
tumor I_DISEASE
formation O
in O
familial B_DISEASE_ADJECTIVE[DISEASE]
adenomatous I_DISEASE_ADJECTIVE[DISEASE]
polyposis I_DISEASE_ADJECTIVE[DISEASE]
syndrome I_DISEASE_ADJECTIVE[DISEASE]
and O
sporadic O
colorectal O
carcinogenesis O
, O
respectively O
. O

Recently O
, O
an O
isoleucine O
- O
- O
> O
lysine O
polymorphism O
at O
codon O
1307 O
( O
I1307K O
) O
of O
the O
APC B_GENE/B_BACTERIUM[BIO]
gene O
has O
been O
identified O
in O
6 O
% O
- O
7 O
% O
of O
the O
Ashkenazi O
Jewish O
population O
. O

To O
assess O
the O
risk O
of O
this O
common O
APC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
allelic O
variant O
in O
colorectal O
carcinogenesis O
, O
we O
have O
analyzed O
a O
large O
cohort O
of O
unselected O
Ashkenazi O
Jewish O
subjects O
with O
adenomatous B_DISEASE/B_GENE
polyps I_DISEASE/I_GENE
and O
. O
or O
colorectal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cancer B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
APC O
I1307K O
polymorphism O
. O

The O
APC B_DISEASE
I1307K I_DISEASE
allele I_DISEASE
was O
identified O
in O
48 B_MEASURE
( O
10 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
) O
of O
476 B_PERSON/B_BIO
patients I_PERSON/I_BIO
. O

Compared O
with O
the O
frequency B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
two B_PERSON/B_BIO
separate I_PERSON/I_BIO
population I_PERSON/I_BIO
control I_PERSON/I_BIO
groups I_PERSON/I_BIO
, O
the O
APC B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
I1307K I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
allele I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
is O
associated O
with O
an O
estimated O
relative B_MEASURE/B_DISEASE
risk I_MEASURE/I_DISEASE
of O
1 B_TIME[MEASURE]/B_DISEASE
. O

5 O
- O
1 B_MEASURE
. O

7 O
for O
colorectal B_PERSON/B_MEASURE
neoplasia I_PERSON/I_MEASURE
( O
both O
P O
= O
. O
01 O
) O
. O

Furthermore O
, O
compared O
with O
noncarriers O
, O
APC O
I1307K O
carriers O
had O
increased O
numbers O
of O
adenomas B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
colorectal B_DISEASE
cancers I_DISEASE
per O
patient O
( O
P O
= O
. O
03 O
) O
, O
as O
well O
as O
a O
younger O
age O
at O
diagnosis O
. O

We O
conclude O
that O
the O
APC O
I1307K O
variant O
leads O
to O
increased O
adenoma B_DISEASE
formation O
and O
directly O
contributes O
to O
3 O
% O
- O
4 O
% O
of O
all O
Ashkenazi O
Jewish O
colorectal B_DISEASE/B_PERSON
cancer I_DISEASE/I_PERSON
. O

The O
estimated O
relative O
risk O
for O
carriers O
may O
justify O
specific O
clinical O
screening O
for O
the O
360 O
, O
000 O
Americans O
expected O
to O
harbor O
this O
allele O
, O
and O
genetic O
testing O
in O
the O
setting O
of O
long O
- O
term O
- O
outcome O
studies O
may O
impact O
significantly O
on O
colorectal B_DISEASE
cancer I_DISEASE
prevention O
in O
this O
population O
. O

Localization O
of O
human O
BRCA1 O
and O
its O
loss O
in O
high O
- O
grade O
, O
non B_DISEASE
- I_DISEASE
inherited I_DISEASE
breast I_DISEASE
carcinomas I_DISEASE
. O

Although O
the O
link O
between O
the O
BRCA1 O
tumour B_DISEASE
- O
suppressor O
gene O
and O
hereditary B_DISEASE
breast I_DISEASE
and I_DISEASE
ovarian I_DISEASE
cancer I_DISEASE
is O
established O
, O
the O
role O
, O
if O
any O
, O
of O
BRCA1 O
in O
non B_DISEASE/B_ORGANISM_FUNCTION
- I_DISEASE/I_ORGANISM_FUNCTION
familial I_DISEASE/I_ORGANISM_FUNCTION
cancers I_DISEASE/I_ORGANISM_FUNCTION
is O
unclear O
. O

BRCA1 O
mutations O
are O
rare O
in O
sporadic B_DISEASE/B_PERSON
cancers I_DISEASE/I_PERSON
, O
but O
loss O
of O
BRCA1 O
resulting O
from O
reduced O
expression O
or O
incorrect O
subcellular O
localization O
is O
postulated O
to O
be O
important O
in O
non B_DISEASE
- I_DISEASE
familial I_DISEASE
breast I_DISEASE
and I_DISEASE
ovarian I_DISEASE
cancers I_DISEASE
. O

epigenetic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
loss B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
however O
, O
has O
not O
received O
general B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acceptance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
due O
to O
controversy B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regarding O
the O
subcellular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
localization I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
BRCA1 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
reports B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
which O
have O
ranged O
from O
exclusively O
nuclear B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
, O
to O
conditionally O
nuclear O
, O
to O
the O
ER B_GENE/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
/ O
golgi B_LOCATION/B_PERSON
, O
to O
cytoplasmic B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
invaginations I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
into O
the O
nucleus B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
. O

In O
an O
attempt B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O
resolve O
this O
issue B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
we O
have O
comprehensively O
characterized O
19 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
BRCA1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
antibodies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

These O
reagents O
detect O
a O
220 O
- O
kD O
protein O
localized O
in O
discrete O
nuclear O
foci O
in O
all O
epithelial O
cell O
lines O
, O
including O
those O
derived O
from O
breast B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
malignancies I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Immunohistochemical O
staining O
of O
human O
breast O
specimens O
also O
revealed O
BRCA1 O
nuclear O
foci O
in O
benign O
breast O
, O
invasive B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
lobular I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancers I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
low B_DISEASE
- I_DISEASE
grade I_DISEASE
ductal I_DISEASE
carcinomas I_DISEASE
. O

Conversely O
, O
BRCA1 O
expression O
was O
reduced O
or O
undetectable O
in O
the O
majority O
of O
high O
- O
grade O
, O
ductal B_DISEASE/B_PERSON
carcinomas I_DISEASE/I_PERSON
, O
suggesting O
that O
absence O
of O
BRCA1 O
may O
contribute O
to O
the O
pathogenesis O
of O
a O
significant O
percentage O
of O
sporadic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
breast I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancers I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O
. O

